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HEMOSTASIS IN CARDIAC SURGERY
Hemostasis during cardiopulmonary bypass
During cardiac surgery with cardiopulmonary bypass (CPB), the coagulation 
system faces major alterations. First, as blood will flow through the large surface 
of the highly thrombogenic tubing of the heart lung machine, patients have to 
be anticoagulated in order to prevent consumptive coagulopathy and the 
formation of (micro) thrombi. Second, patients undergo major surgical trauma 
including sternotomy, venesection, arterial and venous cannulation, leading to 
hemostasis activation. Third, anticoagulation has to be reversed after weaning 
from cardiopulmonary bypass to restore normal clot formation. Fourth, multiple 
perioperative factors, such as acidosis, hypocalcemia, hypothermia and 
hemodilution may adversely affect hemostasis. The combination of these factors 
explain why major blood loss due to postoperative coagulopathy is common after 
cardiac surgery. [1]
In this context, the present thesis describes new methods for optimization of 
hemostasis management during cardiac surgery with cardiopulmonary bypass. 
In the first part of the introduction, the hemostasis system and the influences of 
cardiac surgery with cardiopulmonary bypass are reviewed. Hereafter, prevention, 
prediction, monitoring and treatment approaches for hemostatic disturbances in 
cardiac surgery will be discussed.
pump 2O *
Figure 1.  Schematic overview of the heart lung machine. Blood is drained from the right 




Current view on hemostasis
A thorough understanding of hemostasis is necessary for optimal coagulation 
management. Here we outline the general concept of hemostasis. Hemostasis 
can be described as the complex interaction between the vascular wall, 
thrombocytes and clotting factors. The traditional concept of hemostasis divides 
the clotting system in two sequences: the formation of a platelet plug followed by 
the coagulation ‘waterfall’ cascade, which dates back to 1964. [2,3] Although, 
this approach supports the interaction between clotting factors and is in line with 
the classical laboratory coagulation tests it does not represent in vivo hemostasis.
A novel view on hemostasis is the ‘cell-based model of hemostasis’, which 
incorporates endothelium, platelets and clotting factors into one concept. [4] 
This model hypothesizes that hemostasis should not be regarded as a cascade 
but continuously takes place on cell surfaces in the following three overlapping 
stages: 
1) Initiation of hemostasis occurs on tissue factor (TF) bearing cells, including 
fibroblasts, macrophages, mononuclear cells, outside the vascular 
endothelium. This is a continuous low-grade process in the absence 
of vascular damage, which is active in an equilibrium with a process 
counteracting coagulation.
2) Amplification results from vascular damage leading to contact between 
the TF bearing extravascular cells and large hemostatic intravascular 
components, as factor VIII and von Willebrand factor (vWf). In this phase, a 
platelet plug is formed, while thrombocytes and cofactors are prepared for 
major thrombin generation.
3) Propagation is the generation of large amounts of thrombin on the platelet 
surface due to an abundance of procoagulatory factors that outweigh 
inhibitors of the coagulation. In the final step thrombin in formed which 
results in the cleavage of fibrinogen to fibrin which polymerizes within the 
platelet plug to form a solid clot. 
Besides platelets, the endothelium and coagulation factors as prerequisites of 
adequate hemostasis, blood temperature, pH and calcium levels also need to 
be within normal ranges as they serve as cofactors for adequate hemostasis. 
[5] Hypothermia has been found to prolong the initiation phase, whereas 
hypocalcemia inhibits normal clot formation. [6] Acidemia prolongs the 
propagation phase, and insufficient organ perfusion with metabolic acidosis can 
therefore deteriorate hemostasis, linking hemodynamics and hemostasis. [7] This 
lethal triad, consisting of acidosis, hypothermia and hypocalcemia, is particularly 




shock with subsequent acidosis. Moreover, massive blood transfusion can 
cause hypocalcemia leading to a downward spiral of ongoing bleeding due to 











Figure 2.  Classical coagulation cascade: the intrinsic and extrinsic pathway.
It has been suggested that erythrocytes as main oxygen carriers within the 
circulation are also involved in hemostasis, as they get trapped in the fibrin network 
(figure 3), thereby assisting in the formation of a solid blood clot. However, evidence 
for this phenomenon from in vitro – and clinical studies is limited. [8-11] A recent 
meta-analysis reported no differences in bleeding or thrombotic complications 
between liberal and restrictive red blood cell transfusion thresholds. [12] This 
suggests that aiming for a higher hemoglobin level in the bleeding patient does 
not improve hemostasis. On the other hand, adequate hemoglobin levels may 
contribute to normal oxygen delivery to the tissues, thereby preventing organ 
hypoxia and academia, which is favorable for the hemostatic system.
Another, important component of the hemostatic system is the ability to breakdown 
fibrin polymers after restoration of vascular damage, the so-called fibrinolytic 
pathway. [13] The fibrin network is cleaved by plasmin, which is formed by the 
activation of plasminogen. Pathologic (hyper)fibrinolysis resulting in abundant 
fibrin degradation has been observed in surgical wounds, and might play a 
role in persistent bleeding after cardiac surgery. [14,15] In most cardiosurgical 
procedures (hyper)fibrinolysis is counteracted by the administration of 
antifibrinolytics. 
Hemostasis in cardiac surgery is further complicated by the preoperative use of 
platelet inhibitors and anticoagulants. These drugs are widely used in cardiac 
patients to prevent cardiovascular accidents as recommended by the European 
Society of Cardiology (ESC). [16] Acetylsalic acid is advised to be continued during 
the perioperative period, whereas P2Y12 inhibitors (i.e. clopidogrel, prasugrel 
and ticagrelor) should be discontinued 5-7 days prior to cardiac surgery. [17,18] 
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Increasing evidence suggests that the continuation of preoperative platelet 
inhibition reduces the postoperative risk on ischemic events, such as myocardial 
infarction. [19]  Therefore, the increasing preoperative use of platelet inhibitors 
leads to an additional risk of bleeding. [20-22] 
Figure 3.  A scanning electron micrograph image of a blood clot that shows red blood 
corpuscles and fibrin. Credit: David Gregory and Debbie Marshall / Wellcome 
Images.
Other anticoagulants, such as heparins, vitamin-K-antagonists and direct oral 
anticoagulants (DOACs) are used in cardiac patients for the prevention of clot 
formation in atrial fibrillation, venous thromboembolism and artificial cardiac 
valves. [23,24] While heparins and vitamin-K-antagonists can be rapidly 
antagonized by protamine and prothrombin complex concentrate, respectively, 
most DOACs have no specific antagonist available. When postponement of 
surgery is impossible, unantagonized anticoagulants and long acting platelet 
inhibitors may impair patient hemostasis in emergency situations.
Cardiopulmonary bypass-related effects on hemostasis
The cardiopulmonary bypass circuit, used during most forms of cardiac surgery, 
exerts major effects on hemostasis. First, the extracorporeal circulation circuit 
is primed with fluids, causing significant dilution of coagulation factors. [25,26] 




negatively charged surface of the tubing, thereby activating the coagulation 
cascade. This causes fibrin formation and consumptive coagulopathy. [27,28] 
Third, contact activation during cardiopulmonary bypass leads to initiation of the 
fibrinolytic system, which might cause rapid clot breakdown and exaggeration of 
coagulopathy after CPB. [13]
 









Figure 4.  The effect of surgical trauma and cardiopulmonary bypass on hemostasis.
Heparin anticoagulation
In order to reduce massive hemostatic activation during cardiopulmonary bypass, 
patients are usually fully anticoagulated prior to extracorporeal circulation with 
unfractioned heparin. Heparinoids are physiologically present on the vascular 
endothelium to prevent occult thrombin formation. Heparins bind to antithrombin 
(AT), a plasma protein that inhibits the activated clotting factors II, VII, IX, X and 
XI. By administration of a high dose of heparin, the risk of thrombin formation and 
consumptive coagulopathy is decreased.
Some patients have a reduced AT level, which decreases the effect of heparin 
and requires increased heparin dosage for the desired anticoagulant effect. 
This phenomenon is called ‘heparin resistance’ and can be congenital (1:3000 
patients) or acquired due to kidney disease (increased AT loss), malnutrition or 
reduced liver function (reduced synthesis). The clinically most relevant cause of 
‘heparin resistance’ is due to heparin pretreatment and the use of cardiac support 
devices (IABP, LVAD, ECMO), which may cause a consumption of antithrombin. 
Unfractioned heparin consists of a mix of a short and long chained molecules, 
which have a different affinity for thrombin and factor Xa. The ratio in chain lengths 
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varies among batches and suppliers, leading to a varied anticoagulant effect. 
Additionally, heparin binds to the glycocalyx of the endothelium and plasma 
proteins affecting its biological availability and half-life. The clearance of heparin 
reduces with increasing heparin concentrations due to a rapidly saturated 
clearance by macrophages and endothelium in addition to the slower elimination 
by renal clearance. 
Because of the variable effect of heparin, the level of effective anticoagulation is 
monitored using the activated clotting time (ACT). The ACT measures the time until 
clot formation in whole blood after the addition of a contact activator, activating 
the intrinsic coagulation cascade. The contact activator is used as a surrogate 
for the surface of the HLM. However, the ACT has major limitations as it does 
not correlate with the heparin concentration and the optimal ACT for adequate 
anticoagulation is unknown, resulting in varied ACT targets among practices. 
[29,30] Although an ACT greater than 400 – 480 seconds is commonly thought 
to reflect adequate anticoagulation, thrombin formation is still present. Finally, the 
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Figure 5.  Causes of the variable effect of heparin among different cases. 
Other methods to prevent coagulopathy
Besides the use of heparin, further attempts have been made to reduce the 
massive hemostatic activation during bypass, such as the use of cell salvage. 
Blood sucked from the surgical field is highly activated due to its contact with the 
extravascular surface. [31-33] When this activated blood is directly pumped into 




when pericardial blood is washed by the cell saver, coagulopathic components 
are removed leading to less hemostatic activation. Still, large amounts of cellsaver 
blood transfusion (> 1 liter) may cause dilution of coagulation factors due to the 
retransfusion of erythrocytes without plasma. This might explain why the use of a 
cell saver reduces allogenic red blood cell transfusion, but not overall outcome. 
[34]
Another attempt to reduce hemostatic activation during extracorporeal circulation 
is by heparin coating of the heart lung machine. Also, the surface of certain 
extracorporeal circuits has been modified to prevent protein binding and 
complement and coagulation activation. The use of these circuits has resulted 
in improved outcome, although the effect size is limited. [35,36] Reduction of 
the volume of the extracorporeal circuit may further reduce hemostatic activation 
surface area. These miniaturized CPB circuits have indeed proven to improve 
hemostasis, most likely due to the relatively lower level of hemodilution and 
contact activation. [37] Finally, the avoidance of exposure to an extracorporeal 








Figure 6.  Hemostatic complicating factors with the use of cardiopulmonary bypass.
Bleeding
Due to all the above-mentioned risks for coagulopathy, major bleeding is common 
after cardiac surgery but highly variable among centers, ranging from 0.4% 
to 16.3%. [1,40-43] Still, the definition of massive blood loss is highly variable 
among studies. Dyke et al. attempted to develop a universal definition for major 
perioperative bleeding. [46] They based their definition on several measures 
including the amount of postoperative chest tube drainage, blood product 
transfusion (erythrocytes, platelets, plasma), factor concentrate administration 
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(prothrombin complex concentrate, fibrinogen concentrate), delayed sternal 
closure and surgical reexploration for bleeding. Nevertheless, postoperative 
blood loss remains highly variable among practices and therefore massive blood 
loss should be seen in the light of the average amount of blood loss per center. 
The definition of Dyke et al. should be reserved for research purposes and 
benchmarking among centers. 
Massive bleeding is associated with adverse outcome. [44,45] Ongoing 
hemorrhage risks the patient for rethoracotomy to control the bleeding, which is 
an independent predictor for mortality. [47-49] Besides the risk for rethoracotomy, 
bleeding leads to anemia. Pre- and postoperative anemia is also associated 
with adverse outcome. [50,51] However, not only anemia, also blood product 
transfusion is independently associated with short - and long term mortality. 
[52,53] Even transfusion of small amounts of blood are associated with reduced 
outcome. [54-61] 
Blood transfusion can cause immune suppression, thereby increasing the risk 
of infection and cancer recurrence. [62] Also, although rare in current practice, 
blood product administration can trigger transfusion reactions and transmission 
of infections. Transfusion further risks patients for Transfusion Related Acute 
Lung Injury (TRALI), hemochromatosis, acute kidney injury (AKI), atrial fibrillation 
(AF), respiratory failure, neurological accidents, myocardial infarctions and 
rethoracotomy. [53,63,64] This has led to the design and execution of large 
randomized controlled trials investigating the optimal transfusion trigger for red 






Figure 7.  The relationship between bleeding, rethoracotomy, anemia, transfusion and 
outcome.
Besides these consequences, blood transfusion in cardiac surgery has a 
major burden on the total blood product consumption as up to 20% of all blood 




15 years, recent reports still show absence of a reduction in blood transfusion 
due to surgery in higher risk patients, an increase in the complexity of surgery 
and the lack of implementation of improved management strategies. [69,70] The 
high transfusion rate brings major costs due to the utilization of blood products 
and the subsequent adverse outcome of transfusion. [71] As bleeding, anemia 
and transfusion are associated with adverse outcome the main focus should be 
to prevent, predict, monitor and promptly treat blood loss in order to improve 
outcome. This method is multimodal and commonly referred to as ‘Patient blood 










The first step in patient blood management should be the prevention of 
coagulopathy, bleeding and transfusion. Many attempts have been made to 
prevent coagulopathy during and after cardiac surgery. Common practice is the 
use of antifibrinolytics to prevent massive fibrinolysis caused by the extracorporeal 
circulation and surgical wound. Formerly, aprotinin was used for this purpose 
with pleiotropic positive effects on hemostasis; inhibition of fibrinolysis, thrombin, 
platelets and activated protein C, preventing consumptive coagulopathy during 
bypass. [72,73] However, due to safety concerns aprotinin has been withdrawn 
from the market in 2007 as it was associated with kidney failure and increased 
mortality while it was superior in hemostatic optimization. [74,75] Although, 
aprotinin has recently been readmitted to the market its use has been replaced 
by tranexamic acid and ε-aminocapron acid. 
A hot topic in the prevention and treatment of bleeding in cardiac surgery is the use 
of fibrinogen concentrate. Fibrinogen (coagulation factor I) is converted to fibrin 
by thrombin and the key element in clot formation. Additionally, fibrinogen is one 
of the first elements to cease critically in the case of bleeding. [76] Preoperative 
fibrinogen levels are inversely associated with postoperative bleeding in cardiac 
surgery, but correction of preoperative fibrinogen level to > 2.5 g l-1 is not 
recommended based on the current evidence. [77-79] 
As stated before, inadequate tissue perfusion during major bleeding can cause 
acidosis, which impairs clot formation and contributes to further bleeding. [7] 
Therefore, adequate tissue perfusion is important for the prevention of (further) 
bleeding after cardiac surgery. However, excessive fluid administration to revert 
shock causes dilution of coagulation factors, which also impairs clot formation. 
Although the evidence for goal directed fluid management in cardiac surgery 
to reduce bleeding is lacking, reducing the prime volume and infusion volume 
(and thereby reducing hemodilution) has been proven to improve outcome. [37] If 
reducing the cardioplegia volume affects clinical outcome remains controversial, 
still it reduces hemodilution and might improve hemostasis. [80] Besides the 
prevention of fluid overload, the choice of the infused fluid and prime volume 
is important. Colloids preserve plasma volume and tissue perfusion more than 
crystalloids. Yet, colloids are associated with hemostatic impairment when 
compared to (balanced) crystalloids. [81-85] 
The exposure to allogenic blood products could be prevented by autologous 
blood (pre)donation of blood prior to elective cardiac surgery. Although robust 
studies are lacking, there is some evidence that predonation of blood might 




the safety, criteria and indication for predonation have not yet been clarified. An 
alternative to preoperative autologous blood predonation is acute normovolemic 
hemodilution. A certain amount of patients’ blood is drawn prior to CPB and 
retransfused after cardiopulmonary bypass. This method is better investigated 
and shows a reduction of bleeding and transfusion after cardiac surgery. [90] 
Likewise, there is a specific method for harvesting patients’ thrombocytes before 
surgery by ‘acute preoperative platelet pheresis’. Although a reduction in blood 
product transfusion was seen, the evidence for this technique is scarce, outdated 
and of poor quality. [91] 
A more logical way to prevent transfusion is to optimize preoperative hemoglobin 
levels in order to prevent anemia-related blood transfusion. Only a limited number 
of studies investigated the preoperative treatment of anemia in cardiac surgery. 
[92,93] The use of erythropoietin (EPO) with and without iron supplementation 
contributes to a reduction in transfusion requirements. [94-96] There is insufficient 





Several risk factors for bleeding in cardiac surgery have been identified. Patient 
related risk factors include advanced age, diabetes mellitus, preoperative low 
fibrinogen level, dual antiplatelet use, female gender, a low body mass index 
(BMI) and impaired left ventricular function. [77,98,99] Surgery related risk 
factors are emergency surgery, more complex cardiac surgery, a long duration of 
extracorporeal circulation and the cardiac surgeon. [99] In attempts to facilitate the 
preoperative prediction of need for transfusion, specific risk assessment scores 
have been developed in order to identify patients at high risk for bleeding. [100-104]
Besides these clinical parameters several studies have investigated the predictive 
value of point-of-care (POC) hemostasis monitors for postoperative bleeding. 
To evaluate if rotational thromboelastometry can predict which patients will 
excessively bleed in the postoperative period we conducted a systematic review 
of the literature in addition to the data of our own center in chapter 5.
Other POC devices evaluate the aggregation capacity of thrombocytes after 
activation by different activators, also known as platelet aggregometry or multiple 
electrode aggregometry (MEA). Platelet function testing is found to be a good 
predictor of postoperative blood loss. [105,106] Still, the question remains what 
degree of platelet inhibition is still safe to perform surgery and when and how 




MONITORING AND TREATMENT OF COAGULOPATHY
There are several causes of bleeding after cardiac surgery as summarized in 
figure 9. [108] Bleeding can be caused by insufficient reversal of heparin, leading 
to residual anticoagulation. Other causes of reduced thrombin formation can be 
the loss or dilution of coagulation factors, including fibrinogen. Circumstantial 
support for clot formation might be inadequate such as hypothermia, academia 
or hypocalcemia, as mentioned earlier. Thrombocytes might be deficient or 
dysfunctioning due to the cardiopulmonary bypass or preoperative continued 
antiplatelet therapy. Furthermore, clots may be broken down rapidly after 
formation or there might be a macrovascular (surgical) cause of bleeding. Here 














Figure 9.  Postoperative causes of bleeding (Based on: Ranucci M. Hemostatic 
and thrombotic issues in cardiac surgery. Semin Thromb Hemost; 2015 
Feb;41(1):84–90.)
The first step in the optimization of hemostasis after cardiopulmonary bypass 
is the reversal of heparin with protamine. Although protamine has been used 
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for over 50 years, still no optimal dosing regime has been established and the 
adequate reversal ratio is unknown. [109,110] For many years it was thought that 
overdosing of protamine was harmless. However, the last decades it has come 
apparent that in vitro protamine has anticoagulant properties and preventing an 
excess of protamine might reduce bleeding. [111] In chapter 2 we reviewed the 
literature for the (side)effects of protamine, the evidence for optimal protamine 
dosing and suggested directions for future research. In order to investigate if 
protamine impairs hemostasis in the clinical setting we conducted a randomized 
controlled trial to investigate the effect of high protamine dosing on hemostasis 
and outcome compared to low protamine dosing, as shown in chapter 3. 
Hereafter, we evaluated if a pharmacokinetic model for protamine dosing leads to 
more adequate protamine dosing and prevents a protamine excess (chapter 4).
After (adequate) reversal of heparin by protamine patients may show signs of 
excessive microvascular bleeding for which hemostatic treatment is required. 
Classical laboratory coagulation tests (aPTT and PT) have long turnaround times 
and the time from blood withdrawal till the test results can be up to 45 minutes. 
However, as mentioned before, a bleeding patient needs prompt treatment to 
prevent adverse outcome. A method to gain rapid insight in patients’ coagulation 
status is the use of thromboelastometry. [112] Whole blood is placed in a plastic 
cup and coagulation activators are added. A pin is placed in the cup which 
oscillates back and forth and the resistance of the oscillations are measured. This 
method assesses the viscoelastometric properties of whole blood and thereby 
several aspects of hemostasis are evaluated. The increase of the viscosity due 
to clot formation results in an increased resistance of the oscillations which 
correspond with the formation of a blood clot. The time until clot formation (e.g. 
clotting time (CT)) represents the time until the first increase in resistance, as 
shown in figure 10. The CT is mainly influenced by the amount of clotting factors, 
comparable to the classical coagulation testing (aPTT and PT). The amplification 
phase of hemostasis is represented by the alpha angle or clot formation time 
(CFT), which represents the speed of the clot formation. The maximum resistance 
of the oscillations is related to the clot thickness and corresponds with the platelet 
and fibrinogen part of the clot, represented by the maximum clot formation (MCF) 
respectively. Furthermore, there are specific tests which evaluate; the fibrinogen 
part of the clot (by inactivating the platelets; FIBTEM), the hemostatic activity with 
(INTEM) and without the heparin effect (by the addition of heparinase; HEPTEM) 















Figure 10.  Thromboelastometry trace, CT = clotting time, MCF = maximum clot firmness. 
(copyright M I Meesters 2017)
Performing thromboelastometry gives rapidly a lot of information about the 
different aspects of hemostasis and indicates which components are deficient. 
As we found that the heparinase thromboelastometry assay (HEPTEM) showed 
inconsistencies before and after cardiac surgery we evaluated the value of the 
HEPTEM test in chapter 6. Furthermore, we investigated the influence of storage 
time of the blood sample on the non-activated thromboelastometry assay (NATEM) 
in the citrated blood in chapter 7. 
Thromboelastometry has gained rapid popularity in the last decades without 
many proper studies investigating its effect on clinical practice. Most studies 
had a retrospective design and/or implementation of thromboelastometry was 
accompanied by the change of practice from fresh frozen plasma (FFP) to factor 
concentrates for coagulation factor replenishment. [113] Therefor it is difficult 
to assess if improvement of practice was caused by the implementation of 
thromboelastometry or the use of factor concentrates. Furthermore, the purchase 
of a thromboelastometry device creates more awareness for hemostatic treatment 
and can bias the study results. In chapter 10 we evaluated if the decision to 
transfuse fresh frozen plasma based on the clinical view of the attending 
anesthesiologist to transfuse FFP is in line with the findings of thromboelastometry. 
Besides thromboelastometry there are other devices which rapidly evaluate the 
clotting capacity and might guide hemostasis treatment practice, i.e. sonoclot, 
tromboelastography (TEG), point-of-care fibrinogen monitors, etcetera. In 
chapter 8 we evaluated the accuracy of a point-of-care prothrombin time (PT) 
meter 3 minutes after protamine reversal after cardiac surgery and found a 
large discrepancy between the POC and laboratory PT. In order to assess if this 
discrepancy persisted over time we conducted another investigation to assess if 
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6 or 10 minutes after protamine reversal the device would give accurate results, 
as shown in chapter 9. 
When specific coagulation deficiencies have been identified, several therapeutic 
options are available depending on the deficient component. In the case of a lack 
of coagulation factors fresh frozen plasma or prothrombin complex concentrate 
(PCC) may be transfused. PCC contains coagulation factors II, VII, IX, X, which 
are thought to be the critical coagulation factors for clot formation. PCC further 
contains the natural anticoagulants protein C and S. The advantage of PCC is 
the small volume and lack of risk for blood transfusion related events which can 
occur in FFP transfusion. Furthermore, PCC is rapid available compared to FFP 
which has to be brought from the blood bank and thawed before administration. 
Additionally, the concentration of coagulation factors is low in FFP and its 
large volume risks the patient for fluid overload. Still, PCC is more expensive 
and some clinicians argue that FFP contains all clotting factors and is therefore 
superior to PCC in restoring hemostasis. However, this argument is refuted by 
current evidence. [114] A possible advantage of FFP is the preservation of the 
glycocalyx as shown in the preclinical setting. [115,116] Furthermore, there is 
insufficient safety data on the use of PCC. As PCC was developed for the reversal 
of anticoagulation by vitamin K antagonists PCC is off-label used for bleeding 
management. [117,118] Currently there is no evidence for the advantage of PCC 
over FFP. [119] However, the evidence for FFP transfusion after cardiac surgery 
itself is insufficient. [120]
A component of fresh frozen plasma is fibrinogen, the concentration is very low 
and large quantities need to be transfused in order to raise the plasma fibrinogen 
level. [121] A more effective way to supplement fibrinogen is by administration of 
fibrinogen concentrate. [122] Recently, many studies have been published on the 
use of fibrinogen and its use seems an effective method to reduce bleeding in the 
patient with hypofibrinogemia. [123-127] Again, its safety profile has not yet been 
fully elucidated. [128] In chapter 11, we comment on the most recent and one of 
the largest trials on fibrinogen supplementation in cardiac surgery. [124]
A less known coagulation factor is factor XIII, which is activated by thrombin. 
Factor XIII is responsible for the cross linking of fibrin and stabilizes the fibrin 
network. When this factor is low or deficient the stability of the clot is reduced. 
Cardiopulmonary bypass causes a deficiency of this factor and therefor factor XIII 
has been targeted to reduce postoperative bleeding. [26,129] Still, only one study 
investigated the effect of recombinant factor XIII on postoperative bleeding in 
cardiac surgery. They found that it is reasonable to administrate f.XIII in the case of 




Besides coagulation factor deficiency, thrombocytopenia and thrombocytopathy 
are causes of bleeding after surgery. The number of platelets can easily be 
assessed by laboratory testing and thromboelastometry, with results after 
approximately 20 and 15 minutes. Thrombopenia is treated by platelet transfusion 
and according to most guidelines indicated when thrombocytes are below 
50-100*109 L-1. [131] Platelet function is more difficult to assess and recently 
it has become possible to measure the clotting capacity at the point of care, 
as mentioned before. However, the consequences of the results from platelet 
aggregometry have not fully been elucidated in current literature. [107] A possible 
treatment strategy for the treatment of platelet dysfunction is the administration of 
desmopressin. However, when given as general treatment for bleeding only a 
small reduction in postoperative blood loss is found. [132] Further studies need to 
elucidate if desmopressin might have a greater advantage in the thrombopathic 
and vWF deficient patient. [133]
As a last resort treatment option for massive coagulopathic bleeding activated 
factor VII may be considered. However, as this might cause excessive clotting, 
including in the coronaries, brain and other end organs its use should be saved 




As described, the multimodal approach to reduce bleeding and improve outcome 
is highly diverse and complex. Figure 11 gives a condensed overview of the 
current management possibilities in cardiac surgery, the themes of this thesis 
are marked grey. Although each intervention may have a small impact on clinical 































Figure 11. Multimodal patient blood management in cardiac surgery. Grey marked 
boxes = themes of this thesis. ANH = acute normovolemic hemodilution, aPTT 
= activated partial thromboplastin time, FFP = fresh frozen plasma, PCC = 
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ABSTRACT
Neutralisation of systemic anticoagulation with heparin in cardiac 
surgery with cardiopulmonary bypass requires protamine 
administration. If adequately dosed, protamine accurately neutralises 
heparin and reduces the risk of postoperative bleeding. However, as 
its anticoagulant properties are particularly exerted in the absence of 
heparin, overdosing of protamine may contribute to excessive bleeding 
and increased transfusion requirements. This review describes the 
mechanisms underlying the anticoagulant properties and side effects of 
protamine, the impact of protamine dosing on the activated clotting time 
(ACT) and point-of-care viscoelastic test results, and explains distinct 






Protamines are small, nuclear, basic, arginine-rich, positive charged proteins with 
similarities to histones that are involved in the compact folding and stabilization 
of DNA in the sperm head. Protamines are required for normal sperm function 
in most organisms. [1] Protamine was primarily isolated from salmon fish sperm 
(salmine), but is now increasingly produced through recombinant biotechnology. 
Protamine is available in a sulphate and chloride formulation, with the latter being 
the most resistant to breakdown by peptidases. 
In the first half of the 20th century, protamine was mostly used in insulin preparations 
to prolong the hypoglycaemic action of insulin. This resulted in the development of 
the effective crystalline neutral protamine Hagedorn insulin. [2] The haemostatic 
effects of protamine are first described in the beginning of the 20th century, 
[3,4] and in 1937 it was shown that protamine neutralises the anticoagulant 
effects of heparin in plasma and intact organisms [5] and humans. [6] While 
topical application of protamine on bleeding wounds in dogs did not influence 
haemostasis, it was also found that adding increasing quantities of protamine 
sulphate to fresh whole blood prolonged the clotting time. [7] These anticoagulant 
effects of protamine were appointed to interference with the conversion from 
prothrombin to thrombin. [8,9] From these studies, it became apparent that the 
dosing of protamine is crucial in the shift towards an anticoagulant effect. [7] In the 
years that followed, the anticoagulant action of protamine was noticed, but there 
was more emphasis on heparin and the heparin-neutralising potency of protamine 
and the concomitant side effects. This resulted in an imbalance between Pubmed 
publications focusing on heparin or protamine in cardiac surgery, although the 
attention for heparin also decreased over the last decades (Figure 1). 
While protamine is indispensable in cardiac surgery with cardiopulmonary bypass 
and off-pump cardiac surgery, the ignorance of the anticoagulant properties of 
excessive protamine may result in prolonged bleeding and increased transfusion 
requirements, and increasing attention for adequate dosing is therefore warranted. 
The objective of this review was to present an overview of the anticoagulant 
properties and side-effects of protamine, the evidence for the unfavourable 
effects of protamine overdosing on patient haemostasis, and suggestions for 
optimization of protamine dosing for heparin neutralisation.
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Figure 1.  Pubmed hits for [Heparin] and [Cardiac Surgery] (gray line) and [Protamine] 






Protamine is a highly positive charged peptide consisting of about 32 amino 
acids, and neutralises the effect of heparin through electrostatic binding between 
the cationic arginine groups of protamine and the anionic heparin. Therefore, 
the empirical dosing of protamine is 1 IU for 1 IU heparin (1:1). The resulting 
neutral protamine-heparin salt aggregates are clearly visible as white suspension, 
and are formed within seconds. [10] In parallel, the binding of protamine to 
heparin dissociates the antithrombin-heparin complex, leading to recovery of 
original antithrombin activity. [11-14] The neutralisation of heparin by protamine 
is further influenced by platelet factor 4 (PF4), a heparin-binding protein 
excreted by activated platelets. PF4 is complimentary to protamine regarding 
heparin neutralisation.15 In case of vessel wall damage, PF4 overcomes the 
anticoagulation effect of the endothelium. During extracorporeal circulation, PF4 
release contributes to the stability of the protamine-heparin complex. [15]
Pharmacokinetics
Protamine has a relatively short half-life of about 10 minutes in healthy volunteers 
in the absence of heparin administration. [16] Protamine has a rapid onset of 
action, with a heparin-neutralising effect within 5 minutes. In patients undergoing 
cardiac surgery with CPB, 250 mg of protamine sulphate administered as infusion 
over 5 minutes in the presence of heparin showed a clearance of protamine of 
1.4 L min-1 and a half-life between 1.9 and 18 minutes. [17] Although there is 
almost no insight in the metabolism of the neutral protamine-heparin salt complex, 
the protamine-heparin complex may lead to antibody formation and side effects 
which are described below.
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ANTICOAGULANT PROPERTIES OF PROTAMINE
While protamine primarily neutralises heparin, protamine has anticoagulant 
properties that are attributed to an interaction with platelet function, interference 
with coagulation factors and stimulation of clot breakdown. The effects of 
protamine on these different functions in the haemostasis system are summarized 
in figure 2.
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Figure 2.  Overview of the haemostatic actions of protamine. Protamine not only neutralises 
heparin but also interferes with platelet function, the generation and activation 
of coagulation factors and potentiates clot lysis. ATIII = antithrombin, GP1b = 
glycoprotein Ib; vWF = von Willebrand Factor.
Interaction with platelet function
The effect of protamine on platelet function was first described in 1949, showing 
thrombocytopenia after protamine exposure. [18] Although this effect is nowadays 
ascribed to protamine-heparin complex antibody formation, protamine also 
directly activates platelets and reduces the response of platelets to thrombin. [19-
21] Barstad and colleagues further showed that the glycoprotein Ib interaction 
with surface-bound von Willebrand Factor (vWF) is reduced by protamine, leading 
to disturbed platelet adhesion to the damaged vessel wall. [22]
A recent study showed that protamine reduced platelet aggregation by 50% 
in heparinized patients undergoing cardiac surgery with CPB. [23] This study 
was however limited by a 1:1 protamine-to-heparin dosing ratio that was 
calculated for the total heparin dose administered during CPB regardless of 
heparin consumption. [23] Similar findings were reported in patients undergoing 




protamine-to-heparin ratios exceeding 1. [24] In vitro studies show that blood 
spiked with increasing doses of protamine reduces ADP-induced platelet 
aggregation. However, all studies used relatively high protamine-to-heparin ratios 
ranging from 1:1 to 10:1. [23-25] Using a protamine titration method, Shigeta and 
colleagues showed in a small patient study that the platelet inhibitory effects of 
protamine are indeed dose-dependent, and can be minimized by adaptation of 
the protamine dose to the residual heparin concentration at the end of CPB. [21]
Interference with coagulation factors
In vitro experiments previously elaborated that protamine mediates down-
regulation of thrombin generation leading to a reduced conversion of fibrinogen 
to fibrin, [26,27] reduces the rate of factor V activation by thrombin and factor 
Xa,28 and decreases factor VII activation by tissue factor thrombin activity. [29] 
In haemophilia patients, a direct drop in factor VII clotting activity was observed 
upon protamine dose ranges between 30 and 100 μg ml-1, irrespective of the 
presence of heparin. [30]
In a study in patients receiving a high or low protamine-to-heparin ratio, the 
recovery of thrombin generation following heparin neutralisation was impaired in 
the high protamine dosing group. [31] Others showed that part of the inhibitory 
effects of protamine on thrombin generation is neutralised by the addition of 
platelets or increased factor VIII/vWF concentrations. [32,33] The aforementioned 
observations could also be confirmed during functional viscoelastic testing, 
showing that incremental doses of protamine or protamine-to-heparin dosing 
ratios > 1 resulted in a prolonged clotting time of the intrinsic coagulation 
test. [31,32,34,35] Rotational thromboelastometry experiments show that the 
administration of extra protamine in cardiosurgical patients with an abnormal 
activated clotting time after CPB results in a brief prolongation of clotting times. 
[36] In agreement with these findings, it was also shown that protamine prolongs 
the clot initiation time in thromboelastography, and impairs clot kinetics and 
platelet function. [37] From these observations, it can be concluded that protamine 
may interfere with coagulation factors involved in clot formation, although this 
association is mostly seen for higher protamine doses.
Stimulation of clot breakdown
The decreased thrombin levels associated with protamine administration may 
also negatively influence the fibrinolytic system. [38,39] In vitro experiments in 
human plasma showed that protamine reduces clot strength and reduces the 
time to clot lysis, and enhances tissue-type plasminogen activator mediated 
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fibrinolysis, thereby promoting clot breakdown. [38] These observations could be 
counteracted by the addition of tissue factor to the plasma samples. [38] Although 
protamine-related hyperfibrinolysis might be of relevance in cardiac surgery with 






Protamine administration is associated with immunological and inflammatory 
alterations, and may induce an anaphylactic response with hypotension, 
bradycardia, pulmonary vasoconstriction and allergy as most frequent reported 
side effects.40,41 The reported incidence of anaphylactic reactions varies from 
0.06% to 10.6%.40 Patient risk factors for an anaphylactic response include 
treatment of diabetes mellitus with protamine-containing insulin and allergies for 
fish proteins. [41]
Antibody formation and protamine-induced thrombocytopenia
Protamine reactions are a complication of protamine infusion, and caused by 
IgE and IgG antibody formation. [42-44] In addition, the heparin-protamine 
complexes that are generated following protamine infusion have been shown 
to be immunogenic in several species. Incubation of 125I-labeled protamine with 
blood cells in the presence of heparin resulted in tight binding of protamine to 
platelets and granulocytes. [45] It was further demonstrated that 29% of the 
patients develop antibodies to the protamine-heparin complex within the first 
month following cardiopulmonary bypass. [43] These antibodies can trigger 
neutrophil activation44 and activate platelets in vitro. [46-49] The latter results 
in a decrease in the platelet aggregation capacity as measured by multiple 
electrode aggregometry. [24] In vitro studies further showed an association 
between protamine-related antibodies and thrombocytopenia. [49,50] However, 
only a small percentage of patients with postoperative thrombocytopenia reveal 
protamine-heparin complex antibodies. [46] Moreover, there is no evidence that 
protamine-heparin antibodies are associated with unfavourable clinical outcome. 
[47,48]
Complement activation
Exposure to cardiopulmonary bypass activates the complement system through 
the alternative pathway, while protamine administration is associated with 
complement activation through the classic C4a pathway. [51-54] In particular, in 
vitro experiments demonstrate that protamine-induced complement activation is 
mediated by C-reactive protein. [52] The cumulative activation of both complement 
pathways by the extracorporeal circuit and protamine may contribute to a pro-
inflammatory response following cardiac surgery.
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Vasoplegia
Infusion of protamine is frequently associated with a transient drop in blood 
pressure and a rise in pulmonary arterial pressure. [55] In vitro studies revealed 
that vascular reactivity to protamine is most likely mediated by alterations in 
mechanical stretch-induced intracellular endothelial calcium release [56] and 
nitric oxide production. [57] Unwanted effects of protamine on perioperative 
blood pressure can be prevented by administration of a H1-H2 blocker or 
hydrocortisone and methylene blue. [41,58]
Pulmonary hypertension
Pulmonary hypertension is the most severe clinical complication following a 
protamine-induced anaphylactic response. Comunale and colleagues reported 
a protamine-induced pulmonary hypertensive response defined as in increase 
in mean pulmonary arterial pressure of > 7 mmHg in 0.6% of patients. [59] In a 
second report, 1.78% of patients developed pulmonary hypertension with right 
ventricular failure following protamine administration. [60] It is assumed that 
thromboxane release underlies the pathophysiological mechanism underlying 
this severe complication, [61-64] and can be treated by prostacyclin EI infusion. 
[60,65] Others suggested that protamine-induced pulmonary hypertension is an 
anaphylactic response, which can be prevented by continuation of acetylsalicylic 
acid intake before surgery. [59] Due the low incidence of pulmonary hypertension 
following protamine infusion, clinical data on this topic are mainly restricted to 
case reports.
Rate and location of protamine infusion
The protamine-related haemodynamic side effects are enlarged when protamine 
is rapidly infused over a 3-minute period when compared a 15-minute infusion 
period. [66] Moreover, slow infusion of protamine over a 30-minute period was 
associated with a favourable postoperative coagulation profile when compared 
to fast bolus administration. [14] Chaney and colleagues investigated whether 
the location of protamine infusion influenced the adverse event rate. [67] They 
showed that administration of protamine via the ascending aorta was the least 
associated with blood pressure an arterial oxygenation changes when compared 
to administration through the central venous line, albeit that the changes were not 




Point-of-care haemostatic testing for protamine effects
Point-of-care coagulation tests for perioperative anticoagulation monitoring in 
cardiac surgery are primarily used to detect heparin anticoagulation and residual 
heparin. However, due to the effects of protamine on the coagulation system, 
these tests may also be affected by protamine itself.
Activated clotting time
The celite or kaolin activated clotting time (ACT) is typically used to assess the 
heparin neutralising effects of protamine following CPB. Theoretically, the ACT 
should return to preoperative values after protamine administration. Yet, there is 
substantial evidence that the post-protamine ACT does not accurately reflect the 
levels of residual heparin. In particular, the ACT even increases with incremental 
protamine-to-heparin dosing ratios. [25] It was further shown that a prolonged ACT 
following heparin neutralisation by 1:1 protamine administration has no predictive 
value in detecting residual heparin. [68] Others also reported these observations, 
with a weak correlation between ACT values and heparin concentrations. [69-71] 
Interestingly, several reports show that, despite the use of different protamine-
to-heparin dosing ratios in comparative study arms, post-protamine ACT values 
were comparable. [72-74] These findings suggest that the protamine dose and 
post-CPB ACT value are only marginally associated.
Heparinase-containing viscoelastic test
The worldwide reintroduction of viscoelastic testing for haemostasis monitoring 
in cardiac surgery allows specific evaluation of residual heparin following 
cardiopulmonary bypass. However, the heparinase-containing INTEM rotational 
thromboelastometry test for intrinsic coagulation monitoring (HEPTEM) has 
also shown to be sensitive for protamine overdosing. In particular, the INTEM 
is prolonged in case of higher protamine-to-heparin dosing ratios. [35-37,48,75] 
The reason for this effect of protamine is unrevealed, but the observation has now 
been included as warning in the device manual by the manufacturer. In addition, 
Levin et al. showed that thromboelastography is responsive to different doses of 
protamine and might be used as method for protamine titration. [76] In summary, 
these data suggest that users of viscoelastic test devices should be aware of 
the test-modulating effects of both heparin and protamine, and that these tests 
should be interpreted accordingly.
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PROTAMINE DOSING STRATEGIES
The 2011 Update to The Society of Thoracic Surgeons and the Society 
of Cardiovascular Anesthesiologists Blood Conservation Clinical Practice 
Guidelines recommend protamine titration or empiric low dosing regimens in 
order to reduce postoperative bleeding and transfusion requirements. [77] In 
the management of severe perioperative bleeding guidelines from the European 
Society of Anaesthesiology it is suggested that heparin monitoring using heparin 
concentration-based approaches are associated with smaller protamine doses, 
but that a protamine-to-heparin ratio of 1.3:1 is still common. [78] 
Ideally, protamine dosing should be guided by its effect on patient haemostasis 
by means of the ACT. However, because the ACT is hardly associated with post-
CPB heparin levels, [69-71] and additional protamine administration based on 
a prolonged post-CPB ACT when compared to pre-CPB levels can be harmful 
instead of beneficial for patient haemostasis. The quality of evidence on this 
topic is moderate. Current protamine dosing practices are based on protamine-
to-heparin dosing ratios, low anticoagulation strategies, model-based titration or 
measurement-based titration.
Ratio-based dosing
Protamine-to-heparin dosing ratio strategies vary among institutions, and are 
subjected to local conventions. The dosing ratio is either based on the initial 
heparin dose or the total heparin dose administered during surgery. Protamine 
dosing only based on the initial heparin dose takes heparin consumption during 
bypass into account. The number of clinical studies focusing on the impact of 
different protamine-to-heparin dosing ratios on postoperative bleeding and 
transfusion requirements is limited. 
Despotis and colleagues used a protamine-to-heparin dosing ratio of 0.8 for 
the total heparin dose administered, with the possibility to infuse additional 
protamine in case of a post-CPB ACT that did not return to pre-CPB levels. [79] 
In a multivariate analysis, they showed that a larger total protamine dose was 
associated with a higher risk of postoperative transfusions. [79] Others reported 
prolonged activated clotting times, [25] abnormal viscoelastic clotting times [37] 
and impaired ADP-induced platelet aggregation [25] when the protamine-to-
heparin dosing ratio was above 1.3. In a small prospective study, randomisation 
of patients to a 0.8 versus 2.0 protamine-to-heparin dosing ratio revealed that 
high protamine dosing was associated with changes in platelet count and platelet 




Our group showed that a protamine-to-heparin dosing ratio of 1.3 based on 
the total dose of heparin administered throughout the procedure associates 
with coagulation abnormalities, lower post-protamine thrombin levels and 
postoperative bleeding when compared to a protamine-to-heparin dosing ratio of 
0.8. [32] In contrast, one retrospective study and one randomised trial revealed 
that a higher protamine dose regime was associated with better clinical outcome 
when compared to a lower protamine dose, albeit that both studies were limited 
by excessive volumes of postoperative blood loss. [80,81] Except for the study 
by Meesters et al. [32] none of abovementioned studies were powered to detect 
a difference in postoperative blood loss or transfusion requirements.
Low systemic anticoagulation strategies
Full heparin anticoagulation to achieve a target ACT exceeding 480 seconds is 
considered gold standard in cardiac surgery. In contrast, low anticoagulation 
protocols in combination with a tip-to-tip biocompatible coated extracorporeal 
circuit, aim for a target ACT of 250-300 seconds based on the assumption that 
excessive heparin is unfavourable for postoperative patient haemostasis. [82-84] 
Consequently, the total dose of protamine administered in these studies is reduced 
by about 50% due to the lower anticoagulation approach. [83,84] A lower dose of 
protamine may decrease the risk for an anaphylactic reaction. While low systemic 
anticoagulation strategies seem to be associated with reduced postoperative 
bleeding and transfusion, [82-84] the wide adaptation of these protocols is limited 
due to the presumed safety aspects associated with a low target ACT.
Model-based titration of protamine
There is increasing interest in the application of mathematical or pharmacokinetic 
algorithms for heparin and protamine dosing to support optimization of perioperative 
systemic anticoagulation in cardiac surgery. In particular, the estimation of 
a post-CPB heparin level may improve the accuracy of protamine dosing. Jia 
and colleagues developed a two-compartment pharmacokinetic (PK) model 
based on anti-FIIa levels to predict heparin concentrations during hypothermic 
cardiac surgery. [85] They suggested that their approach would result in a lower 
protamine dose regime after termination of CPB. [85] Others developed a formula 
based on perioperative kaolin ACT measurements to calculate the post-CPB 
protamine dose, which resulted in a decrease in protamine dosing compared 
to a conventional group. [86] However, the study was biased by the excessive 
volumes of chest tube drainage in both groups. [86]
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In a group of patients receiving heparin and protamine based on an empirically 
based algorithm protamine dosing was reduced without any significant difference 
in postoperative bleeding in the algorithm group. [87] Davidsson and colleagues 
developed a statistical model based on body surface area, the administered dose 
of heparin, heparin clearance and the preoperative platelet count, that predicted 
the required dose of protamine in accordance with the haemostasis management 
system as reference. [88] In a second study, the same investigators implemented 
this model in a randomised controlled fashion and compared protamine dosing 
and postoperative coagulation with patients exposed to a protamine-to-heparin 
dosing ratio of 1:1. [89] While the heparin dosing was similar in both groups, they 
showed a reduction in protamine dosage from 426 ± 43 to 251 ± 66 mg, which 
was paralleled by more favourable postoperative haemostatic test results. [89] 
Interestingly, post-protamine ACT values were similar among groups. Using a 
pharmacokinetic two-compartment model, we showed in a retrospective fashion 
that patient-tailored protamine dosing was associated with a 50% reduction 
in the protamine-to-heparin dosing ratio and more favourable postoperative 
haemostatic test results when compared to patients subjected to a conventional 
protamine dosing strategy. [90] The abovementioned studies suggest the need 
for a more accurate protamine dosing strategy in cardiac surgery, but all have 
methodological limitations, including insufficient statistical power. Further studies 
are required to evaluate the benefits of a calculated protamine-based algorithm 
for patient bleeding and transfusion requirements.
Protamine titration based on heparin measurements
Titration of protamine based on measured heparin levels following CPB may 
improve the accuracy of heparin neutralisation and contribute to preserved 
patient haemostasis. Protamine titration is usually based on the measured heparin 
concentration or anti-Xa levels. There are several publications available focusing 
on the effects of protamine titration on postoperative outcome in cardiac surgery, 
with conflicting results. In order to understand the impact of inadequate protamine 
dosing, a theoretical distinction should be made between the effects of protamine 
underdosing and overdosing (Figure 3).
The most frequent clinically applied method for protamine titration is based on 
the measurement of post-CPB heparin levels using a haemostasis management 
system (HepCon/HMS®) or Hemochron RxDx device. Despite several attempts 
to develop novel protamine titration assays, including ultracentrifugation or 
an automatic protein dose assay, these methods never gained widespread 





























Figure 3.  Hypothetical relation of protamine dosing with bleeding complications. 
While protamine underdosing is associated with residual heparin, protamine 
overdosing may lead to bleeding complications due to the anticoagulant 
properties of protamine in the absence of heparin.
Supplemental Table I provides an overview of comparative studies that appeared 
between 1990-2017 of conventional ACT-based heparin and protamine 
management with protamine titration based on blood heparin concentrations 
measured by Hepcon/HMS, RxDx or a protamine dose assay. [21,71,92-106] 
The majority of these studies reported non-clinical outcomes, including heparin 
or protamine dose, [71,92,94,100,103] thrombin antithrombin levels or thrombin 
potential, [93,99,102] haemostatic activation [95,96] or platelet function [21,96] 
as study endpoints. Only a few studies were primarily designed to study the 
association of protamine titration with postoperative blood loss and/or transfusion 
requirements, [98,101,104-106] but frequently without providing a sample size 
calculation. [98,104-106]
The protamine-to-heparin dosing ratios (P:H) are either based on the initial heparin 
dose [92,96,102,106] or total heparin dose, and ratios reported in these studies 
vary from 0.33 [21] to 1.3. [106] In half of the studies, a reduction in the protamine-
to-heparin dosing ratio was associated with improved haemostatic [21,95,96,102] 
or clinical outcome. [71,97,98,105,106] One group showed no benefit of 
protamine titration on 12-hour blood loss, but this can be explained by almost 
similar protamine-to-heparin dosing ratios in the ACT group (0.84) and protamine 
titration group (0.86). [93] Others reported no difference in postoperative blood 
loss when an ACT and protamine titration strategy were compared, [99-101,104] 
albeit that two studies were not designed to show differences in postoperative 
bleeding. [99,100] Finally, two studies reported increased blood loss after 
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protamine titration. The first study found increased 6-hour blood loss in the 
protamine titration group, but this study was limited by the relatively high reported 
6-hour bleeding volumes. [103] Albeit not the primary endpoint, the second study 
also reported higher 12-hour blood loss volumes in the protamine titration group. 
[94] It is however unknown whether the mixed inclusion of on-pump, OPCAB and 
miniaturized extracorporeal therapy cases and absent publication of concomitant 
ACT values may have influenced this outcome. [94]
In summary, despite the availability of several protamine titration studies, the 
quality of studies is limited and clinical outcomes were only rarely used as primary 
study endpoint. Moreover, the wide range in publication years (1994-2015) may 
introduce a bias, as cardiosurgical strategies have been largely improved over the 
last decade. In particular, modern cardiosurgical practices frequently implement 
a multifactorial and multidisciplinary patient blood management program to 
reduce transfusion rates. Larger randomised controlled trials in the modern 
cardiosurgical setting are warranted to understand the impact of protamine 
titration on postoperative blood loss and transfusion requirements.
Protamine-to-heparin dosing ratio and postoperative blood loss
In order to gain insight in the association of protamine-to-heparin dosing ratios 
and 12-hour blood loss an analysis was performed of studies comparing distinct 
protamine dosing strategies based on a fixed ratio, [32] model-based protamine 
titration [89,90] and protamine titration based on heparin measurements [72,93-
95,98,99] and reported 12-hour blood loss (Figure 4). With a moderately good 
correlation, we here show that there might be a trend between protamine dosing 
and postoperative blood loss, albeit that these data have methodological 
limitations and are mostly retrieved from studies where postoperative outcome 
was not the primary endpoint, from mixed cardiosurgical populations with different 
perioperative strategies.
Additional protamine administration
When the post-protamine ACT exceeds the pre-CPB ACT, it is common in some 
hospitals to add additional protamine doses for neutralisation of residual heparin. 
However, in light of the weak association between post-protamine ACT levels 
and residual heparin, [25,68-71] it is unclear whether these additional protamine 
doses act as heparin neutralising agent or anticoagulant. Consequently, the 
administration of additional doses of protamine after compensating for the heparin 





































Figure 4.  Association of the protamine-to-heparin dosing ratio and 12-hour postoperative 
blood loss. Numbers refer to citations in the reference list.
In 1968, Berger et al. already showed that administration of protamine in smaller 
aliquots resulted in sufficient restoration of clot formation after the first dose when 
compared to a full protamine dose, resulting in a protamine dose administration 
of 1.37 versus 0.79 mg for every 100 IU of heparin, respectively. [107] Others 
showed that the administration of additional protamine resulted in an increased 
clotting time. [37] In a small randomised controlled study, a substantial number of 
patients received additional protamine doses in the absence of residual heparin, 
and this approach was associated with increased postoperative blood loss. [108]
Although the number of studies focusing on additional protamine dosing is low, 
there is substantial evidence that protamine dosing should not be adjusted 
based on the post-protamine ACT, as this coagulation test does not reflect the 
presence of residual heparin. Caution is warranted when additional protamine is 
administered in case of oozing, since there is no evidence that this approach is 
beneficial for patient haemostasis and postoperative bleeding.
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AVOIDANCE OF HEPARIN REBOUND
Heparin rebound is the recurrence of anticoagulant activity after heparin 
neutralisation with protamine, and is frequently attributed to protamine 
underdosing. Heparin rebound is a feared phenomenon, as it might contribute to 
postoperative bleeding and increased transfusion requirements. The phenomenon 
is complicated by the diversity in definitions of heparin rebound, and the absent 
accuracy of most coagulation tests to detect heparin rebound. [109] In particular, 
in most studies the definition of heparin rebound is only limited to the presence 
of heparin in blood, without investigating its effect on postoperative bleeding 
complications.
It was recently shown that heparin rebound might be of less importance as 
cause for postoperative bleeding than previously assumed, showing only a weak 
association between post-protamine heparin levels and volume of blood loss. 
[110] Indeed, both low and high protamine dose approaches are associated 
with similar incidences of heparin rebound. [104] Additionally, we showed that 
post-protamine heparin concentrations at 3 and 30 minutes after protamine 
administration were similar in high and low protamine dosing ratio groups, 
and no heparin rebound in the late postoperative period was reported. [32] In 
particular, the high protamine-to-heparin dosing ratio was associated with more 
postoperative bleeding. [32] 
A low dose protamine infusion (25 mg h-1 for 6 hours) following heparin neutralisation 
prevented heparin rebound as defined by the thrombin clotting time and anti-FXa 
levels. [111] They further showed that a protamine infusion aborts the presence 
of heparin following surgery, which was associated with a non-relevant reduction 





A strategy to avoid the side effects and dosing complications of protamine is the use 
of alternatives for unfractionated heparin or protamine. The direct thrombin inhibitor 
bivalirudin is the most commonly used replacement for heparin anticoagulation. 
Bivalirudin has no antidote and is eliminated with a half-life of approximately 25 
minutes, thereby avoiding the use of protamine. [112] In a randomised controlled 
trial, Dyke et al. showed that bivalirudin can be safely and effectively used for 
systemic anticoagulation during cardiac surgery, without differences in blood 
loss and clinical outcome compared to heparin anticoagulation. [113] However, 
as stasis should be avoided during bivalirudin, this anticoagulation therapy 
requires adjustments of perfusion approaches, and a widespread adaptation of 
this approach is slow. Moreover, the costs of bivalirudin outweigh the costs of 
heparin and protamine, and its use is therefore mainly restricted to patients with 
i.e. heparin-induced thrombocytopenia (HIT) and HIT antibodies. [114]
Due to the side effects of protamine, several experimental alternatives have 
been suggested, [115] including platelet factor [4,116] heparinase [20,117] and 
hexadimethrine. [118] Although their heparin-neutralising capacities could be 
proved, widespread introduction in the clinical setting has not yet been realized.
CONCLUSION
Protamine reversal of heparin anticoagulation is a necessary evil in cardiac 
surgery with or without cardiopulmonary bypass, and can be associated with 
haemostatic abnormalities when inadequately dosed. The available evidence 
suggests that protamine administration based on the initial heparin dose should 
target a ratio below 1:1 in order to prevent protamine-related coagulopathy and 
bleeding. However, large randomised controlled trials are warranted to improve 
the quality of evidence for this topic. 
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ABSTRACT 
While experimental data state that protamine exerts intrinsic 
anticoagulation effects, protamine is still frequently overdosed for 
heparin neutralization during cardiac surgery with cardiopulmonary 
bypass (CPB). Since comparative studies are lacking, we assessed 
the influence of two protamine-to-heparin dosing ratios on perioperative 
haemostasis and bleeding, and hypothesized that protamine overdosing 
impairs the coagulation status following cardiac surgery.
In this open-label, multicentre, single-blinded, randomized controlled 
trial, patients undergoing on-pump coronary artery bypass graft surgery 
were assigned to a low (0.8; n=49) or high (1.3; n=47) protamine-to-
heparin dosing group. The primary outcome was 24-hour blood loss. 
Patient haemostasis was monitored using rotational thromboelastometry 
and a thrombin generation assay.
The low protamine-to-heparin dosing ratio group received less 
protamine (329 ± 95 vs. 539 ± 117 mg; P<0.001), while post-protamine 
activated clotting times were similar among groups. The high dosing 
group revealed increased intrinsic clotting times (236 ± 74 vs. 196 ± 
64 s; P=0.006) and the maximum post-protamine thrombin generation 
was less suppressed in the low dosing group (38 ± 40% vs. 6 ± 9%; 
P=0.001). Postoperative blood loss was increased in the high dosing 
ratio group (615 ml; 95% CI 500 – 830 ml vs. 470 ml; 95% CI 420 – 530 
ml; P=0.021) when compared to the low dosing group, respectively. 
More patients in the high dosing group received fresh frozen plasma 
(11% vs. 0%; P=0.02) and platelet concentrate (21% vs. 6%; P=0.04) 
compared to the low dosing group. 
Our study confirms in vitro data that abundant protamine dosing 
is associated with increased postoperative blood loss and higher 
transfusion rates in cardiac surgery. 
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INTRODUCTION
Protamine is used to neutralize the anticoagulant effects of heparin during 
cardiac surgery with cardiopulmonary bypass (CPB). [1-3] While under dosing 
of protamine may result in residual heparinisation and prolonged anticoagulation, 
protamine overdosing is associated with impaired clot formation exerted by the 
intrinsic anticoagulation properties of protamine itself. [4-6] Protamine inhibits 
the activation of coagulation factors, thrombin formation, platelet activation and 
enhances fibrinolysis. [7-13]
In 1968 Berger et al. already showed that reducing the protamine-to-heparin 
dosing ratio from 1.37 to 0.79 was associated with reduced postoperative blood 
loss and fewer rethoracotomies. [14] Moreover, individualized protamine dosing is 
associated with better coagulation parameters and less bleeding. [6,15] Despite 
these potential benefits, the optimal protamine dosing in cardiac surgery has only 
been scarcely investigated. Current guidelines advise empiric low protamine 
dose regimens, but these are only low class evidence recommendations due to 
scarce and inconsequent study results. [16-18] Moreover, as an artificial safety 
net, it is not uncommon that additional doses of protamine are administered in 
case of an oozing operation field after weaning from CPB, elevated post-pump 
activated clotting time (ACT) levels, or in case of a high postoperative thoracic 
drain production. [19]
The objective of this randomized controlled study was to investigate whether 
reducing protamine dosing based on a fixed protamine-to-heparin dosing ratio 
is associated with reduced postoperative bleeding and decreased allogeneic 
blood transfusions requirements. We therefore compared a dosing ratio of 1.3 
with 0.8 in patients undergoing coronary artery bypass graft surgery with CPB, 
and hypothesized that the high protamine-to-heparin dosing ratio deteriorates 
haemostasis and is associated with more postoperative blood loss.
72 
Part I: Prevention of coagulopathy
MATERIALS AND METHODS
Study population
This open-label, multicentre, single-blinded, randomized controlled parallel-
group, superiority clinical trial was performed in the departments of cardiac 
anaesthesiology and cardio-thoracic surgery of the VU University Medical 
Centre (VUmc; Amsterdam, the Netherlands) and Medical Centre Leeuwarden 
(MCL; Leeuwarden, the Netherlands). Both hospitals had their own dedicated 
anaesthesia and surgical team for cardiothoracic surgery, and there was no 
exchange of anaesthesiologists or surgeons between centres. The protocol was 
approved by the Human Subjects Committee of both centres, and registered in 
the Netherlands Trial Register (NTR3528). All eligible patients were approached 
for informed consent by a dedicated investigator, and patients included in the 
study protocol provided written consent. Patient inclusion started January 2013 
and ended January 2015.
Patients aging 18-85 years were eligible in case of elective first-time coronary 
artery bypass graft (CABG) surgery with CPB. Exclusion criteria were emergency 
surgery, a body mass index (BMI) < 18 kg m-2 or > 35 kg m-2, haematology 
disorders, renal replacement therapy and the preoperative use of heparin or 
heparin-like medication. The primary study endpoint was 24-hour blood loss. 
Study procedure
Patients were randomly assigned by a sealed envelope method through block 
randomization for both centres. Groups were based on the protamine-to-heparin 
dosing ratio after CPB, which was calculated based on the total amount of 
heparin administered to the patient. One group received a low protamine-to-
heparin dosing ratio of 0.8 (0.8:1.0; total amount of heparin administrated (mg) 
* 0.8 = protamine dose (mg)), while the second group received a high ratio of 
1.3 (1.3:1.0; total amount of heparin administrated (mg) * 1.3 = protamine dose 
(mg)). Both participating centres routinely used a protamine-to-heparin dosing 
ratio of 0.8 based on the total heparin dose, while the European perioperative 
bleeding guideline advises a protamine-to-heparin dosing ratio of 1.0-1.3. [17] We 
chose to compare our routine dosing ratio with the higher end of the spectrum, a 
protamine-to-heparin dosing ratio of 1.3. Patients were blinded for the allocated 
group.
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Anaesthesia and cardiopulmonary bypass
According to clinical routine in both participating centres, acetylsalicylic acid was 
continued throughout the perioperative period, while clopidogrel was discontinued 
at least 5 days before surgery. Patients were anaesthetized according to local 
protocols based on a combination of sufentanil 3-7 μg kg-1, rocuronium 0.6 mg 
kg-1 and midazolam 0.1 mg kg-1 for anaesthesia induction and tracheal intubation. 
Propofol (0.1–1.3 mcg kg-1 min-1) with or without isoflurane/sevoflurane was used 
for maintenance of anaesthesia. In both centres, all patients received tranexamic 
acid. CPB was performed at a blood flow (2.2-2.4 l min-1 m-2) during normo- or 
mild hypothermia (> 34oC) using either a C5 or S5 heart-lung machine (Stöckert 
Instrumente GMBH, Munich, Germany) or HL-30 heart-lung machine (Maquet, 
Cardiopulmonary AG, Hirrlingen, USA) with a centrifugal pump and biocompatible-
coated circuit. Cell salvage was applied throughout the surgical procedure in 
both centres. 
Heparin and protamine management
Heparinisation started with an initial bolus of 300 IU kg-1 heparin (LEO Pharma 
BV, Amsterdam, the Netherlands), to achieve an activated clotting time (ACT) 
test of 480 seconds. If necessary, additional doses of heparin (5000 IU) were 
administered to maintain this target ACT. The priming solution (1400 ml) contained 
5000 IU (VUmc) or 7500 IU (MCL) heparin. After weaning from CPB, heparin 
was reversed by manual infusion of the calculated dose protamine hydrochloride 
(Meda Pharma BV, Amstelveen, the Netherlands) according to the subsequent 
study arm. The amount of protamine was in accordance with the study arm 
definitions based on the total amount of heparin that was given throughout the 
whole procedure, including the heparin administered during CPB. It was not 
allowed to administer an additional protamine after the study bolus was infused.
Local blood transfusion algorithm
The transfusion of packed red blood cells (PRBC) was based on the Dutch 
transfusion guidelines, recommending transfusion if haemoglobin levels below 
9.7 g dL-1 (6 mmol L-1) in case of ASA IV patients, patients with symptomatic 
cerebrovascular disease, sepsis, heart failure, or severe pulmonary disease. 
PRBC transfusion is advised in case of haemoglobin levels below 8.1 g dL-1 (5 
mmol L-1) in case of acute blood loss from one bleeding focus in a normovolemic 
ASA I patient aging > 60 years, in case of fever or following cardiac surgery. 
Fresh frozen plasma (FFP) or platelet transfusion was performed in case of clinical 
signs of persistent nonsurgical bleeding (oozing). When laboratory coagulation 
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test results were available, FFP was transfused when the international normalized 
ratio (INR) of the prothrombin time exceeded 1.5. Additional platelet concentrate 
administration was indicated in case of extended bypass times, clinical signs of 
bleeding and/or a platelet count below 75*109 l-1. 
Blood sampling
After anaesthesia induction, the first blood sample was collected for baseline 
haemostatic measurements (Pre-CPB). Blood was drawn in a citrated tube from 
the radial artery catheter. Three minutes (PROT-3) and thirty minutes (PROT-30) 
after protamine administration, the second and third blood samples were drawn. 
Blood for plasma determinations and thrombin generation measurements was 
only sampled in the VU University Medical Centre, Amsterdam, the Netherlands. 
At all three time points, blood was centrifuged and platelet-free plasma was 
extracted. Plasma was stored at -80 oC for further analysis.
Thromboelastometry
Rotational thromboelastometry™ (ROTEM delta; TEM International, Munich, 
Germany) was immediately started following blood withdrawal, and included the 
intrinsically activated coagulation test (INTEM), extrinsically activated coagulation 
test (EXTEM), fibrin polymerization test (FIBTEM) and the intrinsically activated 
coagulation test without heparin effect (HEPTEM). [20] Clot formation was 
assessed by the clotting time (CT) or the maximum clot firmness (MCF). 
Coagulation parameters
Routine laboratory testing of the international normalized ratio (INR) of the 
prothrombin time (calcium thromboplastin) and the activated partial thromboplastin 
time (aPTT; cefaline) were determined in platelet-free plasma. Other haemostatic 
parameters included the activated coagulation time (ACT; Hemochron, ITC 
Medical, Edison, NY), haemoglobin levels and platelet count. Blood samples for 




Plasma levels of antithrombin III (ATIII), heparin and platelet factor 4 (PF4) were 
not corrected for hemodilution during CPB. Antithrombin (ATIII) concentrations 
were determined in plasma diluted 40 times in 50 mM Tris-HCl buffer (pH 7.4). 
A calibration curve was made by diluting purified ATIII in eight steps of 1:1 in 
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Tris buffer starting at 12 µg ml-1. Fifty µl heparin (1 IU ml-1) / thrombin (5 IU ml-1) 
mixture in Tris buffer was added to 50 µl of diluted plasma in a microtiter plate 
and prewarmed for 2 minutes in an incubator at 37 ºC. Then 50 µl Substrate 
2238 (2 mM) in Tris was added to each well and incubated for 2 minutes at 37ºC. 
The color formation was stopped by addition of 2% citric acid. The yellow color 
was measured at 405 nm in a spectrophotometer (Power Wave 200, Bio Tek 
Instruments, Vermont, USA).
Heparin concentration by Xa inhibition
Fifty µl Xa solution (1.75 nkat) in Tris buffer pH 5.6 was added to 50 µl plasma 
and 25 µl Tris in a microtiter plate. A standard curve was made from serial diluted 
heparin in Tris buffer and normal human plasma. The baseline OD 405 nm was 
measured in a spectrophotometer and then 50 µl Substrate S2222 (2 mM) was 
added. The microplate was sealed and incubated for 30 minutes at 37ºC, and 
the absorbance at 405 nm was again measured in the spectrophotometer. The 
baseline value was subtracted from the second reading and the amount of heparin 
in plasma was calculated by means of the standards.
Heparin concentration by thrombin inhibition
Plasma (12.5 µl) was added to 62.5 µl citrate/Tris buffer (pH 7.4) in a microtiter 
plate. A standard curve was made from serial heparin dilutions starting at 10 IU 
ml-1 in normal human platelet poor plasma. Then 25 µl thrombin solution (1.5 IU 
ml-1) was added to all wells and the baseline optical density was read at 405 nm 
in a spectrophotometer. The 50 µl Substrate S2238 was added and the sealed 
plate was incubated for 20 minutes at 37ºC. The OD 405 was read and corrected 
for baseline. The heparin concentration was calculated by means of the standard 
curve.
Platelet factor 4
Platelet factor 4 (PF4) was determined by ELISA based on antibodies and PF4 
antigen standard from R&D. A Nunc Maxisorp microtiter plate was coated during 
the night with a carbonate coating buffer (pH 9.6) containing mouse-anti-human 
PF4 capture antibody. The plate was washed with PBS-Tween buffer, blocked 
with 1% BSA in PBS and washed again. Then samples (200 times diluted in 0.1% 
BSA/PBS) and serial diluted standards (starting at 1000 pg ml-1 in 0.1% BSA/
PBS were incubated for 2 hours at room temperature. The plate was washed and 
then incubated for 2 hours with biotinylated goat-anti-human PF4. The plate was 
washed and then incubated with streptavidin-HRP solution in 1% BSA in PBS 
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and after washing the plate was incubated with OPD substrate solution. After 20 
minutes the reaction was stopped with 0.3 M H2SO4. The color formation was read 
at 490 nm in a spectrophotometer and PF4 concentrations were calculated from 
the OD490 against the standard curve.
Thrombin generation assay 
The thrombin generation assay was performed in a subgroup of 20 patients in the 
low dosing ratio group and 22 patients in the high dosing ratio group. Citrated 
platelet free plasma was analysed with calibrated automated thrombography 
(CAT) as previously described. [21,22] Thrombin generation was measured in 
blood samples obtained before surgery and 3 and 30 minutes following protamine 
administration.
Other study parameters
Patient demographics included age, gender and BMI. Surgical data were 
CPB time, aortic cross clamp time and the amount of heparin and protamine 
administration. Clinical outcome included 24-hour blood loss by chest drainage 
and postoperative allogeneic transfusion rates of packed red blood cells (PRBC; 
275 ml), fresh frozen plasma (FFP; 310 ml) and platelet concentrates (340 ml). 
Assessment of drain production started immediately after placement of drains. 
Furthermore, time to extubation, length of postoperative ICU stay and mortality, 
rethoracotomy, myocardial infarction, transient ischemic attack (TIA), cerebral 
vascular incident (CVA), cardiac tamponade and the need for reintubation were 
assessed.
Statistical analysis
We hypothesized that the low protamine-to-heparin ratio would reduce 24-hour 
blood loss by 100 ml. With a power of 0.9 and alpha of 0.05, a sample size of 
49 subjects per group was required to reach our primary study endpoint, with 
a total sample size of 98 patients. An intention-to-treat statistical analysis was 
performed using the SPSS statistical software package 22.0 (IBM, New York, 
USA) or Graphpad Prism 6 (La Jolla, USA). Continuous, normally distributed 
variables were expressed as mean ± standard deviation, while ordinal or skewed 
data were shown as median with interquartile range (IQR). Categorical data were 
expressed as frequencies with or without 95% confidence intervals and analysed 
by a Chi-square test or Mann-Whitney test, respectively. The primary endpoint 
(24-hours blood loss) was expressed as median with interquartile range and 
95% confidence intervals. Normally distributed numeric variables were analysed 
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using an (un)paired T-test. In order to analyse between-group effects over time a 
two-way repeated measures ANOVA was performed for coagulation and plasma 
parameters at baseline and three (PROT-3) and 30 (PROT-30) minutes following 
protamine administration and upon ICU arrival (ICU). A P-value of 0.05 was 
considered as statistically significant.
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RESULTS
Patient characteristics
Forty-seven (VUmc) and 51 (MCL) patients were included. VUmc and MCL 
included an equal number of males (83% vs. 73%; P=0.26) with similar ages (67 ± 
9 vs. 68 ± 9 years; P=0.58). Two patients in the high protamine-to-heparin dosing 
ratio group were excluded due to inappropriate protamine dosing (Figure 1). 
Patient and surgical characteristics were similar among groups (Table 1). There 
were differences in the use of anticoagulant medication before surgery between 
groups. The total administered protamine dose was higher in the high dosing ratio 
group (539 ± 117 mg) when compared to the low dosing ratio group (329 ± 95 
mg; P < 0.001), resulting in an 0.8 and 1.3 dosing ratio per group, respectively 
as per protocol.
Assessed for eligibility (n=108)
Excluded (n=10)
   Not meeting inclusion criteria (n=0)
   Declined to participate (n=10)
Randomized (n=98)
Low P:H dosing ratio
Allocated to intervention (n=49)
   Received allocated intervention : (n=49)
   Did not receive allocated intervention (n=0)
Lost to follow up (n=0)
Discontinued intervention (n=0)
Analysed (n=49)
   Excluded from analysis (n=0)
High P:H dosing ratio
Allocated to intervention (n=49)
   Received allocated intervention : (n=47)
   Did not receive allocated intervention (n=2)
Reason(s) :
- Transferral to low dosing ratio based on weight
(n=2)
Lost to follow up (n=0)
Discontinued intervention (n=0)
Analysed (n=47)
   Excluded from analysis (n=0)
Figure 1.  CONSORT flow diagram of patient inclusion.
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Perioperative haemostatic data
Repeated measures ANOVA revealed no differences between groups in the 
course of haemoglobin (panel A; F value 0.402; P=0.529), the aPTT (panel C; F 
value 0.360; P=0.550) or the ACT (panel D; F value 1.039; P=0.311; Figure 2). 
The prothrombin time was slightly prolonged in the high dosing group at three 
minutes following protamine administration (INR 1.6 ± 0.2 vs. 1.7 ± 0.2; P=0.001; 
see also Panel B), with a between-group subjects effect for protamine dosing (F 
value 10.571; P=0.002).
Low P:H ratio High P:H ratio P-value
N 49 47
Age (years) 67 ± 9 67 ± 9 0.79
BMI (kg m-2) 27 ± 3 27 ± 4 0.81
Males (n (%)) 36 (74%) 39 (83%) 0.26
Preoperative anticoagulation 0.21
  Acetylsalicylic acid (n (%)) 41 (84%) 45 (96%)
  Clopidogrel (n (%)) 2 (4%) 1 (2%)
  Acenocoumarol (n (%)) 3 (6%) 0 (0%)
ECC time (min) 91 ± 29 94 ± 35 0.57
Aorta clamp time (min) 61 ± 22 66 ± 27 0.37
Tranexamic acid (g) 2.8 ± 0.6 3.1 ± 1.7 0.34
Total heparin administration (IU) 41,000 ± 11,800 41,500 ± 9,000 0.81
Protamine administration (mg) 329 ± 95 539 ± 117 <0.001
Protamine-to-heparin dosing ratio 0.8 ± 0.0 1.3 ± 0.0 <0.001
Table 1.  Patient demographics and surgical characteristics for the low and high 
protamine-to-heparin dosing ratio groups. BMI = body mass index; ECC = 
extracorporeal circulation. Data represent frequencies or mean ± standard 
deviation.
The course of the thromboelastometric test results are shown in figure 3. The 
course of the INTEM CT (F value 19.56; P<0.0001) and HEPTEM CT (F value 
17.365; P<0.0001) over time was different between groups as analysed by 
repeated measures ANOVA. At three minutes following protamine administration, 
the INTEM CT (293 ± 72 vs. 243 ± 36 s; P<0.001) and HEPTEM CT (303 ± 68 vs. 
241 ± 39 s; P<0.001) were both prolonged in the high dosing compared to the low 
dosing group, respectively. The course of the EXTEM CT (panel C; F value 2.23; 
P=0.137) and FIBTEM MCF (panel D; F value 0.188; P=0.665) over time did not 
differ among groups. 
80 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































RCT comparing high and low protamine dosing 
3
The course of ATIII levels over time was comparable for both dosing ratio groups 
(Figure 4, panel A; F value 0.117; P=0.733). The available heparin concentration 
as revealed by factor Xa inhibition at 3 minutes following protamine administration 
was 1.21 ± 0.45 IU ml-1 and 1.04 ± 0.50 IU ml-1 in the low and high protamine 
dosing group (P=0.246) without a difference in the course of heparin levels over 
time between groups (panel B; F value 0.032; P=0.860). At 3 minutes following 
protamine administration, ATIII levels were comparable between the low and high 
protamine-to-heparin dosing groups (0.65 ± 0.38 IU ml-1 vs. 0.66 ± 0.33 IU ml-1, 
respectively; P=0.92), without differences over time between groups (panel C; F 
value 0.243;P=0.625). A similar pattern was observed for PF4 levels, showing no 
different course over time among groups (panel D; F value 0.752; P=0.391).
Thrombin generation assay
The lag time, the endogenous thrombin potential (ETP), the peak height and 
the time to peak as derived from the thrombin generation assay are shown in 
figure 5. For every patient, data retrieved at 3 and 30 minutes following protamine 
administration were normalized to preoperative values. After stimulation with 1 
pM of tissue factor the normalized lag time (Panel A; 404 ± 279 vs. 216 ± 144 
%; P=0.01) and time to thrombin peak (Panel G; 240 ± 125 vs. 152 ± 64 %; 
P=0.009) were higher in the high dosing group at 30 minutes after protamine 
administration. Thrombogram parameters derived upon stimulation with 5 pM 
tissue factor, which activates the extrinsic coagulation system (panels B, D, F, H), 
did not differ between groups. 
Blood transfusion and postoperative complications
There was no difference in the volume of retransfused cell saver blood between 
groups as shown in table 2. Postoperative blood loss was higher at 24 hours 
(615 ml; 95% CI 500-830 ml vs. 470 ml; 95% CI 420-530 ml; P=0.021) in the 
high protamine-to-heparin dosing ratio group compared to the low dosing group, 
respectively. More patients received fresh frozen plasma (11% versus 0%; 
P=0.02) and platelet concentrates (21% vs. 6%; P=0.04) in the high protamine-to-
heparin dosing group when compared to the low dosing group (Table 2). There 
were no differences in serious adverse outcome between the groups.
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Figure 5.  Thrombin generation assay. Data represent the lag time (Panels A and B), the 
endogenous thrombin generation potential (ETP; Panels C and D), the peak 
thrombin generation (Panels E and F) and the time to peak thrombin (Panels 
G and H) after stimulation with 1 or 5 pM tissue factor in the low dosing ratio 
group (n=20) and high dosing ratio group (n=22). Data are expressed as 
mean ± standard deviation.
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Low P:H ratio High P:H ratio P-value
Blood product transfusion
Cellsaver blood (ml) 322 (113;450) 326 (223;465) 0.56
PRBC transfusion [% patients; 95% CI] 19% (8-30%) 32% (19-45%) 0.16
FFP transfusion [% patients; 95% CI] 0% (0-0%) 11% (2-21%) 0.02
Platelet transfusion [% patients; 95% CI] 6% (0-15%) 21% (11-34%) 0.04
Postoperative outcome
ICU stay (hours) 26 ± 10 27 ± 15 0.81
Rethoracotomy (n (%)) 1 (2%) 4 (9%) 0.17
Myocardial infarction (n (%)) 1 (2%) 0 (0%) 0.32
TIA / CVA (n (%)) 1 (2%) 0 (0%) 0.32
Cardiac tamponade (n (%)) 0 (0%) 1 (2%) 0.32
Reintubation (n (%)) 1 (2%) 0 (0%) 0.32
Died (n (%)) 0 (0%) 1 (2%) 0.32
Table 2.  Blood product transfusion and postoperative outcome parameters. PRBC = 
packed red blood cells; FFP = fresh frozen plasma; ICU = intensive care 
unit; TIA = transient ischemic attack; CVA = cerebral vascular accident. Data 
represent mean ± standard deviation, median with interquartile range (IQR) in 
brackets, or frequencies with 95% confidence intervals (95% CI).
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DISCUSSION
This study shows that a protamine-to-heparin ratio of 1.3 is associated with 
disturbances in postoperative haemostasis, increased 24-hour blood loss and 
higher transfusion rates in patients undergoing cardiac surgery with CPB when 
compared to a low dosing group. The low dosing ratio of 0.8 did not result in 
residual heparin or prolonged activated clotting times following weaning from 
bypass. Excessive protamine was associated with reduced speed and level of 
thrombin generation irrespective of the total dose of administered heparin. These 
findings suggest that excessive protamine dosing is harmful for the restoration of 
perioperative haemostasis in cardiac surgery, and may contribute to increased 
bleeding and allogeneic blood transfusions.
Although several in vitro studies showed negative effects of high protamine 
dosing on haemostasis, [4,9-13] there are no randomized controlled trials 
available that confirmed these findings in the clinical setting. As a consequence, 
European guidelines still accept a protamine-to-heparin dosing ratio of 1.3:1.0. 
[17] Other guidelines suggest lowering protamine dosing, yet these are low class 
recommendations (IIb) as clinical data are scarce. [16]
Although the earliest publications on the anticoagulant effects of protamine 
originate from 1900 and 1927, the impact of a disturbed equilibrium between 
the heparin-neutralizing effects and anticoagulant actions of protamine has only 
been limitedly investigated. [23-27] Berger et al. were the first who suggested 
to adapt protamine dosing for heparin neutralization in light of the half-life of 
heparin and the intraoperative consumption of heparin. [14] When protamine 
dosing was administered in consecutive doses, the first dose was frequently 
sufficient to establish clot formation, while the second dose resulted in continuous 
bleeding. [5,14] In contrast to our findings, in two studies it was shown that a 
higher protamine dosing ratio (1.3), or the titration of protamine, was associated 
with better clinical outcome when compared to a lower protamine dose. [28,29]
A recent meta-analysis showed a minor reduction of perioperative blood loss when 
protamine titration was compared to conventional practice. [30] However, the 
four studies that were included in this meta-analysis were not primarily designed 
to compare different protamine dosing strategies in cardiac surgery [31,32] or 
based on a small sample size. [33,34]
A common denominator in the aforementioned studies is that protamine itself 
influences patient haemostasis and bleeding, and that protamine titration might 
support restricted allogeneic blood transfusion strategies in cardiac surgery. 
Despite the short half-life of protamine, [35] we still observed impaired coagulation 
at 30 minutes following protamine administration in the high protamine-to-heparin 
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dosing ratio group. This suggests that the detrimental effect of protamine on the 
coagulation system may persist even after protamine has disappeared from the 
circulation.
The most important reasons for protamine overdosing or postoperative protamine 
administration are fear for postoperative bleeding when post-CBP ACT levels 
are elevated, or a heparin rebound effect. Interestingly, we found no differences 
in the ACT between the two protamine-to-heparin dosing regimes, suggesting 
that even the lowest dose of protamine administered was an overdose in the 
light of sufficient normalization of heparin. The aPTT, thromboelastography and 
a heparin assay were more sensitive than the ACT to detect residual heparin 
anticoagulation. [36]
Heparin rebound is the reappearance of anticoagulant activity after adequate 
neutralization with protamine. While in the early days of cardiac surgery heparin 
rebound was a frequently observed phenomenon, a recent study suggested 
that this phenomenon might be of less importance as cause for postoperative 
bleeding. [37] Moreover, ACT values following protamine administration in the low 
and high dosing groups were similar in our study. Finally, we measured heparin 
concentrations after protamine administration and found no difference in the 
heparin concentration at 3 and 30 minutes after protamine administration in both 
groups, and therefore we concluded that residual heparin could be excluded. 
The thromboelastometric intrinsic clotting time with and without the presence of 
heparinase was prolonged in the high protamine-to-heparin dosing ratio group 
when compared to the lower dosing ratio group, while the extrinsic clotting 
time was unaltered. These findings were supported by the thrombin generation 
measurements. During exposure to a low concentration of tissue factor, 
coagulation occurs predominantly through the intrinsic pathway, involving factor 
VIII, IX and XI. [21] The thrombin generation analyses as performed in the present 
study showed that high protamine dosing results in an increased lag time and 
reduced peak level of thrombin generation, [38] rather than recovering thrombin 
formation. This confirms previous statements that protamine interferes with the 
conversion of prothrombin to thrombin in whole blood, [39] or with the activation 
of factor V. [8] The thrombin assay measurements were performed in a small 
subgroup of patients, which restricts the generalizability of these findings to the 
whole population.
Platelet factor 4 (PF4) is a large polypeptide, which is released by activated 
platelets. It binds circulating heparins and thereby inhibits the action of 
antithrombin, promoting haemostasis. In this study (pleuro-)pericardial shed blood 
was washed by cell saver before returning to the patient’s circulation. However, 
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as pericardial suction blood contains blood with activated haemostasis, including 
PF4, centres returning this blood directly to the patient’s circulation might further 
reduce their protamine dosing as heparin captured by PF4.
The present study was limited by the one-sided blinding protocol, which might 
have influenced perioperative blood management strategies. A second limitation 
is the calculation of the protamine dose based on the total heparin dose, leading 
to relatively high doses when compared to others. [6,15] An additional limitation 
of this study is that there were small differences in CPB strategies between 
both centres with respect to the type of heart-lung machine used, the use of 
volatile anaesthesia and the amount of heparin in the extracorporeal circuit. 
However, these differences between centres have only limited influence on 
our study outcome. Due to logistic reasons the thrombin generation assay was 
performed in plasma, and future studies should investigate the effect of different 
protamine dosing regimens in whole blood to evaluate the role of platelets in the 
anticoagulation effect of protamine.
Worldwide, there is still a general belief that additional protamine administration 
in patients with microvascular bleeding might stop blood loss following heparin 
neutralization. Our study confirms that protamine might by itself enhance bleeding 
when inappropriately dosed. In light of patient blood management as multifactorial 
strategy that involves blood conservation techniques, our study contributes to 
improved awareness regarding the impact of common interventions in clinical 
routine.
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ABSTRACT
Objective: This study investigated postoperative hemostasis of 
patients subjected to conventional protamine dosing compared with 
protamine dosing based on a pharmacokinetic (PK) model following 
cardiopulmonary bypass.
Design: Retrospective case-control study.
Setting: Tertiary university hospital.
Participants: Patients undergoing elective cardiac surgery with 
cardiopulmonary bypass.
Interventions: In 56 patients, protamine was dosed in a fixed ratio 
(CD), while 62 patients received protamine based on the PK model.
Results: There was no difference in heparin administration (414 ± 107 
mg (CD) vs 403 ± 90 mg (PK); p = 0.54), whereas protamine dosing 
was considerably different with a protamine-to-heparin dosing ratio of 
1.1 ± 0.3 for the CD group and 0.5 ± 0.1 for the PK group (p<0.001). 
The changes in activated coagulation time (ΔACT) values (ACT after 
protamine minus preoperative ACT; +17 ± 77 s vs +6 ± 15 s; p = 0.31) 
were equal between groups. Yet, the thromboelastometric intrinsically 
activated coagulation test clotting time (CT; 250 ± 76 s vs 203 ± 44 s; 
p<0.001) and intrinsically activated coagulation test without the heparin 
effect CT (275 ± 105 vs 198 ± 32 s; p<0.001) were prolonged in the 
CD group. Median packed red blood cell transfusion (0 [0–2] v 0 [0–
0]), fresh frozen plasma transfusion (1 [0–2] vs 0 [0–0]), and platelet 
concentrate transfusion (0 [0–1] v 0 [0–0]) were different between the 
fixed ratio and PK group, respectively (all p<0.001).
Conclusions: This study showed that patient-tailored protamine dosing 
based on a PK model was associated with a reduction in protamine 
dosing, with better hemostatic test results when compared with fixed-
ratio protamine dosing.
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INTRODUCTION
Protamine is used to reverse heparin after termination of cardiopulmonary bypass 
(CPB). The anticoagulant properties of heparin are antagonized by the formation 
of a neutral 1:1 protamine-heparin complex. Protamine is commonly administered 
in a fixed protamine-to-heparin ratio based on the intraoperative dose of heparin, 
irrespective of the patient’s heparin consumption. Protamine dosing usually 
ranges from 0.5 to 1.3 mg of protamine per 100 IU of heparin administrated. [1,2]
Yet, during CPB, heparin is broken down, with a half-life of approximately 4 hours 
in high dosage, and a small part of heparin is lost by blood loss. When these 
factors were taken into account, protamine dosing based on a fixed ratio was 
inadequate for the great majority of patients, and might lead to unantagonized 
heparin or protamine overdose, both causing coagulopathy. [3,4]
An alternative method for individualized protamine dosing is heparin and 
protamine administration using a point-of-care hemostasis management system. 
[5] The heparin concentration is estimated in vitro and multiplied by the calculated 
blood volume of the patient, leading to an advised protamine dosage. This method 
has been shown to contribute to individualized protamine dosing; however, the 
technique is costly. Therefore, its additive value and cost-benefit for its use in 
routine minor and moderate risk cardiac surgery is debatable.
In order to offer an alternative for the titration method the authors developed a 
two-compartment pharmacokinetic (PK) model that estimates the heparin blood 
concentration from the administered heparin doses and time of administration to 
calculate the loss of heparin over time. [6] By estimating the amount of heparin at 
the end of CPB, the required protamine dosage is calculated to neutralize heparin. 
In this study the authors investigated if implementation of this PK model improved 
clinical practice by evaluating postoperative bleeding, blood transfusion, and 
hemostasis by thromboelastometry.
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METHODS
Study Population
This retrospective observational study was performed in the Departments of 
Anesthesiology and Cardiothoracic Surgery of the VU University Medical Center 
(Amsterdam, The Netherlands). Two cohorts were compared, before and after 
the implementation of the PK protamine dosing. All measurements were part of 
routine clinical practice. The local Human Subjects Committee approved this 
retrospective analysis (METc 2012/438) and waived informed consent. During 
the study period no alterations were made in the perioperative cardiac surgery 
practice. Additionally, there were no changes in the dedicated anesthesia or 
cardiothoracic surgery team.
Patients aged 18 to 85 years were eligible if they were scheduled for elective 
cardiac surgery with CPB. Acetylsalicylic acid was not discontinued prior to 
surgery, whereas clopidogrel was stopped 5 days prior to the cardiac procedure. 
Exclusion criteria were emergency surgery, a body mass index below 18 kg 
m-2 or above 35 kg m-2, a history of hematologic disorders, the necessity for 
renal replacement therapy, and the preoperative use of heparin or heparin-like 
medication.
Study Procedure
The first cohort of patients received protamine based on a fixed ratio at the discretion 
of the attending anesthesiologist. The second cohort received protamine based 
on a two-compartment model to estimate the heparin concentration in blood (Fig 
1). The calculated residual heparin concentration was multiplied by the calculated 
blood volume, resulting in the residual amount of heparin. Protamine was dosed 
in a 1:1 ratio based on the calculated amount of residual heparin after termination 
of CPB.
Protamine Dosing Model
A two-compartment model was implemented using the following equation:
Ct’= C0.A.eαt + C0.B.e−βt
Ct is the residual heparin in the patient at the moment of protamine dosing (t). A 
and B represent the distribution over the subsequent compartments of the initial 
dose (C0), 0.1 and 0.9, respectively, [7] and e is the base of the natural logarithm 
(2.718) with α and β being the time constants of both compartments (α = 10 
minutes and β = 250 minutes). The half-life of heparin increases by incremental 
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dosage. The highest dose investigated was 400 IU and showed a half-life of 150 
minutes in humans. [8] Patients receive an average of 500 IU of heparin during a 
cardiac procedure in this center, leading to a half-life greater than 150 minutes. 
The half-life is expected to increase further with cooling (to approximately 34oC 
during CPB). As the detrimental effect of heparin overdosing is greater than 
protamine overdosing, the half-life of heparin was rounded up to avoid a residual 
heparin effect. In the absence of evidence about the half-life of high-dose heparin 
during CPB, an empirical half-life (β) of 250 minutes was chosen taking all the 
above-mentioned factors into consideration.
The final dose of protamine was calculated combining the remainder of the initial 
bolus (Ct’) plus the remainder of the subsequent bolus (Ct”, Ct”’…). Protamine was 






















Figure 1.  Schematic representation of the pharmacokinetic heparin model. Prior to CPB 
a bolus of 300 IE kg-1 of heparin is administered to achieve an ACT > 480 s. 
During CPB, when the heparin concentration drops due to its half-life, the ACT 
will shorten. When the ACT falls below 480 seconds an additional bolus of 
heparin is administered, resulting in a second peak concentration of heparin 
in the blood. CPB, cardiopulmonary bypass; ACT, activated coagulation time.
Anesthesia and Cardiopulmonary Bypass
Patients were anesthetized according to local protocols based on a combination 
of sufentanil, 3-7 μg kg-1, rocuronium, 0.6 mg kg-1, and midazolam, 0.1 mg kg-1, 
for anesthesia induction and tracheal intubation. Propofol (200-400 μg h-1), with 
or without isoflurane/sevoflurane, was used for maintenance of anesthesia. All 
patients received tranexamic acid (1 gram prior to and 2 gram after CPB).
CPB was performed at a blood flow of (2.2-2.4 L min-1 m-2) during normo- or 
mild hypothermia (> 34oC) using either a C5 or S5 heart–lung machine (Stöckert 
Instrumente GMBH, Munich, Germany) with a centrifugal pump and biocompatible 
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coated circuit. Cell saving was applied throughout the surgical procedure. Shed 
blood from the thoracic cavity and residual blood that remained in the extracorporeal 
system after bypass were sucked up into the cell-saver reservoir using a dual-
lumen tube connected to a vacuum pump, and subsequently transferred to the 
centrifuge bowl of the cell saver (Autolog, Medtronic, Minneapolis, MN). After 
plasma removal, red blood cells were washed, and concentrated red blood cells 
were retransfused.
Heparin and Protamine Management
Heparinization started with an initial bolus of 300 IU kg-1 of heparin (LEO Pharma 
BV, Amsterdam, The Netherlands) to achieve an activated coagulation time 
(ACT) test of 480 seconds. If necessary, additional doses of heparin (5000 IU) 
were administered to maintain this target ACT. The priming solution (1200 mL) 
contained 5000 IU of heparin.
After weaning from CPB, heparin was reversed with protamine hydrochloride 
(MedaPharma BV, Amstelveen, The Netherlands). The amount of protamine in 
the first cohort was at the discretion of the attending anesthesiologist in a fixed 
ratio. After implementation of the PK-based protamine dosing model, the second 
cohort was evaluated.
Local Blood Transfusion Algorithm
The transfusion of packed red blood cells (PRBC) was based on the Dutch 
transfusion guidelines, recommending transfusion if hemoglobin levels are below 
9.7 g dL-1 (6 mmol L-1), in American Society of Anesthesiologists IV patients, and 
patients with symptomatic cerebrovascular disease, sepsis, heart failure, or severe 
pulmonary disease. Packed red blood cells transfusion is advised in cases of 
hemoglobin levels below 8.1 g dL-1 (5 mmol L-1), in cases of acute blood loss from 
one bleeding focus in a normovolemic American Society of Anesthesiologists I 
patient aged > 60 years, and in cases of fever or following cardiac surgery. Fresh 
frozen plasma or platelet transfusion was performed in patients with clinical signs 
of persistent nonsurgical bleeding (oozing). When laboratory coagulation test 
results were available, fresh frozen plasma was transfused when the international 
normalized ratio of the prothrombin time exceeded 1.5. Additional platelet 
concentrate administration was indicated for extended bypass times, clinical 
signs of bleeding, and/or a platelet count below 75×109 L-1.
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Blood Sampling
After anesthesia induction, the first blood sample was collected for hemostatic 
baseline evaluation as part of routine practice. Blood was drawn in a citrated 
tube from the radial artery catheter. Three minutes after protamine administration 
another blood sample was drawn for routine hemostatic evaluation.
Thromboelastometry
Using rotational thromboelastometry (ROTEM delta; TEM International, Munich, 
Germany), the viscoelastic properties of a blood clot were measured in vitro 
using the intrinsically activated coagulation test (INTEM), extrinsically activated 
coagulation test (EXTEM), fibrin polymerization test, and the intrinsically activated 
coagulation test without the heparin effect (HEPTEM). Clot formation was assessed 
by the clotting time or the maximum clot firmness (MCF), which were represented 
in a thromboelastogram.
Other Study Parameters
Patient demographics included age, gender, and body mass index. Collected 
surgical data were CPB time, aortic cross-clamp time, and the amount of 
heparin and protamine administered. Hemostatic parameters included pre- and 
postoperative prothrombin time (PT), activated partial thromboplastin time (aPTT), 
ACT, hemoglobin concentration, and platelet count. Clinical outcomes included 
blood loss assessed at 6, 12, and 24 hours by chest drainage and postoperative 
allogeneic blood transfusion.
Statistical Analysis
Statistical analysis was performed using the SPSS statistical software package 
22.0 (SPSS Inc.®, IBM, New York). Descriptive statistics are presented as 
frequencies (nominal data), median with interquartile range (non-parametric 
data), or mean with standard deviation (numerical data). A Student’s T-test, Mann–
Whitney U test, or chi-square test was used for differences in numeric, ordinal, or 
nominal data, respectively, between the cohorts. Multiple linear regression was 
performed to evaluate the possible confounding effect of the type of surgery on 
thromboelastometric results, and postoperative blood loss for both groups, as this 
was different between groups. A p-value < 0.05 was considered as statistically 
different.
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RESULTS
The study population included 118 patients undergoing cardiac surgery with CPB. 
The conventional dosing (CD) cohort consisted of 56 patients, and 62 patients 
received protamine dosing according to the PK model. Table 1 shows patient 
and surgical characteristics for both patient cohorts. There were no differences 
in patient demographics between groups, except for a higher proportion of male 






Age (years) 66 ± 12 67 ± 11 0.74
BMI (kg m-2) 28 ± 4 27 ± 4 0.61
Males (n) 30 (54%) 47 (76%) 0.02
Preoperative anticoagulation
  Acetylsalicylic acid (n) 20 (36%) 32 (52%) 0.07
  Clopidogrel (n) 1 (2%) 8 (13%) 0.02
  Heparin (n) 2 (4%) 4 (7%) 0.46
ECC time (min) 132 ± 53 117 ± 44 0.09
Aorta clamp time (min) 98 ± 41 85 ± 35 0.07
Lowest temperature (oC) 34 ± 1 34 ± 1 0.10
Lowest hemoglobin 0.79
  mmol l-1 5.3 ± 1.0 5.3 ± 0.8
  g dl-1 8.5 ± 1.6 8.5 ± 1.3
Type of surgery <0.001
  CABG (n) 6 (11%) 31 (51%)
  Valve surgery (n) 29 (51%) 16 (26%)
  CABG + valve (n) 18 (32%) 11 (18%)
  Bentall ± CABG (n) 3 (5%) 2 (3%)
Table 1.  Patient demographics and surgical characteristics. BMI = body mass index; 
ECC = extracorporeal circulation; CABG = coronary artery bypass graft 
surgery. Data represent frequencies or mean ± standard deviation.
Figure 2 shows heparin and protamine dosing in the CD and PK dosing groups. 
Implementation of the PK model did not alter heparin dosing, but significantly 
reduced protamine dosing from 416 ± 82 mg to 186 ± 42 mg (p = 0.001) compared 
with the CD group. This resulted in a major reduction in the protamine-to-heparin 
dosing ratio from 1.1 ± 0.3 for the CD to 0.5 ± 0.1 for the PK dosing (p<0.001).
Table 2 shows whether reduced protamine dosing in the PK group was 
associated with alterations in patient hemostasis, differences for hemoglobin, 
aPTT, prothrombin time, and platelet count between groups before surgery and 
at 3 minutes following protamine administration. 
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Figure 2.  Protamine and heparin dosage. The protamine-to-heparin dosing ratio resulted 








  Hemoglobin <0.001
    mmol l-1 8.1 ± 0.9 8.8 ± 1.0
    g dl-1 13.0 ± 1.4 14.1 ± 1.6
  aPTT (s) 37 ± 6 38 ± 8 0.50
  PT (INR) 1.2 ± 0.4 1.1 ± 0.6 0.73
  Platelet count (10*9 l-1) 245 ± 59 233 ± 73 0.38
3 minutes after protamine
  Hemoglobin <0.01
    mmol l-1 6.1 ± 0.9 5.7 ± 0.7
    g dl-1 9.8 ± 1.4 9.1 ± 1.1
  PT (INR) 1.9 ± 0.5 1.6 ± 0.2 <0.001
  Platelet count (10*9 l-1) 109 ± 35 129 ± 39 <0.01
aPTT (s) after protamine
  3 minutes 42 ± 13 43 ± 5 0.73
  1 hour 41 ± 8 42 ± 7 0.35
  2 hours 39 ± 7 39 ± 9 0.99
Activated clotting time (ACT)
  ACT preoperative(s) 131 ± 15 124 ± 15 0.01
  ACT after protamine dosing (s) 148 ± 74 130 ± 13 0.08
  Delta ACT (preop – postop) + 17 ± 77 + 6 ± 15 0.31
Table 2.  Laboratory findings. PT = prothrombin time, INR = international normalized 
ratio; aPTT = activated partial thrombin time; ACT = activated clotting time. 
Data represent frequencies or mean ± standard deviation.
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Figure 3 shows the thromboelastometric clotting times for the subsequent tests 3 
minutes after protamine administration. Furthermore, INTEM MCF was 52 ± 8 in 
the CD group compared with 59 ± 9 in the PK dosing group, p<0.01. EXTEM MCF 
was higher in the PK group (60 ± 9) when compared with the CD group (54 ± 8, 
p = 0.02), respectively. The fibrin part of the clot (fibrin polymerization test MCF) 



















) *                     *                       
CD group
PK group
Figure 3.  Thromboelastometric test results at three minutes following protamine 
administration. PK = pharmacokinetic dosing; INTEM = intrinsic coagulation 
cascade; HEPTEM = intrinsic coagulation cascade in the presence of 
heparinase; EXTEM = extrinsic coagulation cascade. *p < 0.05. 
There was a difference in median postoperative blood loss 6 hours after surgery 
(110 [73;228)] vs. 180 [121,292] mL, p = 0.01), yet there was no difference at 12 
hours (248 [141:375] vs. 250 [180,329] mL, p=0.34) nor 24 hours after surgery 
(340 [242,525] vs. 387 [293,548] mL, p=0.27) for the conventional versus the 
PK dosing group. Table 3 shows the postoperative transfusion outcome for both 
groups.
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Packed red blood cells 0 (0-2) 0 (0-0) <0.001
0 units (n (%)) 27 (52%) 58 (93%)
1-2 units (n (%)) 13 (25%) 3 (5%)
≥ 3 units (n (%)) 12 (23%) 1 (2%)
Fresh frozen plasma 1 (0-2) 0 (0-0) <0.001
0 units (n (%)) 26 (50%) 61 (98%)
1-2 units (n (%)) 17 (32%) 1 (2%)
≥ 3 units (n (%)) 9 (18%) 0 (0%)
Platelet concentrate 0 (0-1) 0 (0-0) <0.001
0 units (n (%)) 27 (52%) 59 (95%)
1-2 units (n (%)) 23 (44%) 3 (5%)
3 units (n (%)) 2 (4%) 0 (0%)
Fibrinogen concentrate 0 (0-0)n=3
0 (0-0)
n=4 0.98
Prothrombin complex concentrate 0 (0-0)n=1
0 (0-0)
n=8 0.48
Table 3.  Postoperative transfusion. Data are represented as median with interquartile 
range. 
Multiple Linear Regression
Multiple linear regression was performed to evaluate the possible confounding 
effect of the type of surgery on thromboelastometric results and postoperative 
blood loss for both groups (Tables 4 and 5). The effect of PK dosing remained 
significant after correcting for the type of surgery for the INTEM, and HEPTEM was 
improved by PK dosing after correcting for the type of surgery when compared 
with the CD group. There were no differences in EXTEM or postoperative blood 
loss 6 hours postoperative after correcting for the type of surgery.
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DISCUSSION
Protamine dosing based on a PK model for residual heparin after CPB was associated 
with a reduction of more than 50% of the protamine dose when compared with a 
conventional fixed protamine-to-heparin dosing strategy with full neutralization of 
the postoperative ACT. This reduction in protamine administration was paralleled 
by better postoperative hemostasis, less allogeneic blood transfusion, and might 
reduce postoperative blood loss when compared with the control cohort. This 
study suggested that patient-tailored protamine administration based on the 
concentration of residual heparin was beneficial for patient hemostasis following 
cardiac surgery with CPB.
Several studies have shown that unbound protamine has intrinsic anticoagulant 
properties that may impair hemostasis. Nielsen and Malayaman previously 
gave an overview of the negative effects of protamine on hemostasis, showing 
that protamine decreases thrombin (factor IIa) activity, reduces factor VII and 
V activation, enhances fibrinolysis, and impairs platelet function by inhibition of 
GPIb-vWF activity. [4] The complex balance between protamine underdosing, 
which may result in residual heparin, and protamine overdosing, which may result 
in impaired hemostasis, warrants better tools for protamine dosing.
More than half a century ago the first attempts to optimize protamine dosing 
were made. [9] Since then there have been studies showing that a protamine 
dose reduction led to better outcomes. [10,11] A more recent development was 
the introduction of protamine titration, which also showed a (minor) reduction of 
postoperative blood loss. [12] Yet, so far it is common practice that protamine is 
dosed based on a fixed ratio to heparin, with adjustments based on the clinical 
experience of the anesthesiologist. Current guidelines advise a protamine-to-
heparin dosing ratio of 1:1 to 1:1.3, with a level IIb recommendation for lower 
protamine dosing. [1,2] As heparin is lost during CPB, a ratio of 1 mg of protamine 
for every milligram of heparin administered could result in protamine overdosing 
and impairment of hemostasis.
An alternative to a fixed protamine-dosing regimen is protamine titration, a method 
that titrates protamine ex vivo to find the optimal protamine-to-heparin dosing 
ratio. A meta-analysis by Wang et al showed that protamine titration might improve 
protamine dosing in cardiac surgery. [12] However, the meta-analysis was limited 
to the inclusion of studies not designed for comparison of protamine titration, and 
studies with a small sample size. Further attempts to improve protamine dosing 
were based on the perioperative anti-Xa or heparin concentration, the ACT or 
thrombin assay. [13-15] Unfortunately, none of these attempts resulted in major 
improvement of perioperative protamine management.
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Recently, several groups have developed mathematical models for protamine 
dosing. Jia et al established a PK model to predict heparin concentrations during 
cardiac surgery, suggesting a lower protamine dosing regimen after termination 
of CPB. [16] Davidsson and colleagues developed another statistical model for 
protamine dosing and showed a good agreement with point-of-care protamine 
dosing. [17] Finally, Kjellberg et al built a protamine dosing algorithm and reduced 
protamine dosing without any significant difference in postoperative bleeding. 
[18] Yet, these authors were the first to develop a PK model for protamine dosing 
leading to reduced protamine dosing, improved postoperative hemostasis, and 
less blood loss 6 hours after surgery when compared with conventional protamine 
dosing.
Protamine generally is overdosed in cases of elevated ACT levels to neutralize 
residual circulating heparin, neglecting the possible detrimental effect of 
protamine overdosing. Interestingly, the PK dosing group showed a trend towards 
lower postoperative ACT values and no difference in aPTT, which is more sensitive 
for residual heparin, [19] when compared with the CD group. Another concern is 
postoperative “heparin rebound”, the reappearance of circulating heparin after 
neutralization with protamine. Yet, a recent study suggested that this phenomenon 
might be a minor contributing factor to postoperative bleeding. [20] Additionally, 
the authors did not find any evidence of heparin rebound in the PK dosing group, 
as there was no difference in sequential postoperative aPTT values after surgery.
This study was limited by its retrospective design and the relatively small 
sample size per patient cohort. Because the two cohorts were sequential, the 
possibility of a chronology bias cannot be excluded. Furthermore, the absence 
of heparin measurements limits insight in the accuracy of the PK model, and the 
postoperative abundance of heparin or protamine. Moreover, the lack of repetitive 
heparin measurements following surgery limited the conclusions about the effect 
of the protamine dosing method on the occurrence of heparin rebound. Despite 
the limitations of this study, the benefits of PK-based protamine administration for 
postoperative hemostasis and allogeneic blood transfusion requirements warrant 
further exploration of patient-tailored heparin and protamine administration in 
cardiac surgery with CPB.
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ABSTRACT
Objective: The aim was to evaluate the predictive value of 
thromboelastometry for postoperative blood loss in adult cardiac 
surgery with cardiopulmonary bypass.
Design: Retrospective cohort study & systematic review of the literature
Setting: A tertiary university hospital 
Participants: 202 patients undergoing elective cardiac surgery
Interventions: Thromboelastometry was performed before 
cardiopulmonary bypass and 3 minutes after protamine administration.
Measurements and Main Results: The cohort study showed that the 
pre- and postoperative thromboelastometric positive predicting value 
was poor (0-22%), however the negative predicting value was high (89-
94%). 
The systematic review of the literature to evaluate the predictive value of 
thromboelastometry for major postoperative bleeding in cardiac surgery 
resulted in 1311 papers of which 11 were eligible, n=1765 (PUBMED 
and EMBASE, until June 2016). Two studies found a good predictive 
value whereas all other 9 studies showed a poor predictability for major 
postoperative bleeding after cardiac surgery. The overall negative 
predicting value was high.
Conclusions: Thromboelastometry does not predict which patients are 
at risk for major postoperative bleeding.
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INTRODUCTION
While the incidence of major blood loss after cardiac surgery has been reduced in 
the last decades, massive bleeding after cardiopulmonary bypass is still common. 
[1,2] These bleeding patients frequently require blood product transfusion and 
reexploration for bleeding, which are both independently associated with poor 
outcome. [3-7] Therefore, many attempts have been made to predict, prevent 
and treat postoperative blood loss. [2, 8-10]
Several risk scores for blood transfusion in patients undergoing cardiac surgery 
have been validated, showing that post-surgical blood loss can be predicted 
by a set of demographic and surgical characteristics and medication use. [11-
15] However, haemostatic tests, such as thromboelastometry, were only scarcely 
evaluated in these risk prediction models although thromboelastometry is 
increasingly used in cardiac surgery. 
Thromboelastometry is mainly used to guide haemostatic therapy. Still, in the 
cardiosurgical setting thromboelastometry-guided therapy has not proven to 
reduce mortality, although blood product transfusion and thromboembolic events 
are reduced. [16,17] It remains difficult to distinguish whether the improvement 
in haemostatic management is a result of the application of thromboelastometry 
itself, the thromboelastometry-related increase in factor concentrates transfusion, 
or the implementation of an extensive transfusion algorithm creating more 
awareness and knowledge about hemostasis. [16,18]
Although, several studies showed improved outcome after implementation of 
thromboelastometry, there is increasing evidence that thromboelastometry test 
results after cardiac surgery do not predict postoperative blood loss. Yet, in the 
trauma setting thromboelastometry has shown to predict outcome19, Therefore, we 
evaluated the predictive value of thromboelastometry in our centre and conducted 
a systematic review to evaluate the predictive value of thromboelastometry for 
major postoperative bleeding in cardiac surgery.
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This retrospective study investigated haemostatic data of adult patients 
undergoing elective cardiac surgery with cardiopulmonary bypass (CPB) in a 
University hospital between 2008 and 2011. Data were retrieved from databases 
of previous observational studies performed in our centre, in which the patient 
characteristics and thromboelastometric data were prospectively collected. Data 
retrieval for the present investigation was approved by local Human Subjects 
Committee (Amsterdam, the Netherlands; METc 2012/337) and informed consent 
was waived. According to local protocols, acetylsalicylic acid was continued 
throughout the perioperative period, while clopidogrel was discontinued at least 
5 days before surgery if deemed medically safe.
Anaesthesia and cardiopulmonary bypass
Patients were anesthetized according to the local protocol. All patients received 
1 mg kg-1 dexamethasone before cardiopulmonary bypass and 2 grams of 
tranexamic acid after CPB. Heparinization started with an initial bolus of 300 
IU kg-1 heparin (LEO Pharma BV, Amsterdam, the Netherlands), which was 
replenished until the activated clotting time (ACT) test exceeded 480 seconds. 
Cardiopulmonary bypass was performed during normothermia with a centrifugal 
pump and heparin-coated circuit. The priming solution (1400 ml) contained 5000 
IU porcine heparin. After cardiopulmonary bypass, heparin was reversed with 
protamine (MedaPharma BV, Amstelveen, the Netherlands). 
Haemostatic testing
Blood samples for haemostatic testing (haemoglobin, activated partial 
thromboplastin time (aPTT), prothrombin time (PT), platelet count, activated 
clotting time (ACT) and thromboelastometry) were drawn after anaesthesia 
induction and three minutes after protamine administration. Thromboelastometry 
(ROTEM delta; TEM International, Munich, Germany) was used to perform the 
extrinsically activated coagulation test (EXTEM), fibrin polymerization test 
(FIBTEM), intrinsically activated coagulation test with (HEPTEM) and without 
(INTEM) heparinise. Clot formation was assessed by the clotting time (CT) and 
the maximum clot firmness (MCF). 
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Local blood transfusion algorithm
The transfusion of packed red blood cells (PRBC) was based on the Dutch 
transfusion guidelines, recommending transfusion if haemoglobin levels below 
9.7 g dL-1 (6 mmol L-1) in case of ASA IV patients, patients with symptomatic 
cerebrovascular disease, sepsis, heart failure, or severe pulmonary disease. 
PRBC transfusion is advised in case of haemoglobin levels below 8.1 g dL-1 (5 
mmol L-1) in case of acute blood loss from one bleeding focus in a normovolaemic 
ASA I patient aging > 60 years, in case of fever or following cardiac surgery. Fresh 
frozen plasma (FFP) or platelet transfusion was performed in case of clinical signs 
of persistent nonsurgical bleeding (oozing). If laboratory coagulation test results 
were available, FFP was transfused when the international normalized ratio (INR) 
of the prothrombin time exceeded 1.5. Platelet concentrate administration was 
indicated in case of extended bypass times, clinical signs of bleeding and/or a 
platelet count below 75*109 L-1. 
Definition of major postoperative blood loss
Major blood loss was defined as more than 500 ml chest tube drainage at 6 hours 
after surgery (the 90th percentile of the total study population).
Other study variables
Patient demographics collected were age, gender and body mass index (BMI). 
Surgical characteristics were type of procedure, CPB time, aorta clamp time and 
lowest body temperature.
Data analysis
Statistical analysis was performed using the SPSS statistical software package 
17.0 (SPSS Inc.®, Chicago USA) except for comparison of Area under the ROC 
curves which was done in STATA 14 (STATA corp. LP, College Station USA). 
Descriptive statistics were represented as frequencies (nominal data), median 
with interquartile range (ordinal data) or mean with standard deviation (numerical 
data). The Student’s T-test was used to compare means of normally distributed 
variables between groups of patients with and without major blood loss. Mann-
Whitney U test was used to compare distribution of ordinal variables and chi-
square test was used for categorical variables. Univariate logistic regression 
was used to test for the association between known risk-factors and major 
postoperative blood loss. Multivariate logistic regression was used to investigate 
if thromboelastometric values were of added value to the known risk factors for 
prediction of major postoperative blood loss. Only models with two predictors 
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were considered as the limited number of patients with major postoperative blood 
loss made estimation of larger models infeasible. Area under the ROC curves 
were used to quantify the discriminative ability of thromboelastometric values and 
multivariate models for major postoperative blood loss. P<0.05 was considered 
as statistically different. 
II. Systematic review
the systematic review was performed in accordance with the recommendations 
for systematic reviews. [20] The literature search was performed according to 
the PRISMA guideline. The following search was the fundament for the literature 
search: Does [(rotational) thromboelastometry] predict blood loss or blood 
product transfusion in [cardiac surgery patients]? 
Inclusion criteria were papers written in English in non-paediatric cardiac surgery 
using cardiopulmonary bypass with rotational thromboelastometry analysis (not 
thromboelastography (TEG)) and predicting data. Pubmed/Medline and Embase 
were searched with the enclosed search queries in June 2016 (Appendix 1). 
Mesh terms and free text were used. 
Embase search query
(‘thromboelastography’/exp OR (thrombelast*:ab,ti OR thromboelast*:ab,ti OR rotem:ab,ti 
OR roteg:ab,ti OR INTEM:ab,ti OR EXTEM:ab,ti OR HEPTEM:ab,ti OR FIBTEM:ab,ti OR 
TEM:ab,ti)) AND ((‘thorax surgery’/de OR ‘heart surgery’/exp OR ‘heart lung machine’/exp 
OR ‘extracorporeal circulation’/de OR ‘cardiopulmonary bypass’/exp OR ‘heart left ventricle 
bypass’/exp) OR ((thoracic NEXT/1 surg*):ab,ti OR (thorax NEXT/1 surg*):ab,ti OR (cardiac 
NEXT/1 surg*):ab,ti OR (heart NEXT/1 surg*):ab,ti OR (‘heart lung’ NEXT/1 machine*):ab,ti 
OR (extracorporeal NEXT/1 circulation*):ab,ti OR (cardiopulmonary NEXT/1 bypass*):ab,ti 
OR (‘heart lung’ NEXT/1 bypass*):ab,ti OR cpb:ab,ti OR (heart NEXT/1 bypass*):ab,ti)) 
Pubmed search query
((Thrombelastography[Mesh]) OR (Thrombelast*[tiab] OR Thromboelast*[tiab] OR 
ROTEM[tiab] OR ROTEG[tiab] OR INTEM[tiab] OR EXTEM[tiab] OR HEPTEM[tiab] 
OR FIBTEM[tiab] OR TEM[tiab])) AND ((“Thoracic Surgery”[Mesh] OR “Cardiac 
Surgical Procedures”[Mesh] OR “Heart-lung Machine”[Mesh] OR “Extracorporeal 
Circulation”[Mesh:noexp] OR “Cardiopulmonary Bypass”[Mesh] OR “Heart Bypass, 
Left”[Mesh]) OR ((thoracic[tiab] AND surg*[tiab]) OR (thorax[tiab] AND surg*[tiab]) 
OR (cardiac[tiab] AND surg*[tiab]) OR (heart[tiab] AND surg*[tiab]) OR Heart-Lung 
Machine*[tiab] OR Extracorporeal Circulation*[tiab] OR Cardiopulmonary Bypass*[tiab] 
OR Heart-Lung Bypass*[tiab] OR CPB[tiab] OR Heart Bypass*[tiab]))
Appendix 1.  Literature search queries
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Both searches were merged, duplicates removed and independently screened 
by two authors (MIM & DB). After each selection round, the selection of both 
screening authors was merged and further screened. First, all titles were screened 
for possible eligibility. When the title suggested that the study could investigate 
the predictive value of bleeding in cardiac surgery the title was selected. The 
abstracts of the selected titles were screened and when these could possibly 
contain predicting data in combination with viscoelastometric testing, the paper 
was selected. These selected papers were read and, when eligible, included in 
the final selection. The final selection was screened for possible bias and possible 
influencing funding sources. 
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RESULTS
I. Cohort study
Patients demographics and perioperative variables (n=202) for patients with more 
or less than 500 ml blood loss after 6 hours following surgery are shown in table 1. 
< 500 cc ≥ 500 cc P=
N 181 21
Age (yr) 67 ± 12 71 ± 10 0.23
BMI (m kg-2) 27 ± 4 25 ± 3 0.04
Type of surgery (n) 0.04
  CABG 21 (12%) 5 (24%)
  Valve 96 (54%) 5 (24%)
  Valve + CABG 58 (32%) 11 (52%)
  Bentall ± CABG 4 (2%) 0 (0%)
Extracorporeal circulation (min) 136 ± 57 149 ± 59 0.33
Aorta clamp time (min) 102 ± 44 108 ± 49 0.55
Heparin (mg) 493 ± 169 452 ± 99 0.28
Protamine (mg) 510 ± 165 564 ± 118 0.16
Protamine:Heparin ratio 1.1 ± 0.3 1.3 ± 0.3 <0.01
Lowest temperature (oC) 34 ± 1 34 ± 1 0.94
Lowest haemoglobin (mmol l-1) 5.1 ± 0.7 5.0 ± 0.6 0.65
Table 1.  Demographic and surgical data of cohort study. Demographic and surgical 
data of cohort study. BMI = body mass index. Data represent frequencies or 
mean ± standard deviation.
In the 181 patients (90%) bleeding less than 500 ml the average amount of 
blood loss was 168 ml (100:260) 6 hours and 410 ml (281;600) 24 hours after 
surgery. In the 21 patients (10%) with major blood loss (> 500 ml) this was 890 
ml (648;1270) after 6 hours and 1530 ml (1040;1865) after 24 hours, respectively. 
Body mass index, type of surgery and the protamine:heparin dosing ratio were 
different between groups. The minor bleeding group received less red blood cell 
transfusion in the operation room (2 (0;4) vs. 4 (2;6), p<0.01) and ICU (0 (0;0) vs. 
1 (0;3.5), p<0.01) compared to the patients bleeding > 500 ml. Also, the amount 
of FFP transfusion was lower in patients bleeding less than 500 ml in the in the 
operation room (0 (0;2) vs (2 (1;4), p<0.01) and ICU (0 (0;2) vs (2 (1;3.5), p<0.01). 
The same goes for the numer op platelet concentrate transfusions in the operation 
room (1 (0;1) vs (1 (1;1.5), p=0.02) and ICU (0 (0;0) vs (2 (0;3.5) p<0.01). 
Pre- and postoperative haemostatic results show that postoperative platelet 
count, the FIBTEM MCF and INTEM MCF were lower in the group with more than 
500 ml blood loss (appendix 2). 
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Preoperative Postoperative
< 500 cc ≥ 500 cc P= < 500 cc ≥ 500 cc P=
Laboratory hemostasis
Haemoglobin (mmol l-1) 8.1 ± 1.0 8.3 ± 1.0 0.35 6.0 ± 0.8 5.8 ± 0.8 0.22
aPTT (s) 37 ± 8 36 ± 3 0.65 41 ± 8 42 ± 5 0.35
PT (INR) 1.2 ± 0.3 1.1 ± 0.3 0.33 1.8 ± 0.4 1.8 ± 0.3 0.75
Platelets (*109 l-1) 246 ± 71 234 ± 50 0.46 116 ± 42 102 ± 17 <0.01
ACT (s) 137 ± 18 137 ± 18 0.98 137 ± 16 135 ± 11 0.66
Thromboelastometry
INTEM CT (s) 173 ± 37 178 ± 101 0.83 248 ± 100 280 ± 70 0.08
INTEM MCF (mm) 64 ± 5 61 ± 6 0.06 53 ± 7 49 ± 6 0.01
EXTEM CT (s) 70 ± 28 70 ± 20 0.95 104 ± 65 106 ± 27 0.92
EXTEM MCF (mm) 64 ± 9 62 ± 5 0.21 55 ± 6 52 ± 6 0.05
FIBTEM MCF (mm) 19 ± 7 16 ± 5 0.01 12 ± 6 8 ± 3 <0.001
HEPTEM CT (s) 177 ± 55 166 ± 37 0.37 286 ± 165 341 ± 157 0.15
HEPTEM MCF (mm) 64 ± 5 63 ± 5 0.46 53 ± 7 49 ± 6 0.05
Appendix 2.  Pre- and postoperative haemostatic data of cohort study
None of the pre- or postoperative thromboelastometric tests showed a good 
predictive value (PPV) for postoperative major blood loss (table 2). 
Preoperative Postoperative
Spec Sens NPV PPV Spec Sens NPV PPV
INTEM CT 94 10 90 17 63 65 94 17
INTEM MCF 100 5 90 100* 73 45 92 16
HEPTEM CT 92 5 89 7 55 65 93 14
HEPTEM MCF 99 0 89 0 73 45 92 16
EXTEM CT 83 30 91 17 26 80 92 11
EXTEM MCF 99 0 89 0 85 30 91 18
FIBTEM MCF 99 0 89 0 78 55 94 22
Table 2.  Predictive value of thromboelastometry values for bleeding. CT = Clotting time, 
MCF = maximum clot firmness (MCF), INTEM = intrinsic pathway, HEPTEM 
= intrinsic pathway with heparinise, EXTEM = extrinsic pathway FIBTEM = 
fibrinogen, Spec = specificity, Sens = sensitivity, NPV = negative predicting 
value, PPV = positive predicting value, *n=1.
ROC analysis showed that only the INTEM CT and HEPTEM CT showed a 
good area under the curve (AUC) except for post-operative. AUCs of other 
thromboelastometric values were not significantly better (and some even worse) 
than an AUC of 0.5. Univariate logistic regression only showed a significant 
association between major postoperative blood loss and a protamine:heparin 
dosing ratio exceeding 1 (table 3). 
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Preoperative ROC Postoperative ROC
AUC 95% CI AUC 95% CI
INTEM CT 0.374 0.240 – 0.508 0.678 0.573 – 0.784
INTEM MCF 0.382 0.247 – 0.516 0.313 0.197 – 0.429
HEPTEM CT 0.419 0.285 – 0.554 0.662 0.549 – 0.775
HEPTEM MCF 0.428 0.301 – 0.555 0.337 0.226 – 0.448
EXTEM CT 0.524 0.390 – 0.658 0.595 0.470 – 0.720
EXTEM MCF 0.386 0.264 – 0.509 0.358 0.233 – 0.483
FIBTEM MCF 0.324 0.194 – 0.454 0.219 0.128 – 0.309
Table 3.  Receiver operating curve of TEM values for bleeding. CT = Clotting time, 
MCF = maximum clot firmness (MCF), INTEM = intrinsic pathway, HEPTEM 
= intrinsic pathway with heparinase, EXTEM = extrinsic pathway, FIBTEM = 
fibrinogen, AUC = area under the curve CI = confidence interval
The AUC for this risk-factor was found to be 0.69 (95% CI: 0.57 – 0.80) which was 
similar to AUCs found for postoperative INTEM CT and HEPTEM CT. In univariate 
logistic regression, postoperative INTEM CT and HEPTEM CT were not found to 
be significantly associated with major blood loss (table 4). 
Risk factors Odds ratio (OR) 95% CI for OR p-value
Complex surgery 2.08 0.84 - 5.16 0.12
Age (per 1 year increase) 1.03 0.98 - 1.07 0.24
Male gender 1.55 0.58 - 4.20 0.38
BMI (per 1 unit increase) 0.91 0.81 - 1.02 0.11
Duration of CPB (per 1 hour increase) 1.26 0.80 - 1.99 0.33
Preoperative PT (INR) 0.45 0.09 - 2.29 0.33
Preoperative aPTT (s) 0.96 0.89 - 1.04 0.30
Preoperative Hb (mmol l-1) 1.25 0.78 - 2.00 0.35
Postoperative Hb (mmol l-1) 0.67 0.35 - 1.28 0.67
Protamine:Heparin ratio > 1.0 4.89 1.70 - 14.1 0.003
TEM values postoperative
INTEM CT (per 10 s increase) 1.03 0.99 - 1.06 0.19
HEPTEM CT (per 10 s increase) 1.02 0.99 - 1.04 0.16
Table 4.  Results from univariate logistic regression analyses of risk factors and most 
promising TEM values for prediction of major bleeding. BMI = body mass 
index, CPB = cardiopulmonary bypass, PT = prothrombin time, INR = 
international normalized ratio, aPTT = activated partial thromboplastin time, Hb 
= haemoglobin concentration, CT = Clotting time, INTEM = intrinsic pathway, 
HEPTEM = intrinsic pathway with heparinase
When separately added to protamine:heparin dosing ratio exceeding 1 in a 
multivariate logistic regression the odds ratios of both thromboelastometric values 
121 
The predictive value of thromboelastometry for bleeding
5
became smaller (OR = 1.01, 95% CI: 0.97 – 1.06, p = 0.59 for INTEM CT and OR 
= 1.00, 95% CI: 0.98 – 1.03, p = 0.70). AUCs increased to 0.76 (95%: 0.61- 0.81) 
and 0.75 (95%: 0.64 – 0.85) when INTEM CT and HEPTEM CT were added to a 
model with protamine:heparin dosing ratio exceeding 1, however the increases in 
AUC were not statistically significant (p = 0.07 and p = 0.16).
II. Systematic review
Figure 1 shows the flowchart of the literature search. The literature search resulted 
in 1311 studies, of which 10 studies plus our cohort study were included in the 
systematic review. [21-30] This resulted in the inclusion of 1617 patients (table 5). 
Three studies had a possible conflict of interest; the thromboelastometry device 
and reagents were provided by the manufacturer to Coakly et al. and Ranucci 
et al.; the senior author of Lee et al. received a payment for consulting for the 








Pubmed and Embase search June 2016, 
duplicates excluded (n=1311) 
Studies for abstract evaluation (n=136) 
Studies potentially appropriate for inclusion 
in final review (n=17) 
Studies possible eligible for systematic 
review (n=9) 
Studies included in systematic review + 
current case control study (n=11) 
Studies excluded based on title evaluation, no relation 
between thromboelastometry and outcome (n=1030) 
Studies excluded by abstract evaluation for not 
addressing TEM and blood loss / transfusion (n=119) 
Studies excluded by manuscript evaluation for 
addressing TEG or no association between TEM and 
blood loss or blood transfusion (n=9) 
Study found through search of references and citations 
of studies eligible for review (n=1) 
Figure 1.  Flow chart of systematic review 
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PC 150 Elective on-
pump surgery, 
expected CPB 








not stated X X X - Postop EXTEM CFT 
and FIBTEM MCF 
showed moderate PPV 
(71%, 73%) with good 
specificity, 94%, 95%.
(+) Clinicians were 
blinded for TEM results, 
strict transfusion protocol 
(-) Concise analysis for 
the investigation of the 
predictive value of TEM
Davidson25  
J Cardiothor Vasc 
Anesth, 2008
PC 58 Elective on-
pump CABG
Yes 1, 2 & 3 
hours after 
surgery
> 200 m h-1 ‘a single 
postoperative 
hour’
X X X - All pre- and postop TEM 
test results showed a low 
PPV (0-67%) and high 
NPV (85-100%). Highest 
PPV was INTEM CT in first 
postoperative hour.
(+) Clinicians were 
blinded for TEM results, 
multiple postoperative 
TEM testing time-points 
(-) Small sample size, 





J of Thromb and 
Haem, 2011
PC 44 Elective on-
pump surgery
Yes 30 min > 1000 ml 24 hours X - X X Postoperative ROC 
analysis showed a poor 
predictability of TEM for 
postop bleeding, ROC 
AUC ranging from 0.49 – 
0.63, all not significant.
(-) Small sample size, also 
including reoperations 
and ascending aortic 
aneurysm repair. 
Antifibrinolytics were 
only administrated when 
required. Hemostatic 





PC 321 Elective on-
pump surgery 
& high risk 
on bleeding 
patients
No 5 min & 
arrival at 
ICU
> 600 ml 
(75th %) 
> 910 ml 
(90th %)
8 hours X X X - TEM does not add 
predictive value to 
a clinical predictive 
bleeding model.
(+) Clinicians were 
blinded for TEM results 
(-) Inclusion criteria 
changed during study. 





PC 148 Elective on-
pump surgery
Yes 15 min > 12.46 ml 
kg-1 (75th %) 
24 hours - X X X Poor predictability of 
TEM for postoperative 
bleeding. Best predictor 
was postop FIBTEM A30 
ROC AUC 0.70.
(+) Clinicians were 
blinded for TEM results 
(-) Two publications from 
same database with 
different TEM variables 




J of Cardiothoracic 
surg, 2014
RC 148 Elective on-
pump surgery
Yes 15 min > 1507 ml 
(75th %) 
24 hours X - - - Poor predictability 
of INTEM for postop 
bleeding. Strongest 
predictor was INTEM A10 
ROC AUC 0.64.
123 



































PC 400 Elective on-
pump CABG
Yes 30 min > 200 ml h-1 
OR 
> 1000 ml
‘a single hour’ X X - - ≥1 abnormal TEM value 
showed a high PPV 
(100%) and specificity 
(100%).
(+) Large cohort. (-) 
Arbitrary definition 
of surgical and non-
surgical bleeding. 
High reexploration rate 
(»10%). Unclear how the 






PC 78 Elective on-
pump surgery
Yes arrival at 
ICU
> 1000 ml 
(75th %)
24 hours X X X - ROC analysis showed 
a low AUC for all TEM 
values, ranging from 0.50 
to 0.76. Best predictor 
was EXTEM a before 
surgery (ROC AUC 0.76, 
p=0.001).
(+) Patients receiving 
haemostatic therapy 
were excluded. (-) Small 
sample size. Patients with 
(multiple) reexploration for 
bleeding were excluded.
Tarzia30
World J of Card, 
2015





≥ 3 units 
blood 
transfusions
12 hours X X - - EXTEM MCF and 
AUC showed good 
predictability of 
postoperative bleeding 
(cut-off MCF 60 mm and 
AUC 6000).
(+) Analysis for optimal 
cut off for prediction (-) 




RC 116 Elective on 
pump cardiac 
surgery with a 
high bleeding 
risk 





> 1000 ml 12 hours - - X - ROC analysis for FIBTEM 
MCF showed a AUC 
of 0.721. Best cut off 
FIBTEM MCF = 14 mm, 
with poor PPV of 12%.
(+) Analysis for optimal 
cut off for prediction (-) 
Retrospective analysis 
of RCT. Exclusion of 




RC 202 Elective on-
pump surgery
Yes 3 min > 500 ml 
(80th %)
6 hours X X X X Pre- and postoperative 
ROC analysis showed 
a low AUC 0.22 – 0.68. 
Postoperative INTEM CT 
had the best predictive 
value.
(-) Retrospective cohort. 
Low blood loss. Relative 
long inclusion period. 
Table 5.  Details of studies included in systematic review. ACS = acute coronary syndrome, AUC= area under the curve, CABG = 
coronary artery bypass surgery, FFP = fresh frozen plasma, ICU = intensive care unit, PC = prospective cohort, PPV = 
positive predicting value, PRBC = paced red blood cells, RC = retrospective cohort, RCT = randomized controlled trial, 
ROC = receiver operating curve
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DISCUSSION
Our cohort study showed that thromboelastometric tests are poor predictors for 
major postoperative bleeding after cardiac surgery with cardiopulmonary bypass. 
These findings are in line with our systematic review of the available literature, 
which added 8 new studies to the previous literature review. [31] 
Findings from our cohort study confirm previous reports that a lower BMI, longer 
CPB duration, more complex surgery and protamine excess are associated with 
postoperative bleeding. [32,33] The pre- and postoperative thromboelastometric 
positive predicting value was low with a high negative predicting value. The 
addition of heparinise to the intrinsic coagulation test (HEPTEM) did not improve 
the predictive value, further questioning the additive value of HEPTEM. [34] 
The general conclusion from the systematic review is that the predictive value of 
thromboelastometry is insufficient to select patients at risk for major postoperative 
bleeding. This is in contrast with the trauma care where thromboelastometry 
are predict blood transfusion and mortality. [19] Our review showed 
insufficient predictive value in diverse study populations, i.e. with and without 
antiplatelet therapy, elective and emergency surgery, pre- and postoperative 
thromboelastometry values, with and without antifibrinolytics and all sorts of 
cardiac surgery procedures with a wide range of extracorporeal circulation 
duration. 
Limitations of the review are that some studies did not state if the attending team 
was blinded for the thromboelastometry results. Furthermore, the definition of major 
blood loss and timing of thromboelastometric testing was very heterogeneous, 
ranging from measurement during CPB up to one hour after termination of 
cardiopulmonary bypass. Another limitation is the limited number of studies and 
lack of large trials. Also, several studies excluded a surgical cause for bleeding 
while in the clinical situation thromboelastometry might be used to investigate 
the origin of bleeding. Additionally, different statistical methods were used to 
investigate the predictive value of thromboelastometry. Three studies received 
support from the manufacturer of thromboelastometry. Yet, their results are in line 
with the non-supported studies suggesting there was no funding bias.
The definition of significant blood loss varied among studies, not only the cut off 
values and timing of blood loss measurement, also the inclusion of intraoperative 
chest tube drainage and blood product transfusion differed. A universal 
classification of postoperative blood loss remains difficult despite attempts to 
come to a general definition for clinically significant postoperative bleeding. [35] 
This difficulty is due to the heterogeneous practice among cardiothoracic centres 
leading to a diverse distribution of postoperative blood loss and transfusion. 
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[1,36,37] Additionally, there is a great influence of treatment (transfusion and 
reexploration for bleeding) on the amount of chest tube drainage. Also, the rapid 
physiological restoration of coagulation factors might influence the predictive 
value of thromboelastometry. In addition, the thromboelastometry reference 
values are wide impacting the predictive value of abnormal test results. The 
timing of chest tube drainage evaluation plays a supplementary role as late chest 
tube drainage might contain a greater part plasma and interstitial fluid than early 
more concentrated blood loss.
As stated, the treatment of coagulopathy might be a major confounder for the 
lack of predictability of bleeding by thromboelastometry. The natural course of a 
patient with postoperative coagulopathy would lead to a higher risk on bleeding. 
However, when coagulopathy is treated haemostasis will improve, weakening 
the predictive value of pre-intervention thromboelastometric test results. A study 
without haemostatic interventions would be unethical and clinically irrelevant as 
this does not reflect daily clinical practice.
The inability to predict postoperative bleeding might additionally be due to 
the discrepancy between the in vitro evaluation of coagulation and the local 
haemostatic conditions. Previous studies have shown that there is a high local 
fibrinolytic activity in the traumatized mediastinum which is not represented in a 
general blood sample. [38] Another bias might be that the centres investigating the 
predictive value of thromboelastometry have a more state of the art haemostatic 
management practice due to their interest in haemostasis. This would be in 
line with the hypothesis that not thromboelastometry but the implementation 
of thromboelastometry increases awareness and more knowledge about the 
haemostatic system leading to better outcome instead of the device itself. 
Moreover, haemostasis is a stepwise process and requires functioning 
thrombocytes, sufficient clotting factors and fibrinogen. Thromboelastometry is 
able to accurately represent the latter two, however platelet function testing is 
suboptimal by thromboelastometry as the clot formation time (CFT), the main 
parameter for platelet functioning is affected by several other factors. This 
influence might explain the discrepancy between normal thromboelastometry 
values in a patient with impaired platelet functioning causing bleeding. This 
theory is supported by the inability of solely platelet function testing to predict 
postoperative bleeding (i.e. multiple electrode aggregometry, VerifyNow and 
PFA-100). [31]
Although postoperative fibrinogen was lower in the bleeding group the predictive 
value of the FIBTEM MCF was low. In the other studies fibrinogen had relatively the 
highest predictive value although the absolute values were poor to fair. A meta-
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analysis on the predictive value of fibrinogen levels on bleeding found a weak to 
moderate association between fibrinogen levels and postoperative bleeding.39 
As fibrinogen is a key factor in haemostasis and easy to replenish with fibrinogen 
concentrate an increasing number of studies investigated the additive value 
of fibrinogen administration on postoperative bleeding after cardiac surgery. 
Preoperative fibrinogen supplementation showed controversial results although 
postoperative fibrinogen replenishment might reduce postoperative bleeding. 
[40-42] Still, the trigger for fibrinogen supplementation remains controversial. [43]
Interestingly the findings of our systematic review contrast with the findings from 
the paediatric cardiac surgery literature where thromboelastometry has been 
found to predict major bleeding. [44,45] This might be explained by the smaller 
blood volume of children leading to more hemodilution and coagulopathy by CPB. 
These haemostatic disturbances as main cause of major blood loss in children 
would explain the discrepancy in the predictive value of thromboelastometry 
compared to adults. This hypothesis is supported by the fact that the body 
weight and duration of CPB are the best predictors for massive haemorrhage in 
paediatric cardiac surgery. [44-46]
The current cohort study is limited by the small sample size, retrospective data-
analysis, the relative low blood loss and transfusion requirements and the inclusion 
of both patients at low and high risk for bleeding. Furthermore, the earliest data 
from the cohort study dates back to 2011. The number of patients with excessive 
bleeding was too small to perform multivariate logistic regression analyses with 
more than two predictors. Therefore, we used univariate analysis to identify the 
most important risk-factor (protamine:heparin dosing ratio exceeding 1) and 
checked to what extent thromboelastometric values were of added value to this 
risk factor.  Furthermore, as patients demographics and thromboelastometry test 
results in cardiac surgery are not structurally stored in our centre only data from 
previous prospective observational studies in our centre was included, limiting 
the results.
As described above many factors complicate the predictive value of 
thromboelastometry. Nevertheless, the additive value of thromboelastometry 
might not be in predicting blood loss, thromboelastometry can be used to 
guide haemostatic management in a bleeding patient. [16,17] Several studies 
investigated if its implementation reduces bleeding, blood transfusion and 
improved outcome. However, the most recent systematic review shows that 
thromboelastometry can reduce blood transfusion and addresses the poor 
quality of the studies on thromboelastometry guided hemostatic treatment in 
cardiac surgery. [47] Most of the thromboelastometry algorithm studies have 
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a retrospective sequential cohort design. The implementation of a treatment 
algorithm with or without thromboelastometry creates awareness and might 
bias the results. This hypothesis is substantiated by the finding that studies 
implementing a general (non-thromboelastometry) blood management protocol 
showed improved outcome after implementation. [48] 
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ABSTRACT
Introduction: The thromboelastometry INTEM clotting time (CT) with 
heparinase (HEPTEM) is frequently used to detect residual heparin 
after cardiopulmonary bypass (CPB) in cardiac surgery. This study 
investigated whether the HEPTEM CT reflects the presence of residual 
heparin and the association of the protamine-to-heparin ratio to the 
INTEM and HEPTEM CT. 
Methods: We retrospectively evaluated thromboelastometry data that 
were obtained before CPB and after protamine infusion following CPB 
in two tertiary hospitals. The number of patients with an INTEM:HEPTEM 
ratio (IH-ratio) > 1, suggesting residual heparin, were quantified. 
Moreover, the influence of different protamine-to-heparin-dosing-ratios 
(P:H) on the INTEM and HEPTEM CT was evaluated in the clinical setting 
and in blood drawn from healthy volunteers.
Results: An INTEM:HEPTEM CT ratio > 1.1 was observed in 16% of 
the patients prior to CPB, and in 15% after protamine administration. 
Interestingly, 23% and 36% of the patients had an HEPTEM CT exceeding 
the INTEM CT before CPB and following protamine administration. The 
HEPTEM CT was longer than the INTEM CT in patients with a P:H-ratio of 
1:1 (265 ± 132 vs. 260 ± 246 s; P=0.002) or P:H-ratio of 1.3:1 (357 ± 174 
vs. 292 ± 95 s; P=0.001). Increasing P:H-ratios induced a prolonged 
HEPTEM CT in fresh blood. 
Conclusion: Limited agreement was observed between INTEM and 
HEPTEM clotting time in the absence of heparin. INTEM comparison 
to HEPTEM may not always reliably reflect the presence of residual 
heparin, while protamine may additionally affect the latter test. These 
observations complicate HEPTEM results interpretation in clinical 
situations with suspected residual heparin effect after protamine.
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INTRODUCTION
The heparinase thromboelastometric test (HEPTEM) enables the detection of 
heparin in whole blood, and is increasingly used to identify residual heparin after 
protamine reversal following cardiopulmonary bypass (CPB) in cardiac surgery. 
[1] The HEPTEM test consists of the INTEM test in the presence of heparinase, a 
heparin-cleaving enzyme. Heparin prolongs the INTEM assay clotting time (CT) 
compared to the CT of the heparinase assay. In the absence of heparin, it is 
assumed that the INTEM and HEPTEM test produce a similar CT. Controversially, 
in several studies the HEPTEM CT appears to be longer than the INTEM CT 
following CPB. [2-4]
The antagonist of heparin, protamine, is administrated at the end of CPB and 
reverses the anticoagulant effects of heparin by the formation of a neutral 
protamine-heparin complex. [5] Yet, in vitro studies show that protamine itself has 
dose-dependent anticoagulant properties, with inhibitory effects on the intrinsic 
coagulation pathway through suppression of thrombin and factor V activation, 
enhancement of fibrinolysis and inhibition of platelet function. [1,6-13] Besides 
one small study, it is not known whether protamine by itself affects the HEPTEM 
CT in the clinical situation. [14]
As several clinical studies showed that the HEPTEM CT is frequently longer 
than the INTEM CT following CPB, we assessed the occurrence of a prolonged 
HEPTEM CT following CPB. In particular, if the HEPTEM CT does not only reflect 
the presence of heparin in whole blood, its value for coagulation monitoring during 
CPB might need further exploration. Furthermore, we determined the effect of 
different protamine-to-heparin ratios on the HEPTEM CT in blood from healthy 
volunteers in order to gain insight in the influence of protamine dosing on the 
HEPTEM test results.
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The retrospective study investigated thromboelastometric data of patients 
undergoing cardiothoracic surgery with cardiopulmonary bypass in VU University 
Medical Centre (Amsterdam, the Netherlands) and Maastricht University Medical 
Centre (Maastricht, the Netherlands). Thromboelastometry was part of routine 
clinical monitoring. The local Human Subjects Committee of both centres approved 
this retrospective analysis (METc 2012/438) and waived informed consent.
Surgical procedures included valve procedures, coronary artery bypass graft 
(CABG) surgery, and a combination of valve with CABG surgery. Exclusion 
criteria were missing data with regard to post-protamine thromboelastometry, 
aorta surgery, and emergency operations. Preoperative anticoagulant medication 
data was only available in the VUmc Medical Centre.
Anaesthesia and cardiopulmonary bypass
Patients were anesthetized according to local protocols based on a combination 
of sufentanil (3-7 μg kg-1), pancuronium bromide (0.1 mg kg-1) or rocuronium (0.5 
mg kg-1) and midazolam (0.1 mg kg-1) for anaesthesia induction, and propofol 
(200-400 mcg h-1) for anaesthesia maintenance. All patients received tranexamic 
acid.
Cardiopulmonary bypass was performed at a continuous blood flow (2.2-3.0 l min-
1 m-2) during mild hypothermia (> 34oC) using an S5 heart-lung machine (Stöckert 
Instrumente GMBH, Munich, Germany) with a centrifugal pump (Delphin, Terumo 
Europe NV, Leuven, Belgium) and heparin-coated circuit (Medtronic, Minneapolis, 
MN, USA) as described before. [15]
Heparinisation started with an initial bolus of 300 IU kg-1 heparin (LEO Pharma BV, 
Amsterdam, the Netherlands), which was replenished until the Celite activated 
clotting time (ACT) test exceeded 480 seconds (Hemochron® Response, 
Edison, NJ, USA). The priming solution (1400 ml) contained 5000 IU porcine 
heparin (LEO Pharma BV, Amsterdam, the Netherlands). After cardiopulmonary 
bypass, heparin was reversed with protamine hydrochloride (Meda Pharma BV, 
Amstelveen, the Netherlands). The primary dosing of protamine was based on 
local guidelines, which advises approximately 1 mg protamine for every 100 IU of 
heparin administered throughout the procedure.
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Perioperative haemostasis monitoring
Haemostasis was routinely monitored after anaesthesia induction and 3-10 
minutes after protamine administration using standard haemostatic testing 
including the activated partial thromboplastin time (aPTT), prothrombin time (PT), 
platelet count, haemoglobin concentration (Hb), and activated clotting time (ACT). 
The aPTT and PT were determined using calcium thromboplastin and cefaline/
microcrystalline assays, respectively, in a STA-R instrument (Roche Diagnostics 
GmbH, Basel, Switzerland). PT was reported as the international normalized 
ratio (INR). Haemoglobin and platelet count were determined using a Cell-Dyn 
Sapphire® (Abbott Laboratories, Illinois, USA). 
Thromboelastometry
Post-protamine thromboelastometry was routinely performed in both centres. In 
the VU University Medical Centre additional thromboelastometry was performed 
after induction of anaesthesia. Citrated blood samples were analysed using 
thromboelastometry (ROTEM®, TEM International, Munich, Germany).
Whole blood samples were recalcified with 20 microliter of calcium chloride. 
Subsequently, the following tests were performed in the patient study: INTEM 
(intrinsic coagulation pathway, activation by ellagic acid), HEPTEM (INTEM test 
in the presence of heparinase), EXTEM (extrinsic coagulation pathway, activation 
by rabbit brain tissue factor, the reagent supplied by the manufacturer at the time 
of the study period) and FIBTEM (fibrin part of clot formation, EXTEM assay plus 
cytochalasin D for platelet inhibition). Thromboelastometry parameters included 
the clotting time in seconds (CT) and maximum clot firmness in mm (MCF). In the 
in vitro study solely HEPTEM testing was performed. Reference values for clotting 
times for INTEM/HEPTEM and EXTEM are 100-240 s and 38-79 s, respectively. 
Reference values for the maximum clot firmness are 50-72 mm for both INTEM/
HEPTEM and EXTEM and 9-25 mm for FIBTEM. [16]
Other study variables
Study parameters included patient demographics, surgical characteristics, 
standard coagulation and the preoperative and postoperative thromboelastometry 
values (INTEM, HEPTEM, EXTEM and FIBTEM). Demographic variables included 
age, gender, body mass index (BMI). Surgical characteristics were type of surgery, 
aorta cross clamp time, CPB time and lowest temperature. The INTEM:HEPTEM-
ratio (IH-ratio) was calculated by dividing the INTEM by the HEPTEM clotting 
time. According to the manufacturer an IH-ratio > 1 indicates a heparin effect. 
The protamine-to-heparin ratio (PH-ratio) was calculated by dividing the initial 
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protamine sulphate (IU) administration by the total heparin administration (IU). 
Patients were divided into low protamine dosing (PH-ratio < 0.8), normal dosing 
(PH-ratio of 0.8-1.0) and high protamine dosing group (PH-ratio > 1.0). A deviation 
of ± 0.1 was chosen to accept 10% inaccuracy in thromboelastometric tests.
II. In vitro study
Influence of protamine-to-heparin ratio on HEPTEM CT
The study in blood of healthy volunteers was approved by the Human Subjects 
Committee of VU University Medical Centre, Amsterdam, the Netherlands 
(NL43303.029.13). Written informed consent was obtained from each participant 
before blood sampling. Blood samples were collected from 13 adult subjects 
aging between 18 and 40 years and analysed using thromboelastometry. 
Exclusion criteria were the use of anticoagulant medication, known haemostatic 
deficiencies and pregnancy. Blood was sampled from a single venous puncture 
through a vacutainer system using 0.105 M sodium citrate-containing tubes, 
resulting in a final concentration of 3.2% of citrate. Heparin was added to the 
untreated blood samples to retrieve 4.0 IU of heparin per millilitre, which was the 
highest concentration used in the study of Mittermayr that was associated with 
clot formation in the INTEM test. [1] Higher concentrations of heparin completely 
blocked clot formation. [1] Protamine was added to obtain the following 
concentrations: 3.2, 4.0 and 5.6 IU ml-1. A control sample was equally diluted 
with saline without heparin or protamine. Overall, the HEPTEM CT and MCF was 
determined for the following P:H ratios: 0:0 (control), 0.8:1.0, 1.0:1.0, 1.3:1.0.
Data analysis
Statistical analyses were performed using the SPSS statistical software package 
17.0 (SPSS Inc.®, Chicago USA). All data were tested for normal distribution 
prior to statistical analysis. Demographic or coagulation measurement values 
are represented by mean ± standard deviation (SD), median with interquartile 
range or frequencies. Figures represent boxplots of ordinal variables or mean ± 
standard error of the mean. The difference between the distinct P:H ratios was 
tested using a two-way ANOVA (mean ± SD) and a Friedman test for related 
samples (median with interquartile range). Bland-Altman analysis was performed 
using GraphPad Prism 5.0 (La Jolla, CA, USA) and provided the bias, standard 
deviation of the bias, limits of agreement (LoA) and percentage error. Pearson 
correlation analysis was performed to assess the association between the 
postoperative INTEM:HEPTEM ratio and protamine-to-heparin dosing ratio. 
P<0.05 was considered to be statistical significant.
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The study included 159 males (66%) and 81 females (34%). Eight patients 
received preoperative heparin, resulting in an aPTT of 46 ± 8 s in this subgroup 
prior to surgery, and excluding these patients did not alter the study results. 
Furthermore, 71 patients used preoperative acetylsalicylic acid, 1 clopidogrel, 2 
acenocoumerol and 9 low weight molecular heparin. Table 1 shows the patient 
and surgical characteristics. Forty-four patients underwent CABG surgery (18%), 
97 patients valve surgery (41%), 73 patients a combination of CABG and valve 
surgery (31%), 20 patients Bentall surgery (8%) and 4 patients a combination of 
Bentall and CABG surgery (2%). The mean preoperative ACT was 138 ± 28 s, 
and 607 ± 225 s after heparinisation. In table 2 the standard coagulation, blood 
and thromboelastometry test results before and after cardiopulmonary bypass 
are shown.
N Value
Age (years) 240 66 ± 12
BMI (kg m-2) 240 27 ± 4
ECC time (min) 240 144 ± 64
Aortic clamping time (min) 240 103 ± 47
Lowest temperature during ECC (oC) 233 34 ± 2
Cell saver blood transfusion (ml) 189 495 ± 408
Total heparin administered (IU) 239 436 ± 164
Protamine before thromboelastometry (mg) 201 448 ± 122
Total protamine administered (mg) 239 469 ± 172
Table 1.  Patient and surgical characteristics BMI = body mass index; ECC = 
extracorporeal circulation time. Data represent mean ± standard deviation.
Distribution of the INTEM-HEPTEM clotting time ratio
Figure 1 shows the distribution of the INTEM:HEPTEM (IH) clotting time (CT) ratio 
before CPB (upper panel) and 3-10 minutes after protamine (lower panel). We 
observed an IH-ratio exceeding 1.1, which is suggestive for remaining heparin 
activity, in 16% of the patients following anaesthesia induction and in 15% of 
the patients after protamine administration. Interestingly, 23% and 36% of the 
patients had a HEPTEM CT exceeding the INTEM CT before CPB and following 
protamine administration, respectively. Bland-Altman analysis for the level of 
agreement between the preoperative INTEM and HEPEM clotting time revealed 
a bias of -4 ± 37 seconds, with limits of agreement from -76 to 67 seconds and a 
percentage error of 52.2% (Figure 2). 
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Figure 1.  Histograms of the INTEM to HEPTEM clotting time ratio after anaesthesia 
induction (Pre-CPB, upper panel) and 3-10 minutes after protamine infusion 
(Post-protamine, lower panel). The dotted lines show 10% deviation around an 
INTEM:HEPTEM ratio of 1.0 (0.9-1.1).
N Before CPB N After protamine
Standard coagulation tests
PT (INR) 202 1.16 ± 0.39 222 1.76 ± 0.43
aPTT (s) 204 37 ± 8 204 37 ± 8
Platelets (*109 L-1) 236 240 ± 62 237 114 ± 38
Haemoglobin (mmol L-1) 239 8.2 ± 1.0 237 6.0 ± 1.0
Thromboelastometry
HEPTEM CT (s) 195 175 ± 42 228 282 ± 143
HEPTEM MCF (mm) 196 63 ± 5 225 51 ± 7
INTEM CT (s) 199 170 ± 31 229 262 ± 196
INTEM MCF (mm) 200 63 ± 5 229 51 ± 8
EXTEM CT (s) 197 69 ± 26 223 97 ± 31
EXTEM MCF (mm) 199 63 ± 5 214 54 ± 6
FIBTEM MCF (mm) 197 18 ± 5 231 10 ± 4
Table 2.  Haemostatic parameters before cardiopulmonary bypass (CPB) and after 
protamine administration. PT = prothrombin time (PT); INR = International 
Normal Ratio (INR); aPTT = activated Partial Prothrombin Time; CT = clotting 
time; MCF = maximum clot firmness. Data represent mean ± standard 
deviation.
Association of the protamine-to-heparin ratio with the clotting time in patients
Figure 3 shows the relationship between different protamine-to-heparin ratios and 
the INTEM and HEPTEM clotting time. The distribution of distinct protamine-to-
heparin dosing ratios in our population was 16.9% for a ratio < 0.8, 59.5% for a 
ratio between 0.8 and 1.0 and 23.6% for a ratio exceeding 1.0.
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While an increased protamine-to-heparin ratio is suggestive for a reduction in 
residual heparin, the INTEM and HEPTEM clotting time increased. In particular, 
the HEPTEM clotting time was higher than the INTEM clotting time at protamine-
to-heparin ratios of 0.81-1.00 (P=0.002) and a ratio exceeding 1.0 (P=0.001). The 
correlation between the post-CPB INTEM:HEPTEM ratio and the protamine-to-
heparin dosing ratio was weak (r=-0.18; P=0.007).





































Figure 3.  Mean HEPTEM and INTEM clotting time for a pr tamine-to-heparin dosing 
ratio < 0.8, 0.8 – 1.0 and > 1.0. Data represent mean ± standard deviation. * 
HEPTEM clotting time (CT) versus INTEM CT (P<0.05). 
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II. In vitro study
Influence of protamine-to-heparin ratio on HEPTEM CT
The study in blood from healthy volunteers included 6 males and 7 females with 
a mean age of 27 ± 4 years. Table 3 shows the relationship between subsequent 
protamine-to-heparin dosing ratios and HEPTEM test results. The HEPTEM 
clotting time was affected by an increase in the protamine-to-heparin dosing ratio, 
whereas the maximum clot firmness (MCF) was unaffected by a relative increase 
in protamine dosing. Interestingly, HEPTEM clotting time was 201 ± 17 for the 
control sample (0:0 ratio) whereas 273 ± 36 seconds for the 1:1 ratio (P<0.001). 
N 0:0 0.8:1.0 1.0:1.0 1.3:1.0 P-value
HEPTEM CT (s) 13 201 ± 17 244 ± 29 273 ± 36 374 ± 96 <0.001
HEPTEM MCF (mm) 13 54 ± 4 55 ± 4 54 ± 4 52 ± 5 n.s.
Table 3.  In vitro relation between the protamine-to-heparin dosing ratio and the HEPTEM 
test. The protamine-to-heparin dosing ratio is calculated by dividing the amount 
of protamine (mg) by heparin (*100 IU). Clotting time (CT) and maximum clot 
firmness (MCF) for the intrinsic pathway with heparinase (HEPTEM). Data 
represent mean ± standard deviation (SD) or median with interquartile range 
(IQR). 
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DISCUSSION
Heparin anticoagulation during cardiac surgery is neutralised by protamine 
to normalise coagulation. The thromboelastometry HEPTEM test is frequently 
used to assess whether there is remaining heparin activity following protamine 
neutralisation following cardiopulmonary bypass (CPB). In particular, the INTEM 
and HEPTEM clotting time (CT) assess the intrinsic coagulation in the absence or 
presence of heparinase, respectively. Theoretically, the INTEM and HEPTEM CT 
should have a high level of agreement in the absence of heparin, while the INTEM 
CT will exceed the HEPTEM CT in the presence of remaining heparin activity.
The present study however shows that there is a wide diversion between the 
INTEM and HEPTEM CT before initiation of CPB, with a percentage error exceeding 
30%. Moreover, in one quarter of the population we observed a HEPTEM CT that 
was longer than the INTEM CT before surgery. After heparin neutralisation by 
protamine, the HEPTEM CT also frequently exceeded the INTEM CT. Finally, in 
our patient data and in vitro study, we show that in case of higher protamine-to-
heparin dosing ratios, both INTEM and HEPTEM CT values increase, with the 
most prevalent increase in the HEPTEM CT in our patient cohort. These findings 
suggest that protamine dosing might additionally influence the HEPTEM CT.
We are the first to describe these findings, but they are in line with several 
studies in cardiac surgery, showing that the mean INTEM CT is shorter than the 
mean HEPTEM CT. [2-4] Although one may assume that the observed diversion 
between INTEM and HEPTEM clotting times can be caused by local inadequate 
thromboelastometric testing, we could reproduce our findings in two tertiary 
hospitals. 
Two points should be kept in mind with regard to our results. First, our findings 
need to be considered in light of a natural intrinsic variation between the test 
results due to the method of thromboelastometry. Bland-Altman analysis is not 
designed to investigate the level of agreement between tests with different 
purpose, but the large percentage error underlines the wide variation in 
preoperative INTEM and HEPTEM CT values. A recent study by Nagler et al. 
also showed large differences in the INTEM CT when assessed in parallel by 
two distinct ROTEM devices or channels, [17] while Theusinger et al. reported a 
coefficient of variation of 15% when the INTEM CT was repeated. [18] This intrinsic 
test variation might in part explain the differences in the preoperative INTEM and 
HEPTEM CT, although the observed variation between the HEPTEM and INTEM 
tests exceeds the intrinsic test variation of the ROTEM device. Secondly, there is 
a difference between measured residual heparin activity and the observation of 
a bleeding tendency that might be caused by heparin.  The aberrant HEPTEM 
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results might have no clinical impact, as this was beyond the scope of our study. 
The use of thromboelastometric test results should therefore always be placed in 
a clinical perspective, and isolated deviated test results should not lead to clinical 
decisions in a non-bleeding patient as therapy guidance that is solely based on 
test results might lead to inaccurate clinical decision-making. When bleeding is 
suspected to be caused by residual heparin it is advised to only administrate 
protamine in case of an activated clotting time (ACT) > 130 seconds and INTEM 
CT > 240 seconds and HEPTEM CT / INTEM CT < 0.8 as proposed by Weber et 
al. [19] Further studies should evaluate if the aberrant HEPTEM results lead to 
clinical consequences.
The association between heparin dosing and the HEPTEM CT has been clearly 
addressed by others. Mittmayer and colleagues showed in vitro that heparin 
titration prolongs the INTEM CT, whereas the HEPTEM CT remained unaffected. 
[1] Ichikawa and colleagues found a good correlation between the heparin 
concentration and ratio between the INTEM and HEPTEM CT in a clinical cohort at 
two hours following cardiac surgery. [20] Moreover, a recent clinical investigation 
confirmed this finding and showed that the HEPTEM CT is useful for the evaluation 
of haemostasis prior to protamine administration in the setting of high heparin 
concentrations. [21]
In contrast, the influence of protamine (over)dosing on the INTEM and HEPTEM 
CT is still under debate. In a small clinical study, protamine was overdosed in 
13 patients, and a post-hoc anti-Xa assay showed no heparin activity after the 
first protamine dosing. However, both the INTEM and HEPTEM CT prolonged 
after additional protamine, while the HEPTEM remained shorter than INTEM. [14] 
We also showed recently that protamine dosing following CPB was moderately 
associated with the HEPTEM CT. [22] This is in line with the in vitro findings 
presented in the current study, and observations by others, albeit they showed 
that both the INTEM and HEPTEM CT were prolonged by protamine overdosing 
without affecting the IH-ratio. [1,13] 
The manufacturer of the thromboelastometry device (TEM International™) 
nowadays proposes that HEPTEM clotting time values might exceed INTEM 
clotting times due to protamine overdosing. [22] Due to the limited number of 
clinical studies focusing on the influence of protamine dosing on the INTEM 
and HEPTEM CT, no conclusion can be drawn regarding the usefulness of the 
HEPTEM CT in the patient setting in the context of protamine dosing strategies. 
Theoretically, heparinase degrades heparin bound to the heparin-protamine 
complex, resulting in free protamine. As protamine has dose-dependent 
anticoagulant properties when it is unbound to heparin, free protamine might 
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cause a more prolonged HEPTEM CT when compared to INTEM clotting time. To 
investigate this hypothesis we conducted an in vitro experiment where the control 
sample without heparin or protamine was equally diluted as the 1:1 protamine-
to-heparin dosing ratio sample. We expected to find that the control sample and 
the 1:1 protamine-to-heparin dosing sample would reveal comparable HEPTEM 
clotting times, as heparin was in theory completely neutralised by protamine. Yet, 
we found a prolongation of 72 seconds of the HEPTEM CT in the 1:1 protamine-
to-heparin dosing ratio group when compared to the control sample. This could 
confirm our hypothesis that heparinase frees protamine, which in turn exerts an 
anticoagulant effect. Unfortunately, our in vitro data are limited by the omission of 
an INTEM CT test, which makes it impossible to show whether the INTEM:HEPTEM 
CT ratio is affected by high protamine dosing. [1] However, as our clinical findings 
suggest that the HEPTEM CT is more affected by a higher protamine-to-heparin 
dosing ratio, further clinical studies should be executed to further elaborate our 
hypothesis.
The present patient study has all limitations of a retrospective study. The study 
is observational by nature, and protamine dosing was based on the discretion 
of the attending anaesthesiologist based on a 1:1 protamine-to-heparin ratio 
protocol. However, the observations presented in the current study originate 
from two independent hospitals. Moreover, our experiments in blood of healthy 
volunteers suggest that heparin bound to protamine is degraded by heparinase 
(HEPTEM), and the available free protamine subsequently prolongs the clotting 
time. Protamine (over)dosing also prolonged the HEPTEM CT, resulting in 
aberrant results. Interestingly, studies evaluating HEPTEM in the clinical situation 
are scarce and we are the first to evaluate HEPTEM in a large patient cohort. As 
our observations are not in line with previous studies, further clinical exploration 
of the value of the thromboelastometry HEPTEM assay in the clinical setting where 
heparin and protamine are used is warranted.
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ABSTRACT
Introduction: The non-activated rotational thromboelastometric assay 
(NATEM) is increasingly used as sensitive test for the evaluation of the 
endogenous activation of haemostasis. The reproducibility of the test 
results in citrate stored blood has never been investigated.
Methods: The NATEM assay was performed in citrated blood samples 
stored for 0, 45 and 90 minutes using ROTEM® (TEM International, 
Munich, Germany). Blood samples were drawn from healthy volunteers 
and a population of patients admitted to the intensive care (ICU). In 
10 ICU patients, citrate concentrations were measured at baseline and 
after 90 minutes of storage.
Results: The NATEM clotting time shortened in stored citrated blood 
from healthy volunteers (t=0 1226±160; t=45 986±171; t=90 903±177; 
p<0.001) and ICU patients (t=0 986±318; t=90 750±187; p<0.001). 
A similar decrease in clot formation time (CFT) was seen whereas the 
MCF remained unaffected. Citrate concentration did not change over 
time, baseline 13.3 ± 0.5 mmol l-1; after 90 minutes 13.2 ± 0.7 mmol l-1; 
n.s..
Conclusions: The non-activated rotational thromboelastometric assay 
test results change over time in citrate stored blood. The NATEM test 
should be initiated at a standardised time point, in order to prevent bias 
by different test initiation times,
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INTRODUCTION
The non-activated rotational thromboelastometric assay (NATEM) is increasingly 
used as sensitive test for the evaluation of the endogenous activation of 
haemostasis. [1-6] The test solely recalcifies citrated blood prior to analysis, 
without additional coagulation activators. The reproducibility of the test results in 
citrate stored blood has however never been investigated. 
Previous studies showed a low reproducibility of thromboelastography (TEG) 
tests in recalcified citrate stored blood, in particular shortening of the reaction 
time (r) in longer preserved blood samples. [7-12] These studies suggested that 
the citrated blood sample is activated during storage, thereby influencing the 
TEG results. 
In order to gain more insight in a possible bias due to a delayed start of the 
NATEM test in citrate stored blood we performed a study to evaluate the influence 
of storage time on the test results in blood samples drawn from healthy volunteers. 
Furthermore, a population of patients admitted to the intensive care (ICU) was 
investigated in order to see if the results were equal and relevant in the clinical 
setting.
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METHODS
Study population
Blood sample drawing from healthy volunteers was approved by the Human 
Subjects Committee of VU University Medical Centre, Amsterdam, the Netherlands 
(NL43303.029.13). Written informed consent was obtained from each participant 
prior to blood sampling. Exclusion criteria were the use of anticoagulant 
medication, known haemostatic deficiencies and pregnancy. 
The clinical patient study included patients admitted to the surgical intensive care 
unit (ICU) with two or more SIRS criteria. Exclusion criteria were anticoagulant 
therapy in the week preceding ICU admission, haematological disease, chronic 
liver or kidney failure, coagulopathy, increased thrombotic risk, use of an 
Extracorporeal Membranous Oxygenator (ECMO), administration of argatroban 
or protein C. The study was approved by the institutional ethics committee of 
the Klinikum und Fachbereich Medizin Goethe-Universität, Frankfurt am Main, 
Germany (75/11). Informed consent was obtained from patients or their relatives. 
Study procedures
Blood from healthy volunteers was sampled from a single venous puncture 
through a vacutainer system using a tourniquet in healthy volunteers, or a flushed 
non-heparinized intra-arterial line in ICU patients. These methods were chosen to 
fully reflect the clinical situation. Blood was collected in 0.105 M sodium citrate-
containing tubes, resulting in a final citrate concentration of 3.2%. Within 10 
minutes after blood withdrawal, a rotational thromboelastometry NATEM test was 
performed (ROTEM®; TEM International, Munich, Germany). Blood samples were 
recalcified with 20 μl 0.2 M CaCl2 (Star-TEM reagent, ROTEM®; TEM International, 
Munich, Germany) prior to analysis. Several ICU patients received anticoagulation 
with heparin, therefore blood samples in the clinical population were recalcified 
with 20 μl 0.2 M CaCl2 containing additional heparinase (Hep-TEM reagent, 
ROTEM®; TEM International, Munich, Germany) in order to exclude a possible 
heparin effect. The heparinase assay might affect fibrinolysis [13], yet no reports 
indicate an effect on clotting time (CT), clot formation time (CFT) or maximum 
clot formation (MCF). The NATEM variables clotting time, clot formation time and 
maximum clot firmness were measured in blood stored for 0, 45 and 90 minutes 
(healthy volunteers) or 0 and 90 minutes (ICU patients). Other study parameters 
included demographic data: age, gender and reason for admission to the ICU. 
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Statistical analysis
Statistical analysis was performed using SPSS 22.0 Software (IBM, New York, 
USA). Continuous data are represented as mean ± SD. Data were analysed by 
a one-way ANOVA (healthy volunteers) or a Student’s t-test (ICU). Statistical 
significance was achieved if the P-value was <0.05.
154 
Part III: Monitoring coagulopathy
RESULTS
Blood samples were drawn from 14 volunteers and 30 ICU patients. Healthy 
volunteers aged 25 ± 3 years and 50% of the volunteers were male. In ICU 
patients, the mean age was 66 ± 15 years and 23% was male. The reasons for 
ICU admission were cardiovascular (n=16), abdominal (n=5), trauma (n=5), 
neuro (n=2), urology (n=1), lung (n=1), or ENT surgery (n=1). 
Figure 1 shows the NATEM clotting time (CT), the clot formation time (CFT) and the 
maximum clot firmness (MCF) measured after 0, 45 and 90 minutes of storage for 
both groups. The CT and CFT in healthy volunteers and ICU patients decreased 
with storage time (panels A and B, respectively), while the MCF was unaffected 
by storage time (panel C). 
In 10 ICU patients, citrate concentrations were measured at baseline and after 
90 minutes of storage. There were no differences in free citrate concentrations at 
baseline (13.3 ± 0.5 mmol l-1) or after 90 minutes of storage (13.2 ± 0.7 mmol l-1; 
n.s.).
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Figure 1.   Rotational thromboelastometry clotting time (CT; panel A), clot formation time 
(CFT; panel B) and maximum clot firmness (MCF; panel C) for healthy volunteers 
and intensive care unit (ICU) patients in citrated blood (T=0 minutes) and after 
45 and 90 minutes of blood sample storage. Data represent mean ± standard 
deviation. P-values are indicated in the figure. n.s. = not significant.
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DISCUSSION
The NATEM clotting time and clot formation time shorten when citrated blood from 
healthy volunteers or patients is stored, while the MCF remains unaffected. These 
results are in line with findings observed using thromboelastography. It was primarily 
hypothesized that degradation of citrate by the Krebs-cycle in erythrocytes and 
thrombocytes increases the free calcium concentration, thereby reactivating the 
coagulation pathway. [14,15] However, in concordance with Camenzin et al. we 
found no changes in free citrate during blood sample storage. [7] Theoretically, 
the influence of storage time on NATEM parameters could also be explained by 
the initiation of the intrinsic coagulation cascade through contact of coagulation 
factor XII by kaolin or glass. Factor XIIa activates prekallikrein, which in turn is 
capable of activating factor XII, leading to a positive feedback loop. Factor XIIa 
activates factor XI that in turn will activate factor IX in the presence of calcium. 
[16] Over time, factor XIa and XIIa could accumulate, leading to activation of the 
downstream coagulation-cascade when the blood sample is recalcified, leading 
to shortening of the clotting time. Corn trypsin inhibitor (CTI) is a direct inhibitor 
of factor XIIa, and was added to blood samples of healthy volunteers to evaluate 
this hypothesis. [17,18] As expected CTI delayed clot formation. However there 
was no dependency on the time course seen so we could therefore conclude 
that FXIIa pathway activation seems not to play a role in the activation of the 
NATEM samples over time (data not shown). A third explanation may be a time-
dependent accumulation of microparticles that are released from cells during 
activation. In particular, platelet derived vesicles are highly procoagulant, and it 
has previously shown that the concentration of microparticles increases during 
storage of blood. [19,20]
A limitation of the present study is the inclusion of two different subject cohorts 
that only limitedly reflect the clinical setting. We chose for a study in a healthy 
population of volunteers with normal thrombosis and haemostasis profile as first 
requirement to proof that the NATEM test results depend on the blood storage 
time. We further decided to choose a specific clinical population that is known 
for a procoagulant profile, in this case patients with SIRS. It is warranted that our 
findings should be further confirmed in a more heterogeneous clinical population.
Thromboelastometric tests that require the addition of an activator to citrated 
blood samples, like the INTEM, EXTEM and FIBTEM tests, can be stored op to 
2 hours. [21,22] It is thought that the strong activation of haemostasis by the 
addition of ellagic acid or tissue factor compensates for the endogenous change 
in coagulation potency in stored blood samples. Hence, our findings indicate that 
the NATEM test should be initiated at a standardised time point, preferably in 
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freshly drawn citrated blood in order to prevent bias by different test initiation times. 
In conclusion, we feel that initiation of the NATEM test directly after withdrawal of 
citrated blood will give the most realistic representation of the haemostatic status 
of the patients.
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ABSTRACT
Background: Hemostasis monitoring in cardiac surgery could benefit 
from an easy to use and fast point-of-care coagulation monitor, 
since routine laboratory tests have a delay of 30-45 minutes. This 
study investigated the level of agreement between the point-of-care 
prothrombin time (PT) with central laboratory PT before and after 
cardiopulmonary bypass.
Methods: Bland Altman and error grid analysis were used to analyze 
the agreement between the point-of-care Coaguchek XS Pro device 
(POC-PT) and the central laboratory prothrombin time (LAB-PT) 
before cardiopulmonary bypass (CPB) and 3 minutes after protamine 
administration. Prothrombin times were expressed in international 
normalized ratios (INR).
Results: The average POC-PT and LAB-PT values of 73 patients 
were 1.06 ± 0.14 and 1.09 ± 0.13 (P=0.10) before CPB. POC-PT 
measurements before CPB showed a good agreement with the LAB-PT, 
with a bias of -0.02 ± 0.07 INR and 94% of the values being represented 
in the clinical acceptable zone of error grid analysis. The mean POC-PT 
3 minutes after protamine administration was significantly lower than 
the LAB-PT (1.35 ± 0.12 vs. 1.70 ± 0.18; P<0.001). The PT at 3 minutes 
after protamine administration showed a bias of 0.36 ± 0.14, and 82% 
of the values were located outside of the clinical acceptable zone in the 
error grid analysis. 
Conclusions: Point-of-care prothrombin time testing was in 
concordance with conventional laboratory PT prior to cardiopulmonary 
bypass. At 3 minutes following protamine administration, PT values of 
the point-of-care device were structurally lower than the laboratory PT 
values, leading to a disagreement between both tests at that time point.
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INTRODUCTION
Point-of-care prothrombin time (PT) monitoring is widely used in patients with 
vitamin-K-antagonist therapy. [1,2] Recently, point-of-care (POC) coagulation test 
devices have additionally been validated for intraoperative application, as their 
use may reduce the time between blood sampling and test results from 30-45 to 
3 minutes. [3-5] This time reduction may be of particular value in the diagnostic 
support of perioperative plasma transfusion. [6] Most validation studies were 
however performed in non-cardiac surgery, while cardiac surgery is associated 
with the relatively highest number of blood product transfusion and subsequent 
risk of transfusion-induced-morbidity. [7-9] A complicating factor for coagulation 
monitoring in cardiac surgery is that patients are exposed to heparin, protamine 
and extracorporeal circulation, which may influence the coagulation test results.
Although the comparison of the point-of-care prothrombin time with laboratory 
testing in cardiac surgery has already described by others, [10,11] these studies 
did not evaluate the device shortly after cardiopulmonary bypass, whereas 
prompt evaluation could lead to improved hemostatic monitoring and intervention. 
Additionally, these studies did not specifically focus on the level of agreement or 
limited their evaluation to correlation analysis. Moreover, an advised evaluation of 
the clinical relevance of differences between point-of-care and central laboratory 
measurements was not included in these publications. [12] 
In the present study we therefore investigated the level of agreement between 
the point-of-care Coaguchek XS Pro device (POC-PT) for whole blood analysis 
with the central laboratory prothrombin time (LAB-PT) in platelet free plasma 
before cardiopulmonary bypass and 3 minutes after protamine administration. 
Additionally, we evaluated the relevance of the observed differences between 
both methods of prothrombin time testing using Clarke’s error grid analysis.
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METHODS
Patient characteristics
The present study investigated hemostatic laboratory test results of 73 patients 
undergoing cardiothoracic surgery with cardiopulmonary bypass in the VU 
University Medical Center (Amsterdam, the Netherlands). The local Human 
Subjects Committee approved the study (VU University Medical Center, 
Amsterdam, the Netherlands; METc 13/187), and informed consent was obtained 
according to local regulations. Included patients were 18 years or older and 
underwent elective cardiothoracic surgery with cardiopulmonary bypass (CPB). 
Surgical procedures included valve procedures, coronary artery bypass graft 
(CABG) surgery or a combination of valve with CABG surgery. Exclusion criteria 
were emergency operations and off-pump cardiac surgery.
Anesthesia and cardiopulmonary bypass
Patients were anesthetized according to local protocols based on a combination 
of sufentanil 3-7 μg kg-1, rocuronium 0.5 mg kg-1  and midazolam 0.1 mg kg-1 for 
anesthesia induction and tracheal intubation, and propofol (200-400 mcg h-1) for 
maintenance. All patients received dexamethasone and tranexamic acid.
Cardiopulmonary bypass was performed at a continuous blood flow (2.2-3.0 l 
min-1 m-2) during normo- or mild hypothermia (>34 oC) using an S5 heart-lung 
machine (Stöckert Instrumente GMBH, Munich, Germany) with a centrifugal 
pump (Delphin, Terumo Europe NV, Leuven, Belgium) and heparin-coated circuit 
(Medtronic, Minneapolis, MN, USA). Heparinisation started with an initial bolus 
of 300 IU kg-1 heparin (LEO Pharma BV, Amsterdam, the Netherlands), which 
was replenished until the Celite activated clotting time (ACT) test exceeded 
480 seconds (Hemochron® Response, Edison, NJ, USA). The priming solution 
(1400 ml) contained 5000 IU porcine heparin (LEO Pharma BV, Amsterdam, the 
Netherlands). After cardiopulmonary bypass, heparin was reversed with protamine 
(MedaPharma BV, Amstelveen, the Netherlands). The primary dosing of protamine 
was based on local guidelines, which advises approximately 1 mg protamine 
for every 100 IU of heparin administered throughout the procedure (1:1 ratio).
Prothrombin time measurements
According to local protocols, blood samples are routinely drawn directly after 
anesthesia induction and 3 minutes after protamine administration. The INR of 
the prothrombin time (PT) was measured by the POC-device and in the central 
hemostasis laboratory. The Coaguchek PRO XS Pro® (POC-PT; Roche Diagnostics, 
Almere, The Netherlands) was switched on and prepared prior to blood sampling. 
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A blood sample from a flushed arterial line was drawn into a 1 mL syringe and 
one drop of whole blood was immediately placed on the Coaguchek test strip 
containing rabbit brain thromboplastin (Roche PT test strip®, Roche Diagnostics 
FmbH, Basel, Switzerland). Simultaneously, a second blood sample was drawn in 
to a citrated tube and send to the central hemostasis laboratory. Laboratory testing 
included the international normalized ratio (INR) of the prothrombin time based 
on calcium thromboplastin (LAB-PT) and the activated partial thromboplastin time 
(aPTT) based on cefaline/microcrystaliline using a STA-R instrument® (Roche 
Diagnostics FmbH, Basel, Switzerland) in platelet-free plasma. 
Other study parameters
Patient demographics included age, gender and body mass index (BMI). Surgical 
characteristics were type of surgery, CPB time, aorta clamp time, heparin and 
protamine dosing and the lowest body temperature. Hemostatic parameters 
included preoperative heparin use, activated clotting time (ACT), hemoglobin 
concentration (Hb), the activated partial thromboplastin time (aPTT), platelet 
count before CPB and 3 minutes after protamine administration.
Data analysis
Data are represented as mean ± standard deviation, median with interquartile 
range or frequencies. Data analysis was performed with the SPSS statistical 
software package 17.0 (SPSS Inc.®, IBM, New York, USA). A P-value <0.05 was 
considered as statistical significant. 
Bland-Altman analysis was performed using GraphPad Prism 5.0 (La Jolla, CA, 
USA). Bland-Altman analysis provided the bias, standard deviation of the bias, 
and limits of agreement between both methods. Bland Altman analysis shows 
the mean of both prothrombin time measurements of one patient on the x-axis 
((LAB PT + POC PT) / 2) and the difference between the to measurements on the 
y-axis (LAB PT - POC PT). The bias shows the general difference between the 
measurements, with the fluctuations around this difference as standard deviation 
of the bias. The 95%-limits of agreements shows where the values will be for 
most patients (bias ± 1.96 SD), if these differences are not clinically relevant 
the laboratory and point-of-care method are interchangeable. The association 
between cardiopulmonary bypass and aortic clamp time, preoperative and post-
CPB hemoglobin values and LAB-PT or POC-PT test results were analyzed using 
Pearson correlations.
Error grid analysis was used to evaluate the clinical relevance of the differences 
between point-of-care and central laboratory measurements. [12] A prothrombin 
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time below 1.0 INR was indicated as normal, and a PT > 1.5 INR was defined as 
coagulopathy, potentially requiring treatment. The scatter plot was divided into 
three zones showing the clinical relevance of the (dis)agreement between the two 
methods. Zone A shows the clinical acceptable area with an acceptance of 10% 
deviation between the two methods. Zone B represents an error greater than 10% 
and in this area coagulopathy is over- or underestimated with possibly changing 
clinical decision-making. Ten percent was chosen since a deviation of 0.10 – 0.15 
INR from the golden standard (i.e. laboratory prothrombin time) was considered 
clinically acceptable. Zone C reflects a clinically unsafe situation leading to 
inadequate or inappropriate treatment. More than 95% of the values should be 
in zone A and none in zone C for the POC-method to be clinical acceptable, 
reflecting a P-value < 0.05. 
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The study population included 73 patients undergoing cardiac surgery with 
cardiopulmonary bypass, with a mean age of 68 ± 10 years and body mass index 
of 27 ± 4 kg m-2. Table 1 shows the surgical and hemostatic characteristics. 
Surgical and hemostatic characteristics Values
N 73
Preoperative hemoglobin (mmol l-1) 8.6 ± 0.8
Preoperative aPTT (s) 35 ± 4
Preoperative platelet count (10*9 l-1) 272 ± 84
Preoperative ACT (s) 131 ± 16
Pre-CPB ACT (s) 587 ± 187
CPB time (min) 104 ± 33
Aortic clamp time (min) 72 ± 25
Lowest intraoperative hemoglobin (mmol l-1) 5.2 ± 0.7
Lowest intraoperative temperature (oC) 34.5 ± 0.9
Heparin before CPB (*100 IU) 327 ± 78
Heparin during CPB (*100 IU) 173 ± 107
Total protamine dosing (mg) 371 ± 97
Postoperative hemoglobin (mmol l-1) 6.0 ± 1.0
Postoperative aPTT (s) 39 ± 4
Postoperative platelet count (10*9 l-1) 145 ± 51
Postoperative ACT (s) 133 ± 13
Intraoperative red blood cell transfusion [units] 0 (0;0)
Table 1.  Surgical and hemostatic characteristics. Data represent mean ± standard 
deviation, median with interquartile range or frequencies. aPTT = activated 
partial thromboplastin time; CPB = cardiopulmonary bypass; ACT = activated 
clotting time.
The majority of patients were male (71%). Most patients underwent CABG (67%) 
or valve (22%) surgery. Patients did not receive red blood cell transfusion during 
surgery. Figure 1 shows the average values for the POC-PT and LAB-PT before 
and after cardiopulmonary bypass.
The whole blood POC-PT after protamine administration was lower when 
compared to the LAB-PT test in platelet-free plasma.
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Figure 1.  Point of care (CC) and central laboratory (LAB) prothrombin time (I.N.R.) 
before and after cardiopulmonary bypass. Data represent mean ± standard 
deviation.
Level of agreement between POC-PT and LAB-PT
Figure 2 represents the Bland-Altman analyses for the POC-PT and LAB-PT 
after induction of anesthesia (panel A) and 3 minutes following administration of 
protamine (panel B). 




























































Figure 2.  Bland Altman analysis of point of care (CC) vs. central laboratory (LAB) 
prothrombin time (INR) before (Panel A) and after (Panel B) cardiopulmonary 
bypass (CPB).
Before cardiopulmonary bypass, Bland-Altman analysis revealed a good level 
of agreement as shown by the bias with standard deviation of -0.02 ± 0.07 with 
limits of agreement ranging from -0.16 to -0.12. Three minutes after antagonizing 
heparin by protamine, the bias was severely altered and estimated 0.36 ± 0.14, 
with limits of agreement ranging from 0.09 to 0.63. 
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There were no differences in the POC-PT test (1.34 ± 0.13 vs. 1.34 ± 0.13; n.s.) 
and LAB-PT test (1.68 ± 0.16 vs. 1.73 ± 0.16; n.s.) following cardiopulmonary 
bypass between patients undergoing CABG or valve surgery, respectively.
Pearson correlation analysis showed no association between duration of 
cardiopulmonary bypass with the LAB-PT (r=0.069; P=0.56) or POC-PT (r=0.028; 
P=0.082) or the aortic clamp time with the LAB-PT (r=-0.02; P=0.87) or POC-PT 
(r=-0.13; P=0.26). There was no correlation between the cardiopulmonary bypass 
time (r=-0.09; P=0.44) and aortic clamp time with the difference between LAB-PT 
and POC-PT (r=-0.15; P=0.20). There was a correlation between postoperative 
hemoglobin concentration and LAB-PT (r=-0.30; P=0.01), this was not found 
for the POC-PT (r=-0.04; p=0.72). Postoperative hemoglobin concentration 
correlated with the difference between LAB-PT and POC-PT (r=-0.28; P=0.018).
Clarke’s Error Grid Analysis
Figure 3 shows the error grid analysis for the deviation between POC-PT and 
LAB-PT before (panel A) and after (panel B) cardiopulmonary bypass. Before 
cardiopulmonary bypass, 94% of the values were located in zone A, 6% in zone B 
and 0% in zone C. After reversal of heparin by protamine, this distribution shifted, 
and 18% was located in zone A, 82% in zone B and 0% in zone C.
Figure 3.  Error grid analysis of point of care (CC) vs. laboratory (LAB) prothrombin time 
(INR) before and after cardiopulmonary bypass (CPB). The implication of 
zones A (white), B (light grey), and C (dark grey) are described in detail in the 
method section.
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DISCUSSION
This study shows that point-of-care whole blood prothrombin time testing showed 
a good level of agreement with a conventional laboratory plasma prothrombin 
time before initiation of cardiopulmonary bypass, but this agreement disappeared 
at three minutes after protamine administration. Point-of-care PT values were 
lower following cardiopulmonary bypass than laboratory PT values. The majority 
of data pairs as measured before cardiopulmonary bypass were located in zone 
A during Clarke’s grid analysis. However, the error grid analysis showed that 
82% of the values are represented in Zone B following heparin and protamine 
administration, while this should be <5% to be clinically acceptable. Our findings 
suggest that point-of-care testing may be of added value in hemostatic testing 
before heparin and protamine administration in cardiac surgery. However, the 
disagreement between POC-PT and LAB-PT three minutes following protamine 
administration warrants further evaluation of the optimal POC-PT monitoring 
timing after cardiopulmonary bypass before clinical implementation.
An early impression of the hemostatic state of a patient could differentiate 
between surgical and coagulopathic bleeding and influence subsequent therapy. 
Although POC-PT measurements have previously been evaluated in two other 
cardiosurgical studies, these studies evaluated the prothrombin time at least 10 
minutes after protamine administration and found a good relation with laboratory 
PT values. [10,11] Yet, some patients require hemostatic evaluation at the earliest 
convenience following weaning from bypass, as an early goal directed approach 
of coagulopathy may improve outcome. We therefore performed post-CPB 
measurements shortly after protamine administration. However, 3 minutes after 
protamine administration shows to be too early for accurate PT monitoring by 
POC-PT. This prompt timing of prothrombin measurements might explain the 
disagreement of our findings with previous studies. 
It might be suggested that the difference between POC and laboratory PT testing 
3 minutes after protamine administration could be explained by the duration of 
protamine-heparin complex formation, as this takes up to 10 minutes. [13] As 
blood is drawn 3 minutes after protamine infusion not all heparin may have formed 
a complex with protamine. The manufacturer of the POC-PT device states that the 
device is insensitive to heparin concentrations up to 0.8 IU ml-1. This insensitivity 
to heparin by the POC device could explain the shorter POC-PT, as the laboratory 
PT is more affected by the unbound heparin. Yet, the infusion of protamine itself 
takes several minutes in which protamine-heparin complexes can be formed, 
suggesting that nearly all complexes will have been formed at the time of the 
POC-PT measurement. 
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Interestingly, hemoglobin concentrations could rationalize the difference between 
the laboratory and POC prothrombin time. The found negative correlation between 
postoperative hemoglobin level and laboratory PT was absent for the POC-PT test 
suggesting that the POC-PT is less sensitive for the influence of erythrocytes on 
hemostasis. [14] This is in line with earlier findings by van den Besselaar et al. 
showing a distinct influence of hematocrit on the LAB-PT and POC-PT. [15]
The Clarke’s grid analysis shows that, before cardiopulmonary bypass, 94% of the 
values were located in zone A and 6% in zone B. This means that in 6% of the cases, 
the level of coagulopathy as assessed by PT might be over- or underestimated 
with possible effect on the decision to transfuse hemostatic products. Three 
minutes after reversal of heparin by protamine, this distribution shifted to 18% in 
zone A and 82% in zone B. All values in zone B are located on the right side of 
zone A in the Clarke’s grid plot, showing that PT values were structurally shorter 
than laboratory PT values after heparin reversal with protamine. As we compared 
the point-of-care PT with a gold standard, this might suggest that the use of the 
Coaguchek may lead to underestimation of the presence of coagulopathy. On 
the other hand, as the laboratory PT is also influenced by residual heparin or 
protamine overdosing, it is unclear whether the gold standard accurately reflects 
the hemostatic status of the patient. Further studies should reveal which test is the 
best representative for the post-heparin phase during cardiac surgery. 
Our study is limited by the single measurement time point of the prothrombin 
time following cardiopulmonary bypass, as repeating measurements will give 
better insight in the optimal timing of PT monitoring and level of agreement 
between laboratory and point-of-care PT tests. Since point-of-care PT testing 
may contribute to fast insight in the hemostasis of our patients, additional studies 
should be performed to further determine the clinical value of point-of-care PT 
testing.
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ABSTRACT
Point-of-care coagulation monitoring can be used for the guidance of 
hemostasis management. However, the influence of time on point-of-
care prothrombin time testing following protamine administration after 
cardiopulmonary bypass has not been investigated. Bland–Altman 
and error grid analysis were used to analyze the level of agreement 
between prothrombin time measurements from point-of-care and 
laboratory tests before cardiopulmonary bypass, and then 3 min, 6 
min and 10 min after protamine administration. Prothrombin times were 
expressed as International Normalized Ratios. While the point-of-care 
and laboratory prothrombin time measurements showed a high level 
of agreement before bypass, this agreement deteriorated following 
protamine administration to a mean (SD) bias of - 0.22 (0.13) [limits of 
agreement 0.48 – 0.04]. Error grid analysis revealed that 35 (70%) of the 
paired values showed a clinically relevant discrepancy in international 
normalized ratio. At 3 min, 6 min and 10 min after cardiopulmonary 
bypass there is a clinical unacceptable discrepancy between the point-
of-care and laboratory measurement of prothrombin time.
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INTRODUCTION
Point-of-care coagulation monitoring in the peri-operative setting is used routinely 
for the guidance of hemostasis management. The point-of-care prothrombin 
time test was primarily developed for the rapid, outpatient monitoring of warfarin 
therapy. This test has recently been validated for use in non-cardiac surgery, 
reducing the time between blood sampling and test result by up to 60 min [1] and, 
therefore, may be useful for rapid guidance of transfusion practice. [2-5]
The value of prompt insight into patient hemostasis might even be greater in 
cardiac surgery, due to its association with postoperative coagulopathy and 
high rate of allogeneic blood transfusion. The coagulopathy is thought to be 
due to a combination of blood contact with the non-biological surface of the 
cardiopulmonary bypass circuit, hemodilution and acute blood loss. Residual 
heparin or abundant protamine administration may further impair hemostasis. 
These factors complicate peri-operative hemostatic monitoring in cardiac surgery, 
and might have distinct effects on the prothrombin time as measured by point-of-
care and formal laboratory testing.
We recently showed a low level of agreement between point-of-care and laboratory 
prothrombin time results, when measured 3 min after protamine administration. [6] 
However, two previous studies demonstrated that point-of-care prothrombin time 
measurement was comparable with laboratory testing when blood was withdrawn 
more than 10 min after protamine administration. [7,8]
In order to clarify whether the timing of testing following protamine administration 
influences the results, we evaluated point-of-care and laboratory prothrombin time 
measures at 3 min, 6 min and 10 min after protamine administration in patients 
having cardiac surgery.
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METHODS
This prospective observational study was performed in the VU University Medical 
Center (Amsterdam, the Netherlands). Patients undergoing cardiothoracic 
surgery with cardiopulmonary bypass were included. The local Human Subjects 
Committee approved the study and informed consent was obtained from all 
patients. Patients were enrolled if they were undergoing elective cardiac surgery 
with bypass and aged ≥ 18 years. We did not study patients with renal or hepatic 
failure, those who had received pre-operative erythropoietin or warfarin less than 
3 days before surgery and those with hemoglobin concentrations < 89 g l-1.
Patients were anesthetized according to local protocols based on a combination 
of sufentanil (3–7 μg kg-1), rocuronium (0.5 mg kg-1) and midazolam (0.1 mg 
kg-1) for induction of anesthesia, and propofol (200–400 μg h-1) for anesthesia 
maintenance. All patients received tranexamic acid (1 g before and 2 g after 
bypass). Cardiopulmonary bypass was performed at a continuous flow of 2.2–3.0 
l min-1 m-2 during mild hypothermia (> 34 °C) using an S5 heart-lung machine 
(Stöckert Instrumente GMBH, Munich, Germany) with a centrifugal pump (Delphin, 
Terumo Europe NV, Leuven, Belgium) and heparin-coated circuit (Medtronic, 
Minneapolis, MN, USA). Initial heparinization was achieved with 300 IU kg-1 heparin 
bolus (LEO Pharma BV, Amsterdam, the Netherlands), which was then repeated 
until the celite-activated clotting time test (Hemochron® Response, Edison, NJ, 
USA) exceeded 480 s. The priming solution (1400 ml) contained 5000 IU porcine 
heparin (LEO Pharma BV). After bypass, heparin was reversed with protamine 
hydrochloride (Meda Pharma BV, Amstelveen, the Netherlands). The primary dose 
of protamine was based on local guidelines, which advised approximately 0.8 mg 
protamine for every 100 IU of heparin administered throughout the procedure, 
with adjustments at the discretion of the attending anesthetist. Acetylsalicylic acid 
therapy was continued peri-operatively, while clopidogrel was stopped 5 days 
before surgery.
Four arterial blood samples were collected during the procedure from a non-
heparinized arterial line; the first 5 ml of blood withdrawn was discarded before 
blood sampling. Samples were collected after induction of anesthesia and then 3 
min, 6 min and 10 min after protamine administration. The international normalized 
ratio (INR) of the prothrombin time was measured using a point-of-care device 
(Coaguchek® Pro DM; Roche Diagnostics, Almere, the Netherlands) and in the 
central hemostasis laboratory. The Coaguchek Pro DM device was switched on 
and prepared before blood sampling. A blood sample from the flushed arterial 
line was drawn into a 1-ml syringe and one drop of whole-blood was immediately 
placed on the Coaguchek test strip containing rabbit brain thromboplastin (Roche 
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Diagnostics, FmbH, Basel, Switzerland). Simultaneously, a second blood sample 
was drawn into a citrated tube and sent to the central hemostasis laboratory. 
Laboratory testing included the INR of the prothrombin time based on calcium 
thromboplastin, and the activated partial thromboplastin time based on cefaline/
microcrystaliline using a STA-R instrument® (Roche Diagnostics) in platelet-free 
plasma. Other hematological data collected included activated clotting time, 
hemoglobin concentration, hematocrit, activated partial thromboplastin time and 
platelet count. All parameters were measured before cardiopulmonary bypass 
and 3 min after protamine administration.
To calculate sample size, based on a previous study we estimated that mean (SD) 
point-of-care and laboratory prothrombin time measurements at 10 min following 
weaning from bypass would be 1.40 (0.30) and 1.55 (0.30), respectively. [9] 
Based on the estimated difference, we accepted a bias of 0.15 between the point-
of-care and laboratory prothrombin time measurements with estimated limits of 
agreement of −0.15 to 0.45. In order to achieve the desired 95% CI of 0.15 around 
the limits of agreement, we required 50 patients.
Data analysis was performed using the SPSS statistical software package 17.0 
(IBM, New York, NY, USA). A p value < 0.05 was considered as statistically 
significant. Bland–Altman analysis was performed using GraphPad Prism 5.0 (La 
Jolla, CA, USA). Bland–Altman analysis provided the bias, standard deviation of 
the bias, and limits of agreement between both methods. [10] The percentage 
error was calculated as 1.96 × SD of the bias/mean INR of the two methods. A 
percentage error below 20% was considered clinically acceptable. [11] Error grid 
analysis was used to evaluate the clinical relevance of the difference between 
point-of-care and laboratory measurements. [12] International normalized ratio < 
1.0 was considered normal, and INR > 1.5 was defined as a coagulopathy which 
would potentially require treatment. The scatter plot was divided into three zones 
showing the clinical relevance of the (dis)agreement between the two methods. 
Zone A showed the clinical acceptable area with an acceptance of 10% deviation 
between the two methods. Zone B represented an error greater than 10%, and 
in this area coagulopathy is over- or underestimated; 10% was chosen since a 
deviation in INR 0.10–0.15 from the gold standard of laboratory prothrombin time 
measurement was considered clinically acceptable. Zone C reflected a clinically 
unsafe situation leading to inadequate or inappropriate treatment. More than 95% 
of the values should be in zone A and none in zone C for the point-of-care method 
to be clinical acceptable, reflecting a p value < 0.05. The difference between 
point-of-care and laboratory prothrombin time was correlated with fibrinogen 
level, thrombocyte count and hematocrit using Pearson correlation.
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RESULTS
We recruited 50 patients (31 males) with a mean age of 68 ± 10 years and BMI 
29 ± 5 kg.m-2. Overall, 38 patients underwent coronary artery bypass grafting or 
single valve surgery, whereas the remaining patients underwent a combination 
of coronary artery bypass grafting with valve surgery or a Bentall procedure. 
The surgical and hematological characteristics of the participants are shown 
in Tables 1 and 2, respectively. Six patients received packed red blood cell 
transfusion during surgery. Directly after cardiac surgery, six patients received 
platelet transfusions and two patients received packed red blood cells; no patient 
required transfusion of fresh frozen plasma.
N = 50
CPB duration (min) 95 ± 37
Aortic clamp time (min) 70 ± 26
Minimum temperature (oC) 35 ± 1
Heparin dosing (mg) 412 ± 79
Protamine dosing (mg) 241 ± 54
Table 1.  Cardiopulmonary bypass and anticoagulation characteristics for all included 
patients (n = 50). Values are mean (SD).
Preoperative 3 min after protamine
Haemoglobin (g l−1) 139 ± 16 91 ± 13
Haematocrit (%) 41 ± 5 29 ± 4
Platelet count (×109 l−1) 243 ± 60 125 ± 35
Activated partial thromboplastin time (s) 35 ± 5 44 ± 13
Activated clotting time (s) 125 ± 11 130 ± 11
Table 2.  Pre-operative and post-cardiopulmonary bypass haemoglobin, haematocrit, 
thrombocyte count values and haemostatic test results for included patients. 
Values are mean (SD). There were no missing values for haemoglobin, 
haematocrit, thrombocyte count and activated clotting time (n = 50). Activated 
partial thromboplastin time data from three patients were missing (n = 47).
The whole-blood prothrombin time measured using point-of-care testing was lower 
at all time points after bypass compared with those measured in the laboratory 
using platelet-free plasma (Figure 1).
Bland–Altman analyses for point-of-care and laboratory measurements of 
prothrombin time are shown in Figure 2. Before bypass, Bland–Altman analysis 
revealed a high level of agreement between the two measures with bias (SD 
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Figure 1.  Laboratory (grey bars) and point-of-care (open bars) prothrombin times (PT) 
expressed as international normalised ratio (INR) before (Pre-op) and at 3 min, 
6 min and 10 min following protamine administration. Values are mean (SD). 
Student’s t-test was used to compare laboratory and point-of-care prothrombin 
times at the relevant time points. *p < 0.001.






























































Figure 2.  Bland–Altman analysis of the level of agreement between the laboratory (LAB) 
and point-of-care (POC) prothrombin time (PT) expressed as international 
normalised ratio (INR) before (Pre-op; panel a) and at 3 min (panel b), 6 min 
(panel c) and 10 min (panel d) following protamine administration. The figures 
represent the bias (- - -) with limits of agreement (…….).
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[limits of agreement]) of 0.00 (0.04 [−0.09 to 0.14]). After reversal of heparinization 
with protamine, the bias (SD [limits of agreement]) was markedly altered at 3 
min (−0.23 (0.15) [−0.53 to 0.06]), 6 min (−0.23 (0.16) [−0.55 to 0.09]) and 10 
min (−0.22 (0.13) [−0.48 to 0.04]). The time of prothrombin time measurement 
after protamine administration did not influence the results. The precision error 
between both methods at baseline and 3 min, 6 min and 10 min following 
protamine administration was 11.4%, 20.0%, 21.7% and 17.9%, respectively. 
Figure 3.  Clarke’s Error Grid analysis of the level of agreement between the laboratory 
(LAB) and point-of-care (POC) prothrombin time (PT) expressed as international 
normalised ratio (INR) before (Pre-op; panel a) and at 3 min (panel b), 6 
min (panel c) and 10 min (panel d) following protamine administration. The 
implication of zones A (white), B (light grey), and C (dark grey) are described 
in detail in the method section
The error grid analyses for the deviation between point-of-care and laboratory 
measures of prothrombin time are shown in Figure 3. Before bypass, 96% of the 
values were located in zone A and 4% in zone B. After reversal of heparin by 
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protamine, this distribution markedly altered: 32% zone A and 68% zone B after 3 
min; 22% zone A and 78% zone B after 6 min; and 28% zone A and 72% in zone 
B after 10 min. There were no readings in zone C at any time point. 
The difference between point-of-care and laboratory measurements of 
prothrombin time did not correlate with postoperative platelet count (R = 0.56, p 
= 0.714) or fibrinogen concentration (R = −0.45, p = 0.85), although there was a 
weak correlation with postoperative hematocrit (R = 0.31, p = 0.04).
184 
Part III: Monitoring coagulopathy
DISCUSSION
This study showed that, after cardiopulmonary bypass and administration of 
protamine, there is a great discrepancy between point-of-care whole-blood 
prothrombin time testing compared with conventional laboratory plasma 
prothrombin measurement. The average difference was approximately 0.3 INR 
at 3 min, 6 min and 10 min after protamine administration. Only the precision 
error at baseline and 10 min following protamine administration were below the 
Westgard criterion of 20%. [11] However, this seemingly minor difference is 
of great practical importance as around 70% of the values showed a clinically 
relevant discrepancy between the two tests in the error grid analysis, whereas 
this should be < 5% to be clinically acceptable. Bland–Altman analysis showed a 
similar excessive discrepancy between laboratory and point-of-care prothrombin 
time measures after protamine administration. Our results imply that the use of 
the Coaguchek leads to underestimation of the hemostatic disturbance, as the 
point-of-care test measured a shorter prothrombin time when compared with the 
laboratory value. The discrepancy might be explained by the nature of the tests, as 
the point-of-care test uses whole blood, whereas the laboratory test is performed 
with platelet-free plasma. As previously shown, pre-operative values showed a 
good level of agreement between laboratory and point-of-care prothrombin time 
measurements. [6]
Rapid insight in patient hemostasis after bypass can differentiate between 
bleeding due to coagulopathy from that of a surgical origin. Early goal-directed 
treatment of hemostatic abnormalities can prevent further blood loss and minimize 
exposure to allogeneic blood products with their inherent risks. However, our 
results show that the point-of-care prothrombin time test shows insufficient level 
of agreement to be used until at least 10 min after protamine administration in 
patients who have been on bypass. These results are in conflict with two earlier 
reported studies that showed a good correlation between point-of-care and 
laboratory prothrombin time measurements 10 min after protamine administration 
and on arrival in the ICU. [7, 8]
There may be factors that influence the point-of-care prothrombin time testing 
without affecting the laboratory prothrombin time measurement. Previously, it has 
been found that the discrepancy between laboratory and point-of-care prothrombin 
time measurements increases with increasing prothrombin times (> 4.0 INR). [13] 
However, in the case of a higher prothrombin time, the point-of-care prothrombin 
time was prolonged when compared with the laboratory results. Another study 
conflicts this finding showing a good level of agreement at higher prothrombin 
times (> 4.0 INR). [14] Prothrombin time values in our study were all < 2.0 INR.
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Other studies have reported a confounding effect of lower hematocrit and 
fibrinogen levels on point-of-care prothrombin time test results. [15-17] Although 
our study was not powered for this endpoint, we did not find any relationship 
between the postoperative hematocrit, platelet count or fibrinogen level and the 
disagreement between the point-of-care and laboratory prothrombin time results. 
It should be noted, however, that the number of patients with very low fibrinogen 
levels in our study was small.
The strength of this study is the point-of-care measurement of prothrombin time 
at multiple time points after protamine administration. The time interval after 
protamine administration is critical for the management of bleeding and insight 
into the patient’s hemostatic profile is of great value. However, point-of-care 
measurement of the prothrombin time is unreliable during a clinically relevant 
time period after protamine administration, and cannot be reliable upon to guide 
hemostatic therapy. The point-of-care prothrombin time test should not be used 
until at least 10 min after protamine administration in patients who have been on 
bypass.
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LETTER TO THE EDITOR
The prompt decision to transfuse fresh frozen plasma (FFP) after cardiopulmonary 
bypass (CPB) is frequently based on clinical signs of coagulopathy, patient 
characteristics, duration of cardiopulmonary bypass and experience of the 
surgical team, all united in the clinical view of the anaesthetist. [1,2] We investigated 
whether FFP transfusion based on this clinical judgment in the absence of 
haemostatic test results was appropriate when retrospectively validated by a 
thromboelastometry-based algorithm.
Data were retrieved from our observational study databases, in which 
thromboelastometry test results were not used by the attending anaesthetist to 
guide transfusion. Data retrieval for the present investigation was approved by 
local Human Subjects Committee (Amsterdam, the Netherlands; METc 2012/337) 
and informed consent was waived. Blood samples for haemostatic testing 
were routinely drawn after anaesthesia induction and three min after protamine 
administration. FFP transfusion based on clinical judgment of the anaesthetist was 
defined as administration of FFP after protamine administration without availability 
of classical coagulation and rotational thromboelastometry test results.
In most viscoelastic testing-based algorithms a HEPTEM clotting time (CT) > 240 s 
with or without EXTEM CT > 80 s is an indication for coagulopathy, requiring 
coagulation factor replenishment by prothrombin complex concentrate or FFP. [3] 
This definition was used to evaluate post hoc the accuracy of the clinical decision 
to transfuse FFP. Patients requiring protamine (HEPTEM: INTEM CT ratio < 0.8) 
were excluded from the analysis as protamine would be the first line treatment in 
these patients. [4,5] Patients who did not receive FFP showed no signs of clinical 
bleeding.
In our database, 159 patients were retrieved with available viscoelastic test 
results. Patients with a HEPTEM/INTEM ratio < 0.8 were excluded (n = 7). Table 
1 shows patient and perioperative data. Patients in the non-FFP and FFP groups 
were divided according to thromboelastometry-based criteria for coagulopathy 
as defined above. In patients who received FFP, eight of 84 patients should not 
have received FFP according to the TEM algorithm (10%), whereas in the non-
FFP group the decision to not transfuse FFP was retrospectively supported by the 
thromboelastometry algorithm in 68 out of 68 patients (100%). 
Fresh frozen plasma transfusion based on the clinical judgment of the anaesthetist 
was appropriate in 95% of the patients when retrospectively validated by 
thromboelastometric transfusion algorithms. Our data imply that signs of clinical 
bleeding in light of patient and surgical characteristics are a major determinant in 
the decision to transfuse FFP. In agreement with others we found that patients who 
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received FFP were older, had lower preoperative haemoglobin concentrations, 
underwent more complex surgery with longer extracorporeal circulation, and had 
more disturbed thromboelastometry and classical coagulation test results after 
cardiopulmonary bypass (thromboelastometric test results not shown). [6,7]
The clinical rationale for FFP transfusion is based on signs of clinical bleeding in 
combination with patient characteristics and surgical factors. This clinical judgment 
to transfuse FFP had a high accuracy when validated by a thromboelastometric 
transfusion algorithm. In light of the increasing availability of transfusion protocols, 
the presence of clinical bleeding and the judgment of the anaesthetist should not 
be neglected as part of the decision algorithm to transfuse FFP.




Age (yr) 63 ± 13 70 ± 10 <0.01
Type of surgery (n) <0.01
  CABG 14 (21%) 6 (7%)
  Valve 45 (67%) 28 (33%)
  Valve + CABG 8 (12%) 45 (54%)
  Bentall 0 (0%) 5 (6%)
BMI (kg m-2) 27 ± 4 26 ± 4 0.24
Male (%) 44 (65%) 55 (66%) 0.92
CPB time (min) 106 ± 35 161 ± 50 <0.01
Aortic clamp time (min) 79 ± 28 121 ± 42 <0.01
Haemoglobin during CPB (mmol l-1) 6.0 ± 1.1 5.4 ± 0.8 <0.01
FFP transfusion (units) 0 (0-0) 2 (2-2) <0.01
Platelet transfusion (units) 0 (0-0) 1 (1-1) <0.01
Table 1.  Patient and perioperative data
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LETTER TO THE EDITOR
The randomized clinical trial by Dr Bilecen and colleagues showed no benefit of 
fibrinogen concentrate use, compared with placebo, on intraoperative blood loss 
in patients with bleeding following high-risk cardiac procedures. [1] We believe 
that the results may unfairly characterize fibrinogen concentrate use.
First, the authors chose intraoperative blood loss as their primary study endpoint. 
However, intraoperative blood loss is less relevant in cardiac surgery than 
blood loss that occurs after chest closure. [2] Unfortunately, 24-hour blood loss, 
which showed a significant reduction in the fibrinogen concentrate group, was a 
secondary endpoint.
Second, in their sample size calculation, the authors assumed a 40% reduction 
in intraoperative blood loss after fibrinogen supplementation based on findings 
from a small retrospective study, a small prospective study including patients 
with normal fibrinogen levels, and a porcine study. [1] Due to the low level of 
evidence of these studies, we doubt the likelihood of this effect size, leading 
to an underpowered outcome. Moreover, it is unclear whether the anticipated 
intraoperative blood loss of 2200 ml in the control group used for the sample size 
calculation was realized. 
Third, most transfusion protocols in cardiac surgery recommend a fibrinogen 
measurement by the Clauss test or visco-elasting testing as a requirement 
for fibrinogen supplementation. [3] A limitation of this trial is that fibrinogen 
supplementation was not guided by fibrinogen measurements. The placebo and 
intervention groups both showed normal fibrinogen levels exceeding 1.5 g l-1 in 
most patients before trial drug administration, which usually does not require 
fibrinogen supplementation. Additionally, while the authors targeted fibrinogen 
levels of 2.5 g l-1 after fibrinogen supplementation, this endpoint was achieved 
in less than 50% of the patients. Thus, this trial only shows that supplementing 
clotting factors in patients with normal levels will not benefit the patient. [4]
We believe that the benefits of fibrinogen concentrate for perioperative hemostasis 
should be evaluated in a large and sufficiently powered trial with a clinically 
relevant primary endpoint in patients with hypofibrinogenaemia before it can be 
concluded that supplementation is of no benefit for bleeding patients undergoing 
high-risk cardiac surgery.
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GENERAL DISCUSSION
The goal of patient blood management is to reduce bleeding and blood 
transfusion, with the subsequent aim to prevent unfavorable outcome. This is 
a multimodal approach comprising the prevention, prediction, monitoring and 
treatment of microvascular bleeding caused by coagulopathy. Figure 1 gives an 
overview of all individual major patient blood management modalities in cardiac 
surgery. As shown previously, each blood management intervention attributes to 
a small improvement in outcome, and when combined leads to a major reduction 
in blood loss and transfusion requirements. [1,2] All components are combined 
in a multidisciplinary approach involving the anesthesiologist, cardiac surgeon, 
perfusionist, intensivist and hematologist. This thesis focuses on several aspects 
of patient blood management in cardiac surgery, marked in grey in figure 1. 
First, optimal protamine dosing to prevent postoperative coagulopathy was 
investigated. Second, several aspects of different point-of-care monitors were 
assessed in search of optimal hemostasis monitoring to guide patient blood 






























Figure 1.  Multimodal patient blood management in cardiac surgery. Grey marked boxes 
= themes of this thesis. ANH = Acute normovolemic hemodilution, aPTT = 
activated partial thromboplastin time, FFP = Fresh frozen plasma, PCC = 
prothrombin complex concentrate, POC = point-of-care, PT = prothrombin 
time.
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PART I. PREVENTION OF COAGULOPATHY
Protamine dosing
An important step in patient blood management after cardiopulmonary bypass 
is the optimization of hemostasis by the reversal of heparin by protamine. In 
cardiac surgery, protamine is historically dosed in a fixed ratio and not much has 
changed since the first dosing studies which date back to 1968. [3] For many 
years, high protamine dosing was considered safe. [4] However, as described in 
chapter 2, an increasing number of studies show negative effects of protamine 
on hemostasis. Still, well-designed studies investigating the clinical effect of 
protamine overdosing were lacking. 
In 2002, the first evaluation of different protamine-to-heparin dosing ratios 
investigated if reduced protamine dosing resulted in improved clinical outcome. 
[5] No outcome difference between a dosing ratio of [0.75] vs. [1.3] vs. [1 + 0.15 
+ 0.15] mg protamine for every milligram of heparin was found, except for more 
red blood cell transfusion in the low dosing ratio group without a difference in 
postoperative blood loss. This study had major limitations, as it was a retrospective 
sequential cohort study in which three groups were compared, no power analysis 
was performed, no transfusion algorithm was used, a single anesthesiologist and 
cardiac surgeon were involved and the effect on hemostasis was not evaluated. 
We were the first to investigate the effect of different fixed dosing regimens on 
outcome in a prospective randomized design (chapter 3). We showed that 
protamine overdosing in the clinical setting impairs hemostasis. As in line with 
others we refute the misconception that a prolonged ACT after regular protamine 
dosing is caused by residual heparin. [6]
While optimization of clinical fixed dosing ratios is scarcely investigated, several 
studies did investigate the effects of heparin titration based protamine dosing. 
[7] The general conclusion is that postoperative blood loss is reduced when 
protamine titration is used. Still, these studies are limited by their small sample 
size, reporting of non-clinical outcome and lack of a sample size calculation. 
Furthermore, protamine dosing based on the titration method has several 
limitations and possible flaws. [8,9] The method bases the heparin concentration 
on ACT measurements, estimates patient blood volume and neglects the 
sequestration and plasma protein binding of heparin. Besides, only few centers 
use these heparin and protamine titration systems in routine clinical practice. 
[10] Therefore, optimization of a clinical fixed dosing ratio could lead to greater 
adaptation in clinical practice as implementation of a new dosing ratio is easy, 
resulting in improved outcome. 
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An alternative to protamine dosing based on a fixed ratio or the titration method 
is dosing based on a pharmacokinetic model of heparin. This method estimates 
the amount of heparin after bypass by a pharmacokinetic model, as proposed in 
chapter 4. Several studies, including ours, found lower protamine dosages and 
improved outcome when compared to a fixed protamine dosing ratio. [11-15] 
As pharmacokinetic dosing models only use clinical parameters, implementation 
is easy. A great advantage over the heparin titration technique is the lack of 






Figure 2.  The evolution of protamine dosing.
Limitations & Future directions 
The studies on protamine dosing in this thesis are limited by some factors. The 
‘Ratio PRO’ study (chapter 3), comparing a fixed dosing ratio of 0.8 vs. 1.3, 
includes solely CABG patients. In this patient category blood loss may differ 
from other forms of cardiac surgery such as valve surgery. Another limitation 
is the calculation of the protamine dose based on the total amount of heparin 
administrated, including the heparin administrated during cardiopulmonary 
bypass. Still, the aim of this study was to investigate if a high protamine-to-
heparin dosing ratio deteriorates hemostasis in the clinical setting. Interpretation 
for clinical dosing ratio should be seen in the light of this design. Future studies 
should compare a dosing ratio of 1.0 on the initial heparin dose to a protamine 
dosage of 0.7 – 0.8 to find the optimal fixed dosing ratio. 
Our pharmacokinetic protamine dosing study, chapter 4, is limited by its 
retrospective design and the estimation of patients’ blood volume. Heparin 
concentration measurements after protamine administration would add value 
to the evaluation of the adequacy of the model. Future studies should compare 
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the pharmacokinetic model to the protamine titration method in a prospective 
randomized non-inferiority design to see if the heparin management system is 
redundant for protamine dosing. An easy to use web application or smartphone 
app could be developed to implement its use. However, the medicolegal status 
of such an application should be evaluated and disclaimed before distribution. 
The future of protamine dosing might be the measurement of anti-Xa activity, the 
gold standard for heparin measurement. By relating the anti-Xa level to a known 
amount of heparin in a control sample the heparin concentration and protamine 
requirement can easily be calculated. [16] This could be more accurate than the 
prediction of the residual heparin concentration by a pharmacokinetic model and 
lead to more accurate protamine dosing. However, the dosing of protamine will 
still be based on an estimation of patients’ blood volume and the sequestrated 
heparin will be neglected. Point-of-care anti-Xa measurements are currently 
under development. [17-18] 
Another field for further exploration is the phenomena of heparin rebound, defined 
as reappearance of heparin hours after reversal with protamine. This is caused 
by release of heparin from the bound surface of the endothelium, proteins, 
circulating cells and platelet factor 4 (PF4; released by thrombocytes). Another 
hypothesis is the release of heparin from the heparin-protamine-complex before 
elimination. It was thought that the free heparin released during heparin rebound 
would lead to anticoagulation and postoperative bleeding. [19,20] Some studies 
even suggested administration of additional protamine to treat heparin rebound 
in order to reduce blood loss. [21,22] However, several studies refute clinical 
consequences of heparin rebound. [23-28] In order to reject the myth of heparin 
rebound a thorough large study should be performed to evaluate the existence 
and clinical consequences of heparin rebound.
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PART II. PREDICTION OF POSTOPERATIVE BLEEDING
Identification of patients at risk for bleeding
Patients at high risk for bleeding should be identified before and during surgery 
in order to optimize patient blood mangement. Many attempts have been made to 
predict which patients are at risk for major blood loss after cardiac surgery. The 
major risk factors for postoperative bleeding and transfusion are female gender, 
renal impairment, cerebrovascular disease, preoperative anemia, continuation of 
antiplatelet drugs and/or anticoagulants, low body surface area, emergency - and 
complex surgery. [29] Clinical designed risk scores combine several risk factors 
and show a predictive value ranging from 15% to 91%. [30-37] Unfortunately, 
these risk scores are unpractical in clinical practice due to a discriminative rate 
that is too narrow or too broad, resulting in a high sensitivity and low specificity, or 
low sensitivity and high specificity respectively. In the clinical setting preoperative 
risk assessment for transfusion is scarcely used. [38]
Previous reports conclude that classical laboratory hemostatic test results 
do not predict which patients are at risk for bleeding. [39-41] In chapter 5 we 
investigated if thromboelastometry, unlike classical coagulation tests, would be 
able to identify patients at risk for major hemorrhage. This was evaluated by a 
cohort study in our center in addition to a systematical review of the literature. 
Interestingly, we found that abnormal thromboelastometry test results do not risk 
the patient for bleeding. This is an important finding as it suggests that in the 
non-bleeding patient there is no need for prophylactic treatment of hemostasis 
abnormalities. Interestingly, classical laboratory testing is thought not useful to 
guide coagulation treatment, as the test results do not predict bleeding, and 
thromboelastometry is then suggested as an alternative. However, as we have 
shown, also thromboelastometry is not able to predict bleeding in cardiac surgery. 
Limitations & Future directions
Our cohort study on the predictive value of thromboelastometry is limited by 
its relative small sample size and low rate of major blood loss (20%), limiting 
the possibility for extensive statistical analysis. However, the systematic review 
underlines the conclusion that thromboelastometry was unable to detect patients at 
risk for bleeding. A rationale for this finding might be that macrovascular bleeding is 
the main cause of excessive bleeding. Furthermore, rapid physiological restoration 
of the clotting factor level in the postoperative phase limits the predictive value 
of thromboelastometry. [42,43] Additionally, in the bleeding patient coagulation 
factors are replenished by the administration of fibrinogen concentrate, FFP, 
PCC and/or platelet concentrate in order to treat coagulopathy. Both phenomena 
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lead to (rapid) improvement of the hemostatic status after thromboelastometric 
testing. This makes the test results directly after cardiopulmonary bypass used for 
the prediction of bleeding outdated and unlikely to predict bleeding. Therefore, 
thromboelastometry might better be used as a comparator to patients’ baseline 
than using absolute values. 
Another explanation for the inability to predict bleeding by thromboelastometry 
might be the discrepancy between reference values and critical (threshold) 
values. When a value falls outside the reference range the patient might not be 
at risk, as the clotting capacity might be lower but still sufficient. Additionally, 
thromboelastometry reference ranges are wide, caused by the multiple factors 
affecting the test results (i.e. red blood cells, leukocytes, platelets, fibrinogen 
and coagulation factors). The critical level of hemostatic components, i.e. 
thromboelastometry test results, might be more appropriate to predict bleeding. 
A critical level is the threshold sufficient for adequate clot formation and might 
differ from the reference range. The critical level can be different between patients 
and different clinical scenario’s. Therefore, it is difficult to assess the individual 
critical value as it might depend on other parameters and clinical circumstances. 
[44,45] While thromboelastometry test results below the reference range do not 
predict bleeding, results below a critical threshold might. Future studies should 
look for the critical value as this might be a better predictor for bleeding and be of 
guidance for treatment and transfusion.
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PART III. MONITORING COAGULOPATHY
The value of thromboelastometry & clinical decision-making
Thromboelastometry is used in cardiac surgery aiming to optimize patient blood 
management. Thromboelastometry was first described by dr. Hellmut Hartert, 
almost 70 years ago. [46] Only in the last decades, thromboelastometry has 
gained renewed interest for the rapid evaluation of patients clotting capacity 
and usability has improved leading to a more user friendly application. With 
this method, several aspects of the hemostatic system are evaluated, specific 
deficiencies can be identified and replenished aiming to improve outcome.
As mentioned before, thromboelastometry does not predict bleeding in cardiac 
surgery (chapter 5). However, several studies investigated if its implementation 
reduces bleeding, blood transfusion and improved outcome, shown below 
in table 1. Besides one study, all found a reduction in blood transfusion and 
improved outcome compared to the control group. [47] Interestingly, only two 
randomized controlled trials have investigated the impact of thromboelastometry 
implementation, of which one has a controversial design (Weber et al. 2012). 
[48,49] The most recent systematic review addresses the poor quality of the 
studies on thromboelastometry guided hemostatic treatment in cardiac surgery. 
[50]
The implementation of thromboelastometry resulted in an increased use of factor 
concentrates compared to conventional practice. As shown in table 1, there was 
a general increase in the use of fibrinogen in the thromboelastometry groups 
without an effect on the use of prothrombin complex concentrate. The use of 
recombinant activated factor VII ceased. As fibrinogen concentrate use has 
demonstrated to improve outcome this might bias the positive effect attributed 
to thromboelastometry implementation. [51-55] The hypothesis that factor 
concentrates are more effective in treatment of coagulopathy has recently been 
confirmed in a prospective trial. [56]
The main problem with these (retrospective) studies of thromboelastometry 
implementation is that it is unclear the implementation of a transfusion algorithm 
or the implementation of point-of-care hemostatic monitoring led to improved 
outcome. [57] Moreover, the increased use of fibrinogen concentrate can also 
have been the cause of improved outcome. It remains indistinguishable what 
the individual additive value of each variable is and which factor causes the 
improved outcome, the transfusion algorithm and/or the point-of-care testing and/
or increased fibrinogen concentrate use. 
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Year 1st author N. Design RR concentrate use Conclusion
PCC Fib rVIIa
2016 Karkouti 7402 R n.a. 1.26 n.a. Fewer blood transfusion
2016 Trevisan 768 R 2.00 3.00 n.a. Fewer blood transfusion
2016 Pearse 1295 R 1.25 n.a. 0.78 Fewer blood transfusion
2015 Karkouti 2481 R 1.00 1.25 0.33 Fewer blood transfusion
2013 Fassl 62 R 1.00 0.90 n.a. Fewer blood transfusion
2012 Weber 100 RCT 0.84 1.07 0.08 Fewer blood transfusion
2012 Hvas 1676 R n.a. 3.00 0.50 No transfusion difference 
2012 Hanke 10 R 0.33 0.66 n.a. Fewer blood transfusion
2011 Görlinger 3865 R 2.02 2.70 0 Fewer blood transfusion
2010 Girdauskas 56 RCT 0.17 0.87 0.57 Fewer blood transfusion
2007 Spalding 1422 R 0.22 2.00 0 Fewer blood transfusion
2006 Anderson 990 R n.a. n.a. n.a. Fewer blood transfusion
Average: 0.98 1.67 0.32
Table 1.  All studies in cardiac - and/or proximal aortic surgery on rotational 
thromboelastometry based coagulation management. Fib = fibrinogen 
concentrate, PCC = prothrombin complex concentrate, R = retrospective 
study, RCT = randomized controlled trial, RR = relative risk compared to 
control group, rVIIa = recombinant activated factor VII.
A closer look at the transfusion algorithms shows that there is a large discrepancy 
in the indication for different treatment options (table 2). For instance, the indication 
for fibrinogen administration even ranges from a FIBTEM maximum clot firmness 
(MCF) of 6 to 16 mm. The indication for platelet transfusion varies from an INTEM 
with or without heparinase MCF of 35 to 50 mm. Besides, several studies use 
a stepwise approach with reappraisal after each intervention whereas others 
treat all abnormal values at the same time. The heterogeneity between studies 
makes it hard to compare the results. This highlights that the critical value, as 
mentioned earlier, is unknown. Still, the implementation of thromboelastometry 
based transfusion algorithm seems to reduce bleeding and transfusion. [47,50]
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Year 1st author Indication
PCC or FFP Fibrinogen or Cryoprecipitate Protamine Platelet transfusion
2016 Karkouti CTEX>90 A10FIB<8 n.a. A10EX <35 and
A10FIB >8









n.a. A10EX <40 and
A10FIB >10
2015 Karkouti CTEX>100 MCFFIB <7 Prolonged ACT A10EX <35 and
A10FIB >7








2012 Weber CTEX >100 MCFFIB <7 Prolonged ACT A10EX <35 and
A10FIB >7
2012 Hvas CTHEP >300 or
CTEX >100
MCFFIB <9 CTIN > +25% CTHEP MCFHEP<45 and
MCFFIB>9
















2010 Girdauskas CTHEP >260 MCFFIB<8 CTIN/CTHEP >1.5 MCFHEP <35 or
(MCFHEP 35-45 and
MCFFIB >8)
2007 Spalding n.a. n.a. n.a. n.a.










Table 2.  Indications for administration of hemostatic interventions in all studies in 
cardiac - and/or proximal aortic surgery on rotational thromboelastometry 
based coagulation management. CT = clotting time, EX = EXTEM, FFP = fresh 
frozen plasma, FIB = FIBTEM, HEP = HEPTEM, IN = INTEM, MCF = maximum 
clot firmness, PCC = prothrombin complex concentrate.
Most studies have a retrospective sequential cohort design, comparing outcome 
before and after implementation of a thromboelastometry guided treatment 
algorithm. This is a major limitation as the implementation of a treatment algorithm 
with or without thromboelastometry creates awareness for the coagulopathic 
component of bleeding. This might lead to earlier, more adequate and more 
aggressive treatment of coagulopathy resulting in better outcome, possibly 
biasing the study results. This hypothesis is substantiated by the finding that 
studies implementing a general (non-thromboelastometry) blood management 
protocol showed improved outcome after implementation, shown in table 3. 
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Year 1st author N. Design Intervention Outcome
2015 Gross 2662 R PBM protocol Fewer transfusion, better outcome
2014 Bilecen 2534 R Tailor made transfusion protocol
Fewer transfusion and 
myocardial infarction
2013 Silva 533 R PBM protocol Fewer blood transfusion
2013 Gutsche 495 R Anemia guideline implementation
Fewer unnecessary 
transfusions
2012 Xydas 1032 R PBM protocol Fewer blood transfusion
2001 Capraro 58 RCT Hemostasis monitoring vs. clinical judgement No difference in outcome
Table 3.  Studies investigating the effect of blood management (PBM) implementation 
on outcome. R = retrospective study, RCT = randomized controlled trial.
Still, several guidelines suggest that using thromboelastometry improves 
outcome. [58,59] However, the clinical judgement of the cardiac anesthesiologist 
should not be neglected. Together with the cardiac surgeon the anesthesiologist 
determines if there is excessive microvascular bleeding, the first decision in all 
blood management protocols. 
In the era before point-of-care testing the anesthesiologist decided whether to 
treat possible coagulopathy after bypass. This was based on clinical features as 
the duration of extracorporeal circulation, the volume of blood loss, type of surgery 
and patients’ characteristics. This advanced clinical assessment of hemostasis is 
evaluated in chapter 10. We showed that the interpretation of the clinical scenario 
reflects an accurate hemostatic appraisal of the need for fresh frozen plasma 
transfusion when assessed by thromboelastometry. 
The study is limited by its retrospective design and was conducted in a center with 
focus for hemostasis as many previous studies on hemostasis were conducted in 
cardiac surgery in this hospital. This might influence the results as the attending 
team might have more attention for hemostatic abnormalities and gained a more 
‘advanced’ view on a bleeding patient. Furthermore, during the study period the 
surgical and anesthesia teams included solely senior staff members with ample 
experience in cardiac surgery. Results might not be reproducible in a more junior 
team.
The importance of pre-analytic variables
The adequacy of hemostasis monitors to guide patient blood management 
strategies is of vital importance as wrong information leads to wrong decisions. 
Errors in blood analysis most commonly occur in the pre-analytic phase. [60,61] 
This phase resembles all procedures before the testing of the specimen. Here 
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we will focus on possible errors in hemostatic testing, with special notice for 
thromboelastometric testing. [62] 
Starting with blood withdrawal, insufficient filling of the collecting tube causes 
increased dilution by the citrate solution leading to an abundance of citrate. When 
the sample is recalcified prior to the analysis, this can lead to insufficient calcium 
as it binds to the abundant citrate. The lack of sufficient calcium in addition to 
the increased dilution of the blood sample can impair clot formation and thereby 
influence the test results. [63,64] This effect also occurs in thromboelastometry 
testing, however the effect on the viscoelastometric test results is limited. [65] 
During blood withdrawal, the intravascular line from where blood is drawn should 
be adequately flushed in order to prevent dilution of the blood sample. This is 
especially important in the case of an heparin or glucose line as these molecules 
affect the clotting time. [66] The site of blood withdrawal is unimportant as there 
is no difference between venous and arterial drawn blood, whereas intraosseous 
blood seems hypercoagulable in vitro. [67,68]
Inappropriate storage can affect clotting test results. Storing blood samples at 
high or low temperature affects the concentration of (activated) clotting factors. 
The influence of high temperature is relevant after several hours of storage, 
causing coagulation factor activation (f.VII) and degradation (protein S, f.VIII). 
[69,70] Low temperature also affect hemostasis in vivo and vitro. [71-73] As a 
low temperature slows the clotting process down the blood sample should be 
warmed to body temperature before (thromboelastometric) testing.
In the case of point-of-care assays, the setting of testing might influence the 
test results. Thromboelastometry performed at bedside does not change the 
test results compared to thromboelastometry testing in the laboratory. Still, the 
results are 11 minutes quicker available when performed at the point-of-care. [74] 
When decided to perform thromboelastometry in the laboratory, the pneumatic 
tube transport system affects the test results. [75-78] However, this effect is 
clinically irrelevant for most assays. The inter- and intra-rater variability does not 
significantly influence viscoelastometric testing. [79-81] The type of testing cups 
alters the results, therefore smaller cups should not be used. [82] 
Patient and medication factors affect viscoelastometric testing. The hematocrit 
is inversely correlated with the maximum clot firmness, resulting in denser clot 
results for low red blood cell concentrations. [83-85] This appears to be an in 
vitro artefact and clinicians should therefore take care in interpretation of the 
thromboelastometry test results in anemic patients as this might mimic solid clot 
formation. [86] This is especially relevant in a bleeding patient. Furthermore, 
suggamadex seems to alter the test results towards a more thrombogenic profile, 
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which is also attributed to an in vitro artefact. [87] The (pre)analytic factors 
influencing thromboelastometry are summarized in figure 3. The clinician working 
with thromboelastometry should be well aware of these influences in order to 















Figure 3.  (Pre)analytic influences on thromboelastometry. (Copyright M.I. Meesters 
2017)
I. Non-activated Thromboelastometry (NATEM) 
In 2010, the stability of thromboelastometric testing was evaluated and showed 
constant results up to 120 minutes of storage. [88] This study only investigated the 
activated clotting tests, e.g. INTEM, EXTEM and FIBTEM. Still, the reproducibility 
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of the non-activated test (NATEM) has never been investigated. As the NATEM 
test requires much time until test results are available it is not used in routine 
clinical practice. However, an increasing number of studies use NATEM, while it is 
very sensitive to hemostatic changes. For example, fibrinolysis is rarely observed 
in routine viscoelastometric tests (INTEM and EXTEM), whereas NATEM is very 
sensitive to this phenomena. [89] Likewise, the effect of fractionated heparin is 
frequently not detected during routine thromboelastometry testing whereas the 
NATEM test is significantly affected by low molecular weight heparins. [90]
Since the NATEM test is very sensitive, also to pre-analytic variables, we 
investigated its stability for citrated blood samples over storage time in healthy 
volunteers and intensive care patients, chapter 8. We showed significant 
coagulation activation during storage. Endotoxin, released by gram negative 
bacteria during infection, might be responsible for this activation in the intensive 
care population. [91] However, our study in healthy volunteers showed similar 
results. 
Future directions
The findings from our NATEM study are relevant since there will be a difference in 
test results between direct (near patient) testing and testing in the laboratory as 
transportation and handling of the specimen requires time. This phenomenon must 
be taken into consideration in addition to the influence by pneumatic transportation 
on the test results, which both lead to considerable activation of the blood sample. 
[78] Repeat sampling from the same citrated collecting tube has been shown 
to give a progressive hypercoagulable trace which might bias test results. [92] 
Future studies on the effect of citrate storage time on thromboelastometric test 
results should therefore warrant not to reuse the same collecting tube at different 
time-points. 
Several studies found a difference between fresh and citrated whole blood. [92-
94] This might be caused by the activation of non-citrated blood in the test tube, 
as the wall of the test tube or syringe may function as a coagulation activator. 
Therefore, citrated blood sampling and testing is preferred. When non-citrated 
whole blood is used, the time between blood withdrawal and testing should be 
minimized in order to prevent hemostatic activation of the blood sample.
II.  Heparinase-modified thromboelastometry
Addition of heparinase to a blood sample is an old method to investigate the 
coagulation capacity without the effect of heparin, as it was first used in 
1972 in laboratory coagulation testing. [95] This principle is also used in the 
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thromboelastometry heparinase assay (HEPTEM). The HEPTEM test consists 
of the INTEM test with the addition of heparinase, which inactivates heparin by 
cleavage of the molecule. In the case of a heparin effect, the INTEM clotting time 
(CT) will be prolonged whereas the heparin effect will be omitted in the heparinase 
assay (HEPTEM), resulting in an CTINTEM > CTHEPTEM.
The first viscoelastometric testing with heparinase investigated the hemostatic 
potential during cardiopulmonary bypass in the setting of pre- and peroperative 
anticoagulation with heparin. [96] In 2001, the heparinase assay was used to 






Figure 4.  The HEPTEM and INTEM assay before (panel A) and after (panel B) the 
administration of heparin. (Copyright M.I. Meesters 2017)
Later, the first evaluation of the clinical validity of the rotational thromboelastometry 
heparinase assay was performed. [99] The in vitro results showed a good 
neutralizing effect of heparinase on the heparin influence. Interestingly, it was 
found that protamine overdosing could be detected by the HEPTEM test as 
clotting times prolonged without affecting the CTINTEM : CTHEPTEM ratio. These results 
were reproduced in a clinical study of 22 patients undergoing cardiac surgery. 
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[100] It was suggested that the heparinase assay can be helpful to distinguish 
between a heparin or coagulopathic cause of a prolonged activated clotting time 
(ACT) after heparin reversal.
More recently several studies found abnormal results in the HEPTEM assay as 
fibrinolysis was inappropriately shown. [101,102] Furthermore, it was found that 
heparin concentrations greater than 0.5 IU ml-1 (as during CPB) resulted in a 
dose depend increase in HEPTEM clotting time, indicating incomplete heparin 
neutralization by heparinase. [103] However, this was later refuted by others. [104] 
In clinical practice, we frequently observed unusual thromboelastometric 
results for the CTINTEM : CTHEPTEM ratio. Therefore, we conducted an analysis of 
all thromboelastometric test results in cardiac surgery in two centers, shown in 
chapter 7. The CTINTEM : CTHEPTEM ratio frequently showed irrational results. Prior 
to surgery the heparinase assay was frequently shorter than the INTEM assay 
while these patients did not receive heparinoids on the day of the procedure. 
Moreover, before and after surgery the CTHEPTEM was often longer than the CTINTEM. 
We hypothesized that this might be explained by high protamine dosing, having 
more effect on HEPTEM than INTEM test results. However, this theory is not 
supported by previous reports. [99,100] Also, the preoperative difference cannot 
be explained by this hypothesis. Still, several studies showed an CTINTEM < CTHEPTEM. 
[105-107] Unfortunately, so far no rationale for this finding could been found.
Limitations & Future directions
In line with a previous report we found a dose dependent HEPTEM clotting time 
increase with protamine dosage. [104]  A major limitation of the in vitro part of 
our study is the lack of INTEM testing to prove the hypothesis that protamine 
affects HEPTEM without changing INTEM results. The previous study did not find 
a discrepant increase in HEPTEM compared to INTEM. [104]
Several other studies showed an CTINTEM < CTHEPTEM. [105-107] However, the 
scarce studies specifically investigating the INTEM : HEPTEM relationship did not 
find illogical differences between INTEM and HEPTEM. [100,108] Therefore it is 
difficult to draw conclusions about the validity or need for caution when interpreting 
the HEPTEM test results. Future studies should investigate if our results can be 
reproduced. Furthermore, the adequacy of the HEPTEM test should be further 
investigated to explore on our unusual test results. [101,102]
III. Point-of-care Prothrombin Time 
Point-of-care prothrombin time testing (POC-PT) has been developed for rapid 
outpatient management of patients on vitamin-K-antagonists. [109,110] However, 
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these tests might also be useful for the prompt evaluation of patients’ coagulation 
status after cardiopulmonary bypass. The great advantage of the POC-PT test is 
the short turnaround time of less than 5 minutes whereas sending and testing a 
blood sample in the central laboratory takes up to 45 minutes. Another advantage 
of the POC-PT is the testing off whole blood compared to plasma in the laboratory 
test. This eliminates several preanalytical variables affecting the test results 
including; insufficient tube filling, delayed transport, centrifugation errors, storage 
time and temperature. [111] 
Still, there are some pre-analytic variables influencing the POC-PT. Anemia 
(hematocrit < 30%) has been found disturb the test results. [112] Also, severe 
coagulopathy (INR > 4.0) causes a significant discrepancy between laboratory 
and point-of-care testing. [113,114] However, the difference at higher INRs 
does not affect the clinical decision in cardiac surgery as an INR > 1.5 is an 
indication for coagulation factor replenishment irrespective of the exact INR. 
Also, a low fibrinogen level disturbs the POC-PT test results. [115] Furthermore, 
direct oral anticoagulants (DOACs) disturb POC-PT results without influencing the 
laboratory PT. [116,117] Besides, it is suggested that liver enzyme abnormalities 
might change the test results. [118] Finally, there is a small, clinically irrelevant 
difference between capillary and venous blood sample for POC-PT testing. [119]
The applicability of the POC-PT in cardiac surgery has only scarcely been 
investigated. [120,121] Therefore we investigated the accuracy of the POC 
prothrombin time measurement after cardiopulmonary bypass. In contrast to 
previous reports, we found a major discrepancy between POC-PT and laboratory 
results 3 minutes after protamine administration, as shown in chapter 8. Previous 
studies found a good agreement between the POC-PT and laboratory test at least 10 
minutes after protamine administration which might have caused the discrepancy 
from our results. [120,121] In order to investigate if the difference between the POC 
and laboratory test persisted over time we conducted another investigation. We 
evaluated the agreement between the laboratory and point-of-care PT 3, 6 and 10 
minutes after protamine reversal in chapter 9. In contrast to previous reports the 
difference between laboratory and POC-PT remained clinically and statistically 
significant 6 and 10 minutes after protamine administration. We conclude that 
the POC-PT cannot be used after cardiac surgery with cardiopulmonary bypass. 
Figure 5 summarizes all (pre)analytic influences on the POC-PT.
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Figure 5.  (Pre)analytic influence on the point-of-care prothrombin time device 
(Coaguchek XS Pro, Roche, Basel, Switzerland). (Copyright M.I. Meesters 
2017)
Limitations & Future directions
Most studies inestigating the accuracy of a novel diagnostic device perform 
Pearson correlation and/or Bland Altman analysis. [122] However, Error Grid 
analysis as performed in our POC-PT studies is superior as it investigates the 
diagnostic accuracy of a novel test in the clinical context. [123] As mentioned 
before, an INR > 4 that highly differs between point-of-care and laboratory testing 
has a major influence on the Bland Altman and (Pearson) correlation analysis. 
However, this difference might be clinically irrelevant as an INR >1.5 is an indication 
for coagulation factor replenishment in the bleeding patient, irrespective of the 
exact INR. This limitation is overcome by Error Grid analysis which incorporates 
the clinical consequences in the correlation between the tests. 
Besides the discrepancy between the laboratory and point-of-care PT test results, 
an abnormal PT does not (necessary) mean insufficient thrombin generation and 
the subsequent need for hemostatic intervention. [43] Besides, the prothrombin 
time after cardiac surgery does not predict bleeding. [39-41] For this reason 
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it is frequently suggested that PT cannot guide hemostatic treatment and 
thromboelastometry should be used, however neither thromboelastometry predicts 
bleeding, as shown in chapter 5. Still, thromboelastometry guided coagulation 
treatment has proven to reduce transfusion, unlike classical coagulation tests. [50] 
A limitation of the use of POC-PT testing is the lack of information about the 
other hemostatic components which might cause bleeding, mentioned in the 
introduction and shown in figure 6. Therefore, an adequate POC prothrombin time 
test should be combined with a point-of-care aPTT (to detect residual heparin), 















Figure 6. Postoperative causes of bleeding (Based on: Ranucci M. Hemostatic 
and thrombotic issues in cardiac surgery. Semin Thromb Hemost; 2015 
Feb;41(1):84–90.)
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PART IV. TREATMENT OF COAGULOPATHY
Does the focus on patient blood management risk the patient for thrombosis?
Patient blood management focusses on the reduction of bleeding and blood 
transfusion in order to improve outcome. However, as hemostasis is a balance 
between pro- and anti-coagulatory factors (figure 7) it is of major importance to 
evaluate the individual patient blood management components for the risk of 
pathologic thrombogenicity, e.g. the risk for thrombosis and infarction.
A suitable example is the highly procoagulant drug factor VIIa (fVIIa). Recombinant 
factor VIIa was designed for the treatment of patients with hemophilia who 
became resistant to coagulation factor replacement due to antibody formation. 
[124] As the drug has powerful capacity to stop bleeding its use spread to high 
risk surgery such as cardiac procedures. Activated factor VII showed a reduction 
of bleeding, rethoracotomies and transfusion in cardiac surgery suggesting a 
positive effect on outcome. [125] However, a Cochrane review showed that a 
critical percentage of the patients developed serious adverse thromboembolic 
events. [126] This highlights the importance of a thorough evaluation of the 
possible negative effects of an intervention to detect serious adverse events, 
preferably in several large multicenter randomized controlled trials with sufficient 
power. Only hereafter the risk benefit balance can be made for each treatment 
modality. In our interventional studies we did not find an increased incidence of 
adverse events, other than an effect on bleeding and transfusion. Still, the studies 




Figure 7.  Physiological hemostasis is the balance between pro- and anticoagulants.
The problem with many new diagnostic and treatment modalities is that they 
spread from other fields and are used off-label. This also goes for the use of 
prothrombin complex concentrate (PCC) which was developed for the acute 
reversal of vitamin K antagonist therapy. Only two RCTs on the use of PCC for 
coagulation factor replenishment were performed in the cardiosurgical setting. 
[127,128] Only one of these was designed for the treatment of postoperative 
coagulopathy in the bleeding patient. Nevertheless, as mentioned before with 
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the introduction of thromboelastometry many studies started using PCC for the 
treatment of coagulation deficiency without available safety data on the factor 
concentrates in cardiac surgery. [129,130] 
It can be argued that evidence regarding the applicability and safety data of a 
drug can be extrapolated from other fields. [131] However, a recent report showed 
an increase risk on thromboembolic events with the use of factor concentrates 
including PCC. [132] More recently, even an absolute increase in adverse events 
has been observed with PCC use specifically in cardiac surgery. [133] Yet, this 
might be explained by the increase in PCC use without a relative increase in 
complications caused by the drug. 
The risks of new drugs use should be weight against the risk-benefit ratio of the 
alternative. In the case of PCC, the alternative is fresh frozen plasma for which 
neither sufficient evidence is available. Yet, adverse events are well described for 
FFP, including an increased thrombotic risk, which might justify the use of PCC. 
[134 -136]
Besides the possible thrombogenic effects of a patient blood management 
intervention, all possible adverse events should be evaluated. The American 
Heart Association recently proposed to standardize the outcome of clinical trials 
in cardiac surgery. [137] They found that there is a high heterogeneity in the 
reporting of research findings. This hinders the possibility to compare outcome 
and limits the results of meta-analysis. In 2009 the Society of Thoracic Surgeons 
(STS) formulated relevant outcome parameters for studies in cardiac surgery. 
[138] These parameters include mortality, renal failure, stroke, rethoracotomy, 
prolonged mechanical ventilation, sternal wound infection and mortality. 
However, despite the formulation of these outcome parameters the adaptation 
in research is poor. [137] Still, it is important to keep general outcome (morbidity 
and mortality) in sight when investigating patient blood management strategies. 
Blood management should not be the sole purpose while overall better outcome 
for the patient should be.
Is patient blood management being implemented in clinical practice?
In the last two decades, many patient blood management interventions have been 
developed in cardiac surgery. [139] Especially the combination of several (small) 
interventions lead to a major reduction in blood loss and blood transfusion. [1,2] 
Unfortunately, despite the publication of an extensive patient blood management 
guideline in 2007 (updated in 2011), there is still an increase in blood product 
utilization in many cardiac surgery centers. [58,140,141] This can partly be 
explained by the increase in complexity of surgery and change of the surgical 
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population. However, although increasing blood conservation evidence emerges, 
general implementation seems to fail. This may be due to the fact that many 
hospitals do not follow patient blood management guidelines, [142,143] resulting 
in a large heterogeneity in blood loss between centers. [144-147] Transfusion 
rates even vary from 0 to 50% for platelet concentrate and 0 to 100% for red blood 
cell concentrates and fresh frozen plasma between institutions, suggesting room 
for improvement in many centers. [148]
In 2005 almost 700.000 cardiac surgery procedures were performed in the United 
States alone. [149] As blood loss and transfusion lead to adverse outcome many 
blood transfusions, morbidity and mortality can be prevented when the adherence 
to patient blood management guidelines would increase. This is not the only benefit 
of patient blood management, as many studies have shown cost effectiveness 
of implementation of blood conservation methods, including thromboelastometry 
[150], cell salvage [151], preoperative erythropoietin use [152], tranexamic acid 
[153], and more. 
Currently, a European guideline on patient blood management in cardiac 
surgery is under development. This guideline is a collaboration between the 
society of cardioanesthesiology and cardiothoracic surgery, the European 
Association CardioThoracic Anesthesiologist (EACTA) and European Association 
CardioThoracic Surgeons (EACTS) respectively. This collaboration hopefully 
creates more awareness and concern for patient blood management on both sides 
of the sterile drape, improving health care in cardiac surgery. The publication of 
the guideline is planned for the end of 2017. 
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CONCLUSION
Patient blood management aims to prevent, predict, monitor and treat hemostatic 
disturbances in order to reduce blood loss. Bleeding leads to anemia, blood 
transfusion and can result in the need for reoperation, all with an independent 
negative effect on patient outcome. The current thesis aimed to asses, improve 
and develop strategies in all phases of patient blood management in cardiac 
surgery. 
First, we focused on the prevention of postoperative coagulopathy by the 
optimization of protamine dosing. We demonstrated that protamine, in the 
absence of heparin, impairs hemostasis in the clinical setting. This highlights the 
importance of adequate protamine dosing which, as we showed, can be improved 
by the implementation of a pharmacokinetic model for protamine dosing. Second, 
we showed that thromboelastometry cannot be used to predict which patients 
are at risk for major hemorrhage. Third, we critically investigated the applicability 
different point-of-care hemostasis monitors. We showed that the applicability 
of the thromboelastometry HEPTEM test in clinical practice deviates from the 
findings of previous research reports. Additionally, we noted that the storage 
time of the citrated blood sample affects the NATEM test results. Furthermore, we 
found that the POC-PT assay cannot be used in cardiac surgery as test results are 
inaccurate after cardiopulmonary bypass. Finally, we highlighted the importance 
of the clinical judgement of the anesthesiologist in patient blood management and 
evaluated the treatment of coagulopathy by fresh frozen plasma and fibrinogen 
concentrate. These investigations led to the more knowledge in all fields of patient 
blood management aiming for improved outcome.
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Cardiac surgery is performed in patients with severe atherosclerosis of the 
coronary arteries, cardiac valve disease and/or aortic abnormalities. In order to 
perform most type of surgery on the heart no blood should be flowing through as 
this would lead to massive blood loss and operating on a beating heart is difficult. 
For this reason, the blood flow, oxygenation and ventilation are taken over by a 
heart lung machine (HLM) also known as cardiopulmonary bypass (CPB), shown 
in figure 1. In order to bypass the heart, blood is removed prior to the heart and 
pumped into the aorta, which is the major artery suppling blood to the body.
pump 2O *
Figure 1.  A schematic overview of the heart lung machine. Blood is sucked from the right 
atrium, oxygenated by an oxygenator and pumped in the aorta, bypassing 
heart and lungs. (Copyright M.I. Meesters 2017)
When the heart is stopped by the administration of cardioplegia fluid, surgery 
can safely be performed while oxygen transport is assured by the heart lung 
machine. In order to prevent clot formation in the heart lung machine, the patients’ 
blood is anticoagulated by administration of heparin. After surgery, the patient is 
weaned from the heart lung machine, and blood coagulation needs to be restored 
to prevent blood loss from the surgical wound. This is done by administration of 
protamine, a drug that binds and inactivates heparin. However, as protamine itself 
has anticoagulant properties, overdosing of protamine should be avoided. On 
the other hand, insufficient protamine will lead to residual heparin, which inhibits 
coagulation. Adequate protamine dosing is required to prevent blood loss due to 




























Figure 2.  A schematic overview of the importance for adequate protamine dosing.
When the patient is bleeding despite adequate heparine reversal, prompt 
intervention is necessary as bleeding leads to loss of red blood cells and 
clotting factors. This might result in blood transfusion and possible reoperation 
when bleeding does not cease. Bleeding, blood transfusion and reoperation for 
bleeding are associated with an increased risk of infection and death, highlighting 
the importance of rapid treatment of coagulation abnormalities. 
In case of bleeding due to coagulation abnormalities, adequate supplementations 
of the deficient coagulation factors is necessary. This can be guided by rapid 
coagulation tests, such as thromboelastometry or other point of care coagulation 
assays. Another approach is transfusion based on patient and surgical 
characteristics guided by the experience of the attending anesthesiologist.
Chapter 1 describes the complexity of all possible modalities to prevent, 
predict, monitor and treat bleeding in cardiac surgery. These components are 
usually referred to as ‘patient blood management’. There are several ways to 
prevent bleeding after cardiac surgery including: cessation of drugs that inhibit 
coagulation before surgery, administration of medication to optimize patients 
clotting capacity and anemic patients can be treated to improve their red blood 
cell concentration. The patient at risk for bleeding can be identified by the use of 
risk scores based on patients and surgical characteristics and advanced clotting 
tests. In the case of ongoing hemorrhage there are several drugs that can be 
used to prevent further bleeding, which drug should be used can be guided by 




The thesis starts with methods to prevent bleeding, including optimization 
of protamine dosing. As mentioned before, protamine is used to reverse the 
anticoagulant properties of heparin after cardiac surgery. However, in laboratory 
studies it has been found that protamine acts as an anticoagulant in the absence 
of heparin. Chapter 2 summarizes what is known about protamine starting from its 
origin and the discovery of the heparin neutralizing effect. The pharmacological 
properties and well-known side effects are reviewed, including anaphylaxis and 
the effect on heart and blood vessels. However, the emphasis is on the negative 
effect of protamine on coagulation including blood platelets, coagulation factors 
and clot breakdown. Moreover, the effect of protamine on several coagulation 
testing methods is discussed. Finally, methods for protamine dosing and 
alternatives to protamine are reviewed. 
In chapter 3 we investigated if the anticoagulant effect of protamine is clinically 
significant and influences the amount of blood loss and coagulation status in 
patients undergoing cardiac surgery. We therefore randomized patients to low 
or high protamine dosing, all within the spectrum of clinically used dosages. We 
found that the high dosing group had significantly more blood loss and needed 
more blood transfusion compared to the low dosing group. This can be explained 
by the anticoagulant effect of protamine as clotting tests were worse in the high 
dosing group. This is the first study to prove that too much protamine in patients 
impairs the coagulation system and has a clinical significant effect on bleeding. 
In order to further improve protamine dosing, we investigated a novel dosing 
regime in chapter 4. The method estimates the amount of heparin at the moment 
that protamine is planned to be administrated. This is realized by a complex 
pharmacological model that estimates the patient blood volume and takes the 
administrated dose of heparin and loss of heparin due to its breakdown into 
account. When the amount of heparin is known, the amount of protamine needed 
can easily be calculated. We compared the clotting capacity and need for blood 
transfusion before and after the implementation of the novel dosing strategy. 
We found that the new protamine dosing method reduced the need for blood 
transfusion and improved clotting when compared to regular protamine dosing. 
Next, the thesis focusses on the prediction of bleeding. In chapter 5 we 
systematically reviewed the literature on the predictive value of the advanced 
coagulation monitoring device rotational thromboelastometry (figure 3). This 
device has been developed for the rapid detection and guidance of coagulation 
abnormalities at the point of care for the patient in the case of (severe) bleeding. 
Although rotational thromboelastometry was developed to guide coagulation 
treatment it remained unclear if abnormal thromboelastometry test results risk 
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patients for bleeding. Therefore, we performed an analysis of the predictive value 
of thromboelastometry in our center and additionally performed a systematic 
literature search which resulted in 1311 publications of which 10 regarded the 
predictive value of rotational thromboelastometry in cardiac surgery patients. 
We combined the results of our study with the results of the 10 publications and 
concluded that rotational thromboelastometry does not predict which patients are 
at risk for bleeding.
Figure 3.  The rotational thromboelastometry test device. (Copyright M.I. Meesters 2017)
During cardiac surgery patients frequently develop coagulopathy (e.g. 
coagulation abnormalities) due to blood loss, the surgical wound and the use 
of the cardiopulmonary bypass system. Several hemostasis monitors have been 
developed to measure patients’ hemostatic capacity and guide hemostatic 
treatment. We investigated the adequacy of different devices to monitor 
coagulation abnormalities during cardiac surgery.
Thromboelastometry includes several tests to investigate different aspects 
of the coagulation cascade. These tests measure the coagulation capacity 
and include assays with (EXTEM and INTEM) and without (NATEM) artificial 
coagulation activators. Another test focuses on a specific important coagulation 
factor (fibrinogen), the FIBTEM test. The HEPTEM test is same as the INTEM 
test with the addition of heparinase. Heparinase is an enzyme that breaks down 
heparin and thereby investigates the coagulation capacity without the effect of 
heparin. Heparin prolongs the INTEM test results. The HEPTEM test, without a 




to the INTEM test. However, in clinical practice we found that the HEPTEM test 
is frequently longer than the INTEM test. Furthermore, we recurrently found a 
difference in HEPTEM and INTEM test results before the administration of heparin 
before surgery. In chapter 6 we investigated the incidence of these abnormal 
results in cardiac surgery patients of two university hospitals. We found that 15 – 
36% of the HEPTEM-INTEM assays in routine cardiac surgery showed abnormal 
test results. Furthermore, our results suggested these aberrant HEPTEM results 
might be caused by protamine (over)dosing. However, further studies should 
elaborate on this hypothesis.
Besides the HEPTEM assay we investigated the accuracy of the thromboelastometric 
NATEM test. The non-activated rotational thromboelastometric assay (NATEM) 
does not use any artificial activators and is therefore very sensitive to changes in 
patients’ coagulation status. The test is increasingly used in research due to its 
high sensitivity. In chapter 7 we investigated if the storage time of the patients’ 
blood before the start of the test influences NATEM test results. We drew blood in 
healthy volunteers and intensive care patients and directly performed the NATEM 
test. We repeated the test after 45 and 90 minutes and evaluated if the test results 
changed after storage. We found that over storage time the blood clotted quicker 
as measured by the NATEM test. This suggests that the coagulation cascade 
gets activated within the blood sample over time. The regular thromboelastometry 
tests used for clinical practice have previously shown that blood storage does not 
affect the test results up to 6 hours after blood withdrawal. However, we found 
that the NATEM test is so sensitive to notice this change. Unfortunately, we could 
not identify the factor that changed the test results over time. We advise to start 
the test as soon as possible after blood withdrawal in order to prevent biased test 
results due to the storage time. Future, research should evaluate the factor(s) 
responsible for the activation of clotting over time in the stored blood sample. 
Besides, thromboelastometry there are other devices which rapidly investigate 
the coagulation capacity of a patient, an example is the point-of-care (POC) 
prothrombin time (PT) as shown in figure 4. The PT is a conventional laboratory 
coagulation assay, however as mentioned before these tests require much time. 
To overcome this limitation the POC-PT was developed where the test is modified 
to obtain the test results more rapidly and near the patient, at the ‘point-of-care’. 
As the test was developed for patients on anticoagulation medication the device 
was not validated for the use in cardiac surgery. Therefore, we investigated the 
accuracy of the POC-PT in cardiac surgery as described in chapter 8. Before 
and after cardiac surgery we drew a blood sample and investigated if the POC-PT 
corresponded with the laboratory PT. Before cardiac surgery there was a good 
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agreement between the rapid POC-PT and the laboratory, however 3 minutes after 
protamine administration after cardiac surgery the test results were very different. 
In order to investigate if after 6 or 10 minutes after protamine administration the 
test results would agree we performed another investigation, as described in 
chapter 9. However, also 6 and 10 minutes after protamine administration the 
results remained much shorter in the POC-PT assay. Therefore, we concluded 
that the POC-PT is not applicable in cardiac surgery. 
Figure 4.  The point-of-care prothrombin time device. (Copyright M.I. Meesters 2017)
Hereafter we focused on treatment options for hemostatic abnormalities. In the 
case of coagulopathy patients might require transfusion of coagulation factors 
and/or blood platelets. It remains difficult to determine the need for transfusion 
of coagulation factors, i.e. fresh frozen blood plasma composed from donated 
blood. Conventional coagulation tests can indicate a deficiency in coagulation 
factors, however these tests are time consuming and in the bleeding patient the 
time to wait for the test results is lacking. Therefore, the decision to transfuse 
coagulation factors is frequently based on clinical signs of bleeding. These signs 
usually include oozing of blood from the surgical field, long time connection to 
cardiopulmonary bypass and complex surgery. However, thromboelastometry can 
help to guide the need for coagulation factor supplementation as test results are 
rapidly available. In chapter 10 we investigated if the clinical decision to transfuse 
blood plasma is confirmed by the findings of thromboelastometry. We found that 
the clinical decision of the (experienced) cardiac anesthesiologist to transfuse 





Another method to treat coagulopathy is the administration of pharmaceutically 
produced coagulation factor concentrates instead of plasma transfusion. A recent 
study by Bilecen and colleagues investigated if the administration of fibrinogen 
concentrate (a specific coagulation factor concentrate) reduced bleeding after 
cardiac surgery. (Effect of Fibrinogen Concentrate on Intraoperative Blood Loss 
Among Patients With Intraoperative Bleeding During High-Risk Cardiac Surgery: 
A Randomized Clinical Trial. JAMA, 2017 317(7), 738–747) They concluded that 
fibrinogen concentrate did not reduce bleeding during cardiac surgery. In our 
letter to the editor (chapter 11) we noted that blood loss during surgery is not a 
relevant endpoint as most bleeding occurs after surgery and their study showed 
that fibrinogen concentrate did reduce this amount of blood loss. Furthermore, 
fibrinogen was administrated to patients who were not deficient in fibrinogen. 
These notes tone down the strong conclusion drawn by the authors.
In chapter 12 we describe the limitations of the studies of this thesis. Furthermore, 
the results from the individual chapters are combined and placed in perspective. 
First, the results of the protamine dosing studies and directions for future studies 
are given. Hereafter, predictors for bleeding after cardiac surgery are discussed. 
Then the implementation of thromboelastometry and the current evidence for 
its use is elaborated. It is highlighted that most studies on thromboelastometry 
guided coagulation therapy are limited by the implementation of the device and 
the use of coagulation factor concentrate and a transfusion algorithm, making it 
difficult to determine the additive value of each individual component. Also, the 
evidence and risks of the use of fibrinogen concentrate are discussed. Next, the 
disturbing factors in thromboelastometry testing are highlighted in addition to the 
storage time and use of heparinase. The clinical applicability and validation of 
point of care coagulation testing is shortly reviewed. Finally, the possible ‘dark 










Openhartoperaties worden verricht bij patiënten met ernstige aderverkalking 
van de kransslagaders van het hart en/of afwijkingen aan een hartklep en/of 
de grote lichaamsslagader (de aorta). Om de meeste vormen van hartchirurgie 
te kunnen uitvoeren is het van belang dat er geen bloed door het hart stroomt 
en het hart stilligt. Dit is noodzakelijk omdat er anders veel bloedverlies op zou 
treden, en het kloppen van het hart het opereren bemoeilijkt. Daarom wordt 
de functie van hart en longen overgenomen door een hart-longmachine, zoals 
schematisch weergegeven in figuur 1. Voordat het bloed via de rechter boezem 
het hart instroomt wordt het naar de hartlongmachine geleidt. Aldaar wordt het 
bloed van zuurstof voorzien en van koolzuur ontdaan. Vervolgens wordt dit bloed 
in de grote lichaamsslagader gepompt, waardoor het lichaam van zuurstofrijk 
bloed wordt voorzien. Wanneer de hart- en longfunctie door de hartlongmachine 
is overgenomen kan het hart stil worden gelegd.
pump 2O *
Figuur 1.  Een schematische weergave van de hart-longmachine. Bloed wordt voor het 
hart weggezogen, van zuurstof voorzien en vervolgens het lichaam ingepompt 
via de grote lichaamsslagader. (Copyright M.I. Meesters 2017)
Als het hart is stilgelegd kan er veilig aan het hart worden geopereerd terwijl 
het zuurstoftransport wordt gewaarborgd door de hartlongmachine. Om te 
voorkomen dat er stolsels in de hartlongmachine ontstaan wordt het bloed van 
de patiënt ontstolt met het medicijn heparine. Als de operatie aan het hart is 
afgerond en het hart weer zelf het bloed gaat rondpompen moet het bloed weer 




De antistolling wordt opgeheven door toediening van protamine, een medicament 
wat heparine bindt en inactiveert. Omdat protamine zelf ook de stolling kan 
remmen is het van belang dat protamine juist wordt gedoseerd. Een tekort aan 
protamine leidt tot resterend heparine in het bloed waardoor de stolling geremd 
blijft. Een overschot aan protamine belemmert ook de vorming van een stolsel 
door zijn remmende effecten op de stolling. Adequate protamine dosering is dus 



























Figuur 2.  Een schematische weergave van het belang van juiste protamine dosering.
Als de patiënt bloedt ondanks adequate protamine dosering is snelle interventie 
nodig aangezien bloeding leidt tot verlies van rode bloedlichaampjes en 
stollingsfactoren. Door verlies van stollingsfactoren kunnen stollingsstoornissen 
ontstaan, wat tot een negatieve spiraal van nog meer bloedverlies leidt. 
Daarnaast kan er zoveel bloedverlies optreden dat bloedarmoede ontstaat en 
bloedtransfusie of zelfs een heroperatie noodzakelijk is. Bloeding, bloedarmoede, 
bloedtransfusie en heroperaties zijn allen geassocieerd met een verhoogd risico 
op infectie en overlijden. Dit benadrukt het belang van tijdige behandeling van 
stollingsstoornissen om verder bloedverlies te voorkomen.
In het geval van een bloeding ten gevolge van stollingsstoornissen is adequate 
aanvulling van de tekortschietende stollingsfactoren noodzakelijk. Dit kan 
worden gedaan op basis van snelle specifieke point-of-care stollingstesten zoals 
tromboelastometrie. Point-of-care testen zijn snelle mobiele meetmethoden die 




stollingsstoornissen kan ook worden ingeschat op basis van het medicatiegebruik 
vóór de operatie, en karakteristieken van de patiënt en operatie gezien door de 
ervaring van de aanwezige anesthesioloog. 
Hoofdstuk 1 beschrijft de complexiteit van alle mogelijkheden om bloeding na 
openhartoperaties te voorkomen, voorspellen, monitoren en behandelen. Deze 
vier componenten worden in de literatuur vaak beschreven als patiëntgericht 
bloed management. Er zijn verschillende methoden om bloedverlies te voorkomen, 
waaronder het staken van antistollingsmedicatie (bv. sintrom) voorafgaand aan 
de operatie, toediening van medicatie die de stollingscapaciteit van de patiënt 
verbeteren en het behandelen van bloedarmoede waardoor meer bloedverlies 
kan worden verdragen. De patiënten met een hoog risico op een bloeding na de 
operatie kunnen worden geïdentificeerd met behulp van risicoscores gebaseerd 
op eigenschappen van de patiënt, het operatietype en specifieke stollingstesten. 
In het geval van een oncontroleerbare bloeding zijn er verschillende medicijnen 
die kunnen worden gegeven om bloeding te behandelen. Welk medicijn of 
bloedproduct moet worden gegeven kan worden gebaseerd op geavanceerde 
stollingstesten.
Het proefschrift vervolgt met methode om bloeding te voorkomen, waaronder het 
optimaliseren van protamine dosering. Zoals eerder beschreven wordt protamine 
toegediend om heparine te binden en daarmee de antistolling op te heffen. 
Echter, uit laboratoriumonderzoek is gebleken dat protamine in de afwezigheid 
van heparine ook antistollingseigenschappen heeft. Hoofdstuk 2 geeft een 
overzicht over wat er bekend is van protamine, beginnend bij de ontdekking van 
het medicament en het heparine neutraliserende effect. De eigenschappen en 
mogelijke bijwerkingen van protamine worden beschreven, waaronder ernstige 
allergische reactie en het effect op hart en bloedvaten. De nadruk in dit hoofdstuk 
ligt met name op het negatieve effect op de stolling, waaronder de bloedplaatjes, 
stollingsfactoren en afbraak van stolselvorming. Ook het effect van protamine op 
de specifieke stollingstesten wordt beschreven. Tot slot wordt er een overzicht 
van de mogelijkheden om protamine te doseren en alternatieven voor protamine 
besproken.
In hoofdstuk 3 onderzochten wij of het antistollingseffect van protamine relevant 
is tijdens openhartoperaties en of de protaminedosering invloed heeft op de 
hoeveelheid bloedverlies en stollingscapaciteit van de patiënt. Dit hebben 
we onderzocht door patiënten te loten voor een hoge of een lage protamine 
dosering. Beide doseringen waren binnen het spectrum van klinisch gebruikte 
doseringen. De groep die een hoge protamine dosering kreeg had meer 
bloedverlies en bleek vaker bloedtransfusies nodig te hebben in vergelijking met 
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de lage doseringsgroep. Dit kon worden verklaard doordat de patiënten in de 
hoge doseringsgroep meer stollingsafwijkingen vertoonde ten gevolge van een 
overmaat aan protamine. Dit is de eerste studie die aantoont dat een teveel aan 
protamine leidt tot stollingsstoornissen met meer bloedverlies tot gevolg.
Om het doseren van protamine verder te verbeteren onderzochten we een 
nieuwe doseringsstrategie. Deze methode schat de hoeveelheid heparine op 
het moment dat protamine zal worden gegeven. Deze schatting is gebaseerd 
op een complex farmacologisch model dat het bloedvolume van de patiënt, 
de hoeveelheid toegediend heparine en het verlies aan heparine meeneemt 
in een berekening. Als de geschatte hoeveelheid heparine bekend is, is het 
eenvoudig de benodigde hoeveelheid protamine te berekenen. In hoofdstuk 4 
vergeleken we de stollingscapaciteit en noodzaak tot bloedtransfusies vóór en 
na de implementatie van de nieuwe doseringsstrategie. De nieuwe protamine 
doseringsstrategie bleek de hoeveelheid bloedtransfusies te reduceren en 
de stollingscapaciteit te verbeteren vergeleken met de reguliere methode van 
protamine dosering.
Vervolgens richt het proefschrift zich op het voorspellen van bloeding na 
openhartoperaties. In hoofdstuk 5 evalueren we systematisch de voorspellende 
waarde van de moderne snelle stollingstest; tromboelastometrie, weergegeven 
in figuur 3. Deze test is ontwikkeld voor snelle detectie en ondersteuning van de 
behandeling van stollingsstoornissen in het geval van hevig bloedverlies. Ondanks 
dat tromboelastometrie ontwikkeld is om stollingstherapie te begeleiden is het 
onduidelijk of afwijkende test resultaten een risico vormen voor bloeding. Daarom 
hebben we in ons ziekenhuis de voorspellende waarde van tromboelastometrie 
onderzocht. Daarnaast hebben we een systematisch literatuuronderzoek gedaan 
wat resulteerde in 1311 publicaties waarvan er 10 de voorspellende waarde van 
tromboelastometrie onderzochten. De resultaten van ons onderzoek hebben we 
gecombineerd met de resultaten van het literatuuronderzoek en de test bleek niet 
te voorspellen welke patiënten een verhoogd risico op bloeding hadden.
Tijdens openhartoperaties ontwikkelen patiënten vaak stollingsstoornissen ten 
gevolge van bloedverlies, de operatiewond en het contact van het bloed van 
de patiënt met de hartlongmachine. Verschillende stollingstesten zijn ontwikkeld 
om de stollingsstatus van patiënten te onderzoeken en behandeling daarvan te 
sturen. We onderzochten de mogelijkheden en betrouwbaarheid van verschillende 
testen om deze stollingsstoornissen te monitoren. 
Tromboelastometrie bevat verschillende testen welke ieder een verschillend aspect 
van de stollingscascade analyseert. Deze testen meten de stollingscapaciteit 




stollingsactivatoren. Anderen tests richten zich specifiek op de hoeveelheid 
fibrinogeen (FIBTEM test). De HEPTEM test is een geactiveerde test met de 
toevoeging van heparinase. Heparinase is een enzym dat zorgt voor de afbraak 
van het medicijn heparine, gebruikt als antistolling tijdens de openhartoperaties 
(zie eerste alinea). De HEPTEM test onderzoekt hiermee de stollingscapaciteit 
zonder het effect van heparine. In hoofdstuk 6 hebben we onderzoek gedaan naar 
het voorkomen deze afwijkende HEPTEM-resultaten rondom openhartoperaties 
in 2 universiteitsziekenhuizen. We vonden dat in 15% tot 36% van de gevallen 
de HEPTEM test afwijkende resultaten toonde. Mogelijk kunnen deze resultaten 
worden verklaard door een overmaat aan protamine. Toekomstig onderzoek zal 
hier verder inzicht moeten geven.
Figuur 3.  De roterende tromboelastometrie machine. (Copyright M.I. Meesters 2017)
Behalve de HEPTEM test hebben we ook de betrouwbaarheid van de NATEM test 
onderzocht. De NATEM test onderzoekt de stollingscapaciteit zonder toevoeging 
van een kunstmatige activator aan het bloedmonster. De test wordt in toenemende 
mate gebruikt in wetenschappelijk onderzoek vanwege de grote gevoeligheid 
voor veranderingen van de stollingsstatus. Omdat de test zo gevoelig is voor 
veranderingen onderzochten we in hoofdstuk 7 of er een effect van de bewaarduur 
van het bloedmonster is op de NATEM-resultaten. We hebben hiervoor bloed 
van gezonde vrijwilligers en intensive care patiënten afgenomen en direct na 
afname de NATEM test hierop verricht. Na 45 en 90 minuten onderzochten wij 
hetzelfde bloedmonster opnieuw en bekeken of er verandering in de NATEM test 
resultaten optrad. Een stolsel bleek zich na 45 en 90 minuten sneller te vormen. 
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Dit suggereert dat de stolling, gemeten met NATEM, met de tijd geactiveerd raakt. 
Uit eerder onderzoek bleek dat dit bij de geactiveerde testen (INTEM, EXTEM en 
FIBTEM) niet het geval was. Helaas konden we de factor verantwoordelijk voor 
de stollingsactivatie in ons onderzoek niet identificeren. Ons advies is de NATEM 
test zo snel mogelijk na afname in te zetten om activatie en daarmee verstoring 
van de testresultaten te voorkomen.
Naast tromboelastometrie zijn er ook andere apparaten welke de stollingsstatus 
van een patiënt snel kunnen onderzoeken. Een voorbeeld is de point-of-care 
protrombine tijd (POC-PT), weergeven in figuur 4. De klassieke protrombine 
tijd (PT) bepaling is een tijdrovende laboratorium stollingstest. De POC-PT is 
ontwikkeld om sneller resultaten te verkrijgen. De test is oorspronkelijk ontwikkeld 
om patiënten die antistolling gebruiken zelf de stollingswaarde te laten meten en 
zo nodig de medicatiedosering aan te passen. Echter, door het kleine formaat 
kan het apparaat ook op de operatiekamer gebruikt worden. 
Figuur 4.  De point-of-care protrombine tijd meter. (Copyright M.I. Meesters 2017)
Omdat het na openhartoperaties vaak noodzakelijk is snel inzicht in de 
stollingsstatus te krijgen onderzochten wij in hoofdstuk 8 of de POC-PT test ook 
in deze situatie kan worden gebruikt. Voor en na de openhartoperatie namen 
wij bloed af en vergeleken de resultaten van de POC-PT met de klassieke PT uit 
het laboratorium. Voorafgaand aan de operatie was er een goede overeenkomst 
tussen de testen. Echter, 3 minuten na het toedienen van protamine, na afloop van 
de operatie, bleek er een groot verschil tussen beide testen. Om te onderzoeken 




het laboratorium verrichtte wij nog een onderzoek, zoals beschreven in hoofdstuk 
9. Echter bleek dat er ook 6 en 10 minuten na het opheffen van het heparine effect 
middels protamine er een groot verschil tussen de resultaten van de POC-PT en 
het laboratorium bleef bestaan. Derhalve concludeerde wij dat de POC-PT niet 
geschikt is voor gebruik na openhartoperaties.
Stollingsstoornissen kunnen worden behandeld met transfusie van bloedplaatjes 
en/of stollingsfactoren in de vorm van bloedplasma. Het is lastig in te schatten 
of er stollingsstoornissen ten grondslag liggen aan een bloeding of dat er een 
chirurgische voor bloedverlies is. Een chirurgische oorzaak van bloedverlies 
kan bijvoorbeeld een grote beschadiging van een bloedvat zijn, zonder dat de 
stolling gestoord is. 
Laboratorium testen kunnen uitwijzen of er een tekort aan stollingsfactoren is, 
echter deze testen nemen veel tijd in beslag en in het geval van een bloeding 
is er vaak geen tijd om op deze resultaten te wachten. Derhalve berust de 
beslissing om bloedplasma te geven vaak op klinische aanwijzingen voor een 
gestoorde stolling. Deze aanwijzingen zijn onder andere het sijpelen van bloed op 
verschillende plekken van het operatiegebied, een lange duur aangesloten zijn 
aan de hartlongmachine en complexe operaties. In hoofdstuk 10 onderzochten 
we of de beslissing om bloedplasma toe te dienen op klinische aanwijzingen 
overeenkomt met de bevindingen van tromboelastometrie. We vonden dat de 
beslissing van de (ervaren) cardioanesthesioloog om bloedplasma toe te dienen 
op basis van klinische aanwijzingen van stollingsstoornissen in 95% van de 
gevallen overeenkwam met de tromboelastometrie test resultaten. 
Naast bloedplasma zijn er ook andere methoden om stollingsstoornissen 
te behandelen, waaronder farmaceutisch geïsoleerde stollingsfactoren 
zoals fibrinogeen concentraat. Een recent onderzoek door dr. Bilecen en 
collega’s onderzocht het effect van fibrinogeen concentraat op bloedingen na 
openhartoperaties. (Artikel: Effect of Fibrinogen Concentrate on Intraoperative 
Blood Loss Among Patients With Intraoperative Bleeding During High-Risk 
Cardiac Surgery: A Randomized Clinical Trial. JAMA, 2017 317(7), 738–747) 
Zij concludeerden dat fibrinogeen concentraat de hoeveelheid bloedverlies 
tijdens openhartoperaties niet verminderde. In onze ingezonden brief aan de 
auteurs, in hoofdstuk 11, plaatste wij de kanttekening dat bloedverlies tijdens 
openhartoperaties geen relevante maat is aangezien het meeste bloedverlies na 
afloop van de operatie optreedt en het toedienen van fibrinogeen dat bloedverlies 
wel verminderde. Verder hadden de patiënten uit het onderzoek geen tekort aan 
fibrinogeen in het bloed. Met deze opmerkingen hebben wij gepoogd de sterke 
conclusies van het artikel wat af te zwakken.
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In hoofdstuk 12 beschrijven we de beperkingen van de studies uit dit proefschrift. 
Verder plaatsten we de individuele hoofdstukken in perspectief van de huidige 
literatuur. Eerst geven we een overzicht van de resultaten van andere protamine 
doseringsstudies waarna we richting geven aan toekomstig onderzoek naar 
protamine. Hierna bespreken we voorspellers van bloeding na openhartoperaties. 
Vervolgens benadrukken we dat in de studies die onderzochten of het gebruik van 
tromboelastometrie leidt tot betere behandeling gelijktijdig een stroomschema 
voor stollingsbehandeling én stollingsconcentraten werden geïntroduceerd. 
Hierdoor is niet te bepalen welk van de drie interventies (tromboelastometrie, het 
stroomschema of de stollingsconcentraten) de oorzaak van betere resultaten was. 
Ook wordt het bewijs voor het gebruik van fibrinogeen concentraat uiteengezet. 
Vervolgens gaan we in op andere verstorende factoren op tromboelastometrie, 
naast het effect van de bewaartijd van een bloedmonster en het gebruik van 
heparinase. De klinische toepasbaarheid van point-of-care stollingstesten 
wordt besproken. Tot slot beschrijven we de mogelijke nadelige kant van het 
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van jullie heb ik enorm veel geleerd op het klinisch vlak waarvoor veel dank!
Geachte prof. Girbes en dr. Tuinman, door mij ruimte te geven voor mijn 
wetenschappelijke activiteiten heb ik tijdens mijn IC jaar veel manuscripten 
kunnen afronden. 
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